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Abstract 
Background 
The pneumococcus (S. pneumoniae) is a common cause of many serious and life 
threatening infections, including pneumonia, bacteraemia and meningitis, and is also a 
common bacterial cause of acute respiratory infections (ARIs). For the last decade, 
pneumococci have become increasingly resistant to penicillin and many other 
antibiotics. This trend of increasing antibiotic resistance, especially resistance to 
penicillin, is of particular concern in young children. Children frequently suffer from 
ARIs and penicillin is the drug of choice for pneumococcal infections. However, the 
emergence of penicillin resistance has made the choice of therapy for pneumococcal 
infections more difficult. Pneumococci, once acquired, persist for prolonged periods of 
time in children and are highly transmissible among children in settings like day -care 
centres. Recently, rapid increases in the incidence of infection with penicillin resistant 
pneumococci (PRP) have been reported worldwide. In this thesis I have explored the 
likelihood that reduced use of antibiotics in children could curtail the upsurge of 
penicillin resistance in pneumococci without increasing morbidity from respiratory 
illnesses in children. 
Research questions 
1. Is the rate of carriage of antibiotic resistant pneumococci higher in children who 
consume more antibiotics? 
2. Does the use of antibiotics in ARIs alter the severity of acute respiratory illness? 
Methods 
I conducted a prospective cohort study of 502 children, who were under two years of 
age at recruitment. This study was part of a randomised controlled trial of clinical 
practice guidelines as an intervention to reduce antibiotic prescribing for acute 
respiratory infections in children. The trial was conducted between September 1997 
and November 1999 in the Australian Capital Territory (ACT). Respiratory illnesses 
and treatments were recorded by parents in a daily diary. A nasal swab was collected 
from the children four times during the study period to monitor pneumococcal 
resistance to antibiotics. 
Pneumococci isolated from the children were tested for their sensitivity to antibiotics. 
Multivariate analysis was performed to explore the relationship between antibiotic use 
and antibiotic resistance. The effect of antibiotic use on respiratory illness was also 
examined. 
Results 
Isolation of PRP was significantly associated with the use of a beta lactam antibiotic 
during the previous two months (adjusted OR 2.03, 95% CI 1.15 -3.56, p= 0.01). The 
association was also observed by multivariate analysis for children who received either 
only penicillin or only cephalosporin during the previous two months. However, the 
odds of carrying PRP was about five times higher in children who had received both 
antibiotics during the two months compared to the children who did not receive any beta 
lactam antibiotic during the period (adjusted OR 4.67, 95% CI 1.27- 17.09, p= 0.02). A 
dose -response effect was observed; the rate of penicillin resistance increased with 
increases in the duration of total beta lactam use during the six months before swab 
collection. 
I performed multiple linear regression analysis to detect the effect of antibiotic use on 
the severity of an episode of respiratory illness. Antibiotic use in an episode did not 
change the severity of a less severe respiratory episode (beta coefficient 0.008, Robust 
standard error 0.027). Antibiotic use failed to show a beneficial effect even in more 
severe episodes: beta coefficient was 0.07 for episodes that received antibiotics on the 
first visit and was -0.005 for episodes that received antibiotics on the second visit. 
Conclusion 
Reducing antibiotic use in ARls is likely to reduce penicillin resistance in the 
community, without compromising clinical care of children. These findings suggest 
that implementation of guidelines to reduce antibiotic prescribing for ARls in Australian 
general practice would curtail the increase of pneumococcal resistance to penicillin. 
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Chapter 1 Introduction 
1.1. Overview 
Acute respiratory infections (ARIs) are common causes of childhood morbidity and 
mortality around the world. Despite a fall in mortality from ARIs in Australia, ARIs 
remain the most frequent reasons for paediatric encounters in GPs' surgeries in 
Australia.' The common ARIs in children include upper respiratory tract infections 
(URTIs), acute otitis media, tonsillitis and acute bronchitis. Regardless of etiology, 
antibiotics are widely prescribed for ARIs worldwide, although over 90% of respiratory 
infections are of viral orígin.2 In Australia, respiratory infections constitute the reason 
for 55% of all antibiotic prescriptions.' Essentially this current pattern of antibiotic 
prescribing not only costs the community, but is also believed to contribute to the 
problem of antibiotic -resistance among community -acquired respiratory pathogens such 
as Streptococcus pneumoniae (S. pneumoniae /pneumococci). Pneumococcal resistance 
to penicillin is of concern because penicillin has been the drug of choice for 
pneumococcal infections. The prevalence of penicillin- resistant pneumococci is 
growing rapidly in Australia. The rate was 1.7% in 1989 and increased to 6.7% in 19953 
and 25% in 1997? The cause of this alarming increase in antibiotic -resistance is not 
clearly identified, although cross -sectional studies have demonstrated an association 
between prior antibiotic use and antibiotic -resistance.',' 
It is possible that more judicious antibiotic use might help to combat the rapid increase 
in antibiotic -resistance. In doing that, a vital question is whether reduced antibiotic use 
would result in poorer clinical outcome. The central research question in this thesis is 
whether less use of antibiotics in treating children's acute respiratory infections reduces 
the level of penicillin- resistance without compromising clinical care. 
To answer this question we elected to study children and their GPs. Most of the 
antibiotics used in humans are prescribed from general practice.? Children under two 
years of age were recruited as study subjects and followed for two years because under 
the age of five years children are a recognised susceptible group for respiratory 
infection, high consumers of antibiotics and important sources of spread of antibiotic - 
resistant bacteria.' 
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The current situation of antibiotic -resistance is explored in Chapter 2. I explore the 
evidence from the literature suggesting the association of antibiotic use with antibiotic - 
resistance. The effectiveness of antibiotics in acute respiratory infections is also 
reviewed in this chapter. 
In Chapter 3, I outline the methodology used in this study. This study was conducted as 
a prospective cohort of 502 children for 25 months within the framework of a 
randomised controlled trial (RCT). The chapter describes the process of recruitment of 
study participants, methods and instruments of data collection and methods of statistical 
analysis. 
The results of recruitment of the cohort and characteristics of the study participants are 
described in Chapter 4. In Chapter 5, I present the results of four sets of nasal swabs, 
that were collected from the children during the study. The results demonstrate the 
changes in pneumococcal carriage and antibiotic -resistance in children over the two 
years of the study period. Chapter 6 presents the association of previous antibiotic use 
with carriage of penicillin- resistant pneumococci in the children. The multivariate 
analysis included pneumococci isolated from the four sets of nasal swabs and antibiotic 
use during the study period. Chapter 7 details the respiratory episodes experienced by 
the children of the late -intervention group during the first 18 months of the study. It 
also documents the association between antibiotic use in an episode and the severity of 
the episode. 
1.2. Researcher's role 
Professor R. M. Douglas, National Centre for Epidemiology and Population Health 
(NCEPH), ANU received a grant from the General Practice Evaluation Program (GPEP) 
to evaluate clinical practice guidelines in acute respiratory infections. Ms Eileen Wilson 
(another PhD student) and I planned the detail and implemented the project. Although 
both of us worked closely in the day to day management of the project, we had distinct 
domains of the research within it. Ms Wilson concentrated on the RCT aspect of the 
project. I concentrated on the issue of antibiotic -resistance and illness outcomes in the 
study cohort. 
Together with Professor Douglas, our joint supervisor, we recruited study participants, 
managed the RCT and its extensive database including the development of guidelines, 
preparing the instruments and collection of respiratory diaries. The development of 
12 
research questions, design, and implementation of the work on antibiotic -resistance and 
illness analysis were entirely my own work. The methodology for swab collection and 
laboratory procedure was prepared under the guidance of Dr Peter Collignon, Canberra 
Hospital. Ms Helena Beltrami and Ms Letitia Toms performed the laboratory 
procedures in the Microbiology Department of the Canberra Hospital. Dr Louis Pilotto 
was closely involved in the project especially during recruitment of the study 
participants. The methods for statistical analysis were developed under the supervision 
of Dr Leslee Roberts, Professor Louis Pilotto and Ms Robyn Attewell. 
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Chapter 2 Review of literature 
2.1. Overview 
The spread of antibiotic -resistance is one of the most important emerging infectious 
disease threats in the world. In recent years concerns have been raised because of the 
rapid increase in resistance in community -acquired pathogens such as pneumococci. 
Antibiotic use in young children may have contributed to this increase in antibiotic - 
resistance. Young children frequently suffer from acute respiratory infections (ARIs) 
which constitute a major reason for antibiotic use. Although most ARIs in children are 
of viral origin, pneumococcus is the major bacterial pathogen when bacteria are 
implicated with ARIs. Therefore, children may be an important focus of antibiotic - 
resistant pneumococci. Organisms persist for prolonged periods of time in children and 
are highly transmissible in child settings like day -care and school. Resistant 
pneumococci may be acquired by children from day -care centres and may subsequently 
spread to the families and then to the community.8 The evidence of the role of antibiotic 
use in ARIs in children and in development of antibiotic -resistance is reviewed in this 
chapter. 
2.2. Acute respiratory infection in children 
ARI is a syndrome complex consisting of clinical conditions of varying etiology and 
severity. Traditionally, the syndromes of ARI are classified on the basis of anatomical 
location into upper (URTIs) and lower respiratory tract infections (LRTIs) .9 Common 
URTIs in children are: common cold (non -specific URTI), sore throat, otitis media and 
sinusitis. Common LRTIs are: bronchitis, bronchiolitis and pneumonia. 
2.2.1. Incidence 
ARI is the most important cause of childhood morbidity and mortality around the world. 
Most of the general practice consultations for ARI are for URTIs, which account for 7.1 
per 100 encounters in contrast to 3.5 per 100 encounters for LRTIs. Overall, ARI causes 
four and a half million childhood deaths each year, accounting for 30% of all deaths in 
childhood.t» The majority of these deaths occur in the developing countries from 
pneumonia.l1 Mortality from these infections has fallen in developed countries owing to 
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the advent of potent antimicrobial drugs and vaccines against respiratory pathogens. 
However, ARI remains the leading cause of morbidity in developed countries.'2 
Children under five years of age are the major sufferers from ARI. Globally, children of 
this age group experience six to eight episodes of ARI per year.13 The average 
Australian child experiences five to eight respiratory infections annually which is 
similar to other countries." Respiratory problems account for 40% of all reasons for 
which children are taken to GPs.' Irrespective of age in Australia, ARls account for 
20% of all medical consultations, 30% of absences from work and 55% of all antibiotics 
prescriptions.' 
2.2.2. Etiology of ARIs 
It has long been apparent that the known bacterial pathogens account for less than 10 
per cent of acute respiratory infection. Most acute upper respiratory infections are caused by 
viruses including those that cause predominantly nasal symptoms and those that cause 
pharyngeal exudate, fever, and adenopathy. Bacterial secondary infection does not occur and 
this explains the absence of beneficial effects from antibiotics (Coriell, L. L).15 
Although the majority of the ARIs are of viral origin, bacterial agents can also cause 
them. ARIs of viral origin are usually mild and self- limiting.16 In contrast, bacterial 
infections are relatively severe. 
Viral agents mainly involve the upper respiratory tract.2 The overwhelming majority of 
common colds, pharyngitis and tonsillitis are caused by viruses and the commonly 
implicated viruses are rhinovirus, coronavirus, Epstein -Barr virus, coxsackievirus and 
herpes simplex virus." However, a few cases of pharyngitis can be primarily caused by 
bacteria, Streptococcus pyogenes. Otitis media and sinusitis are generally considered 
bacterial infections. For example, a pathogenic bacteria is isolated from 50 -70% of 
middle ear fluid in children with otitis media and virus alone is isolated from 20- 30 %.18 
However, both bacteria and virus can be isolated from another 20 -30% of children with 
otitis media.19 The common bacteria frequently associated with these infections are S. 
pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.20,21 
Respiratory syncytial virus (RSV) is the most common cause of LRTIs in infants and 
young children.22 About 1400 nonbacterial agents were isolated from children with 
lower respiratory disease seen in a paediatric group practice from 1963 to 1971. Among 
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these 1400 agents, 75% were RSV, parainfluenza virus Types 1 and 3 and Mycoplasma 
Pneumoniae.22 Bacterial co- infection can occur with viral infection and the rate of co- 
infection varies in different studies ranging from 1.2 %23 to 48 %.24,25 The recognised 
bacterial pathogens for LRTIs are S. pneumoniae, H. influenzae, Moraxella catarrhalis, 
Staphylococcus aureus, Mycoplasma spp. and anaerobes. Among the LRTIs, 
pneumonia is considered a more serious infection, especially in developing countries, 
where bacterial agents can be isolated from as high as 62% of cases and viral agents can 
be isolated from 17- 40 %.12 
2.2.3. Risk factors for ARI 
Age and sex 
The incidence of ARI is inversely related to age, peaking at four to nine infections per 
year in the first two years of life, dropping to three to four by school age and remaining 
at two to three per year for adults.22,26 However, the frequency of pneumonia is highest 
among both the very young and the very old.27 
Several studies have reported a slightly increased incidence of ARI in young male 
children.26,27 However, in older children a reverse pattern has also been documented. A 
more recent study of viral chest infections found no differences in incidence by sex.28 
Socioeconomic status (SES) 
The risk of ARI associated with lower SES is not always consistent. In one study, 
families with incomes below the poverty line were associated with increased mortality 
from ARIs in children;29 this finding was also supported by Monto and co- workers 26 
However, Gardner et al. used a combined measure of family income, insurance status 
and parental education level to measure SES and found lower SES to be related to 
LRTIs but not to URTIs.30 
Crowding 
Crowding has been a well -documented risk factor for respiratory infections. General 
conditions of crowding may favour the transmission of illness. Woods in 1927 reported 
a highly significant correlation between overcrowded housing and pneumonia mortality 
in England and Wales, and the strongest correlations were found in the 0 -5 years age 
group.31 This fmding was supported by Payling- Wright et al.. in 1945.29 The number 
and age of siblings in families predicts the incidence of ARIs in children.3o,32 
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In developed countries, the increasing use of day -care centres for children has become 
another leading source of transmission of ARls because of crowding. Children 
attending group day -care centres are at increased risk of ARIs than other children.30,33 
Approximately one -third of all URTIs among day -care attenders and two -thirds of all 
ear infections among full -time day -care attenders were attributable to day -care 
attendance.34,35 
Nutrition 
Malnutrition is widely believed to be associated with an increased risk of LRTIs, 
especially pneumonia. In a two -year ambulatory study of lower respiratory illnesses, 
Berman et al. found that the greatest morbidity and mortality occurred in those children 
who suffered moderate or severe malnutrition?' Since malnutrition is closely related to 
crowding, poverty, poor education and poor housing in developing countries, it was 
difficult to identify an independent effect of this factor on risk of respiratory infection.27 
2.2.4. Treatment of ARI 
Globally a substantial amount of antibiotic use in children is for ARls. Antibiotics are 
widely used for respiratory infection in children regardless of whether it is bacterial or 
viral.36 In the United States, respiratory infections account for more than three- quarters 
of the antibiotics prescriptions annually.37 The situation is even more serious in 
countries where antibiotics are available without a prescription. Self- medication with 
antibiotics before being seen by a health provider is well -documented in both developed 
and developing countries.38 -40 
Treatment of ARIs remains the subject of controversy between scientists and medical 
practitioners. As 90% or more of the respiratory infections are vira1,2,16 antibiotics 
should not be the treatment of choice. Several studies in both developed and developing 
countries concluded that antibiotic treatment in most of the ARIs neither shortens the 
course of illness, nor prevents the development of complications.13,36,41 
In general, Australia has a very high rate of antibiotics use compared with other 
developed countries.42 Antibiotics are prescribed for 51% of consultations for upper 
respiratory tract infections, 79% for acute bronchitis, 93% for tonsillitis and 77% for 
acute otitis media., There have been strong suggestions over recent years that the 
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prescribing of antibiotics in Australia is unsatisfactory because of overuse of the broad - 
spectrum drugs at the expense of simpler, cheaper and safer drugs.43 
2.2.5. Effectiveness of antibiotic use in ARIs 
A major portion of antibiotic use in humans is from general practice. Common ARIs 
frequently seen by general practitioners (GPs) are common colds, sinusitis, pharyngitis, 
otitis media and bronchitis, and approximately three- fourths of all outpatient antibiotics 
have been prescribed in recent years for these five conditions.37 While pneumonia and 
bronchiolitis are more severe acute conditions, sufferers are not usually treated as 
outpatients. To review the effectiveness of antibiotics on ARls, five common AR's that 
are usually treated from general practice are individually evaluated in this section. 
Nonspecific upper respiratory tract infection (common cold) 
The International Classification of Health Problems in Primary Care (ICHPPC -2) 
defines the common cold as an illness with evidence of acute inflammation of nasal or 
pharyngeal mucosa and the absence of other specifically defined respiratory conditions, 
e.g. streptococcal tonsillitis, laryngitis, bronchitis, pneumonia, asthma and hay fever. 
The common cold is an acute illness associated with one or more of the following 
symptoms: runny nose, sore throat, fever, cough with or without productive sputum. 
Children younger than five years of age experience three to eight episodes of cold per 
year44,45 and most of them are caused by viruses. However, in 1969, 95% of the 
physicians surveyed in USA gave one or more prescription drugs for the common cold, 
about 60% of which were antibiotics 46 This practice is common in other countries as 
well. In a New Zealand study, Mc Gregor et al. found that 78% of the patients in 
general practice received antibiotics for common cold and about one third of them 
received broad -spectrum antibiotics.47 
The efficacy of antibiotics in the treatment of common cold has been the subject of 
many review papers. One review conducted by Arroll and Kenealy in 1999 for the 
Cochrane Library48 assessed the effect of antibiotics in resolution of symptoms and rate 
of recovery from common cold. Seven randomised controlled trials involving 2,056 
people aged between 6 months and 49 years were included in that analysis. The group 
treated with antibiotics did not have a reduction of symptoms or duration of illness 
compared with the group that received a placebo. Moreover, the antibiotic- treated 
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group had a significant increase in side effects of antibiotics, including diarrhoea and 
vomiting. 
Another meta -analysis by Gadomski in 199313 specifically looked at the effect of 
antibiotics to prevent LRTIs after a common cold. This study, which included five 
RCTs, suggested that there was no beneficial effect of antibiotic treatment of the 
common cold in preventing progression to LRTIs. This review also suggested no 
significant difference in clinical resolution of symptoms between antibiotic and placebo 
groups. One of the trials, however, reported more side effects, such as, diarrhoea, in the 
antibiotic group. 
Ackerman49 conducted a prospective double -blind study of 60 infants to assess the 
effectiveness of treatment in common cold. Three groups of infants were compared for 
duration and severity of illness and also for complications after providing 10 days of 
penicillin V or tetracycline or glyceryl guaiacolate. The percentage of clinical 
improvement after 48 hours of treatment was equal in the three groups. The mean 
duration of fever was 2 -3 days in all groups. There was no difference in the rate of 
complications between the three groups. 
Hardy and Traisman50 conducted another double -blind study of 217 children under 14 
years of age in an outpatient clinic. The children had a temperature above 38.3 C for 12 
hours or more and physical examination revealed no positive fmdings, except 
nasopharyngitis. They were treated either with a placebo or penicillin or 
chlortetracycline or sulfisoxazole every six hours for four days. The use of antibiotics 
did not decrease the duration of symptoms or the incidence of complications. 
Another prospective double -blind study compared the effectiveness of antibiotics versus 
placebo on 781 children with a common cold.$' In children who did not develop any 
secondary bacterial infection, fever lasted for a mean of 3.6 days regardless of treatment. 
Fever lasted 3.7 days in the placebo group and 3.5 days in the antibiotic group among 
the children who developed complications. The rate of complication was not different 
between groups. 
There is thus substantial evidence that antibiotic use is not beneficial in the treatment of 
common cold. 
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Sinusitis 
Sinusitis is a frequent diagnosis and also a common reason for antibiotic prescription in 
children.37 Sinusitis is defined as an inflammation of the sinus mucosa caused either by 
infectious or non -infectious agents. Viral URTI is often associated with inflammation 
of sinus mucosa which may result in obstruction of sinus ostia.52 The resulting 
accumulation of fluid in the sinus cavities may lead to proliferation of bacteria resulting 
in acute bacterial sinusitis. 
Viral URTI and bacterial sinusitis may be indistinguishable solely on the basis of 
clinical features. However, the symptoms of uncomplicated URTI usually completely 
resolve within two weeks53 and thus, acute bacterial sinusitis can be diagnosed if 
symptoms persist without improvement by 10 to 14 days.54 Sinusitis can also be 
diagnosed if URTI is associated with more severe symptoms in the first few days: high 
fever ( >38 °C), persistant fever, periorbital swelling, facial pain, or dental pain.55 
Purulent nasal discharge is sometimes believed to be an indicator of bacterial sinusitis. 
However, nasal discharge changes from clear to purulent during the first few days of 
cold caused by rhinovirus and the colour or characteristics of the nasal discharge do not 
predict a sinusitis of bacterial origin.56 Clinical diagnosis of acute bacterial sinusitis 
strictly requires either prolonged ( >10 to 14 days) or severe nonspecific upper 
respiratory signs and symptoms.54 
Radiography of sinuses is only moderately helpful in confirming the diagnosis of acute 
bacterial sinusitis in children since similar findings can also be observed in common 
cold 2' In a study of 171 children with nasal discharge, daytime cough or both, lasting 
from 10 to 30 days, 80% had abnormal maxillary sinus radiograph fmdings.57 In 
children who were diagnosed with acute sinusitis by a strict definition of prolonged 
symptoms (10 to 30 days) or severe respiratory symptoms associated with abnormal 
radiographic findings, a bacterial pathogen was recovered from the affected sinuses only 
from 56% of children.54 
Wald and colleagues conducted a double -blind, placebo -controlled trial in children to 
determine the effectiveness of antibiotic treatment for acute sinusitis in children 
diagnosed by symptoms of 10 to 30 days and radiographic fmding. Children treated 
with antibiotics were more likely to be cured both at 3 days (p <.01) and at 10 days 
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(p <.05) than children who received placebo. The clinical cure rate at day 10 was 65% 
for antibiotic compared to 43% for placebo.57 
Williams et al. conducted a Cochrane review including 7,330 subjects to evaluate 
antibiotic treatment for acute maxillary sinusitis. They concluded that there were 
overall moderate benefits of antibiotic treatment in acute maxillary sinusitis.58 
The overall evidence is in favour of antibiotic treatment in acute bacterial sinusitis. 
However, diagnosis by strict criteria of prolonged or severe symptoms seems prudent, to 
curtail a significant amount of antibiotic use. If antibiotic treatment is justified, initial 
therapy with a narrow -spectrum agent should be a drug of choice in acute bacterial 
sinusitis.54 
Otitis media 
Otitis media is inflammation of the middle ear, which may be associated with the 
presence of fluid in the middle ear. The most frequent outpatient use of antibiotics is for 
otitis media, which accounts for more than 90% of all antibiotic use during the first two 
years of life.59 There are two common conditions of otitis media: acute otitis media 
(AOM) and otitis media with effusion (OME). 
AOM is defined as the presence of fluid in the middle ear in association with signs or 
symptoms of acute local or systemic illness. AOM is generally considered a bacterial 
infection because a pathogenic bacteria can be isolated from the middle ear fluid in two - 
thirds of cases of AOM.60 However, epidemiological surveillance data show a strong 
association between respiratory virus infections and AOM. Respiratory viruses were 
detected in nasopharyngeal specimens of 42% of patients with AOM at the time of 
diagnosis.19 The percentage of viral isolation might even be an under estimation, 
because the specimens for viral diagnostics were obtained from 45% of patients after 
five days of illness, when there has already been maximal virus shedding.61 
The treatment of acute otitis media (AOM) remains controversial. The rate of antibiotic 
use for AOM varies from 31% in the Netherlands to 98% in the USA, Australia and 
New Zealand.62 Several reviews have assessed the effects of antibiotics in AOM and the 
result is still not conclusive. 
A Cochrane review included six trials from the developed countries with a total of 1,962 
children.63 The trials showed no reduction in pain at 24 hours, but a 34% relative 
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reduction in pain at 2 to 7 days. However, approximately 85% of the patients settled 
spontaneously within this time. The authors concluded that antibiotic use provides a 
small benefit for AOM in children. 
Jack Froom et al. reviewed seven randomised blinded trials that compared 
antimicrobials with placebo in patients with AOM. They concluded that the benefit of 
routine antimicrobial use for otitis media, judged by short or long -term outcomes, is 
unproved. The effect of antimicrobials in preventing complications is also uncertain.64 
However, in a meta -analysis of 33 RCTs, Rosenfeld et al. were in favour of routine 
antibiotic use for AOM.65 Although 81% of the AOM with placebo resolved 
spontaneously by 7 -14 days, the authors suggested a modest but significant impact of 
antibiotics on AOM. 
In 1990, the Dutch College of General Practitioners adopted a guideline for the care of 
AOM. According to the guideline, AOM should be treated with symptomatic treatment 
(acetaminophen with or without decongestant nasal drops) for the first three days in 
children aged two years or older. If pain or fever continues for three days, antibiotics 
may be prescribed for seven days after re- evaluation. In children under two years of 
age, a mandatory contact with the doctor is advised after 24 hours, when doctors may 
start antibiotics after re- evaluation.64 
Although there is no controlled study that has investigated whether the Dutch guideline 
results in worse outcomes than widely used routine antibiotic practice, Van Buchem et 
al. conducted a study with 60 general practitioners who treated AOM in 4,860 children 
aged two years or more with nose drops and analgesics alone. Ninety per cent of 
children recovered from AOM within the first three days. Only 2.7% of children had a 
severe course with fever, pain or discharge after 3 to 4 days and only two children 
developed mastoiditis. The outcomes at two months for these children were similar to 
those in patients in other countries where routine antibiotic therapy in AOM is 
universa1.62 The authors were in agreement with Dutch guidelines about the treatment of 
AOM in children.66 
OME is defined as the presence of fluid in the middle ear in the absence of signs and 
symptoms of acute infection.67 It is commonly a sequel of previous ear infection, which 
occurs in association with 5 -40% of AOM. Meta -analysis of published trials has 
concluded that antibiotics have limited effects on the short-term resolution of OME. 
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Longer -term benefit for OME has not been shown.68,69 The incidence of OME was not 
different between an antibiotic group and a placebo group when assessed one month 
after treatment was completed.ó9 In another study, the author concluded that about seven 
children need to be treated with antibiotics for one to have small benefit in OME.70 In 
the absence of AOM, antibiotic use is recommended only for the children with both 
middle -ear effusion and documented hearing loss for three months or longer.71 
Sore throat /pharyngitis /tonsillitis 
Sore throat is another common complaint in children. Most episodes of pharyngitis are 
caused by viral agents.72 Group A streptococci (GAS) is the most common bacterial 
cause of pharyngitis, and accounts for only about 15% of all pharyngitis episodes. In a 
study of children, group A streptococci was isolated from only 12% of patients who had 
both pharyngeal exudate and fever, whereas viral infection was documented from 31 %. 
Diagnostic testing was not available for rhinovirus and coronavirus, which may have 
caused infection in other children from whom no etiologic agent was identified." 
Despite the low incidence of streptococcal sore throats, antibiotics are routinely 
prescribed for sore throat to relieve symptoms and to prevent complications: otitis 
media, glomerulonephritis, rheumatic fever. 
A review was conducted in 1999 by Del Mar et al. on antibiotics for sore throat 
including 22 controlled studies with a total of 10,484 cases of sore throat. Antibiotics 
shortened the duration of symptoms by a mean of only about half a day at Day 3 and by 
eight hours overall. However, symptoms of half of the untreated patients had also 
settled by Day 3. Antibiotics reduced the incidence of suppurative complications (acute 
otitis media and acute sinusitis) and exhibited a protective effect against non - 
suppurative complications (glomerulonephritis, acute rheumatic fever). However, the 
incidence of these complications is rare in developed countries. The authors, thus, 
concluded that protecting sore throat sufferers against suppurative and non -suppurative 
complications in modern Western society can only be achieved by treating with 
antibiotics many who will derive no benefit.74 
Little et al. conducted a RCT of prescribing strategies in managing sore throat with 716 
patients aged four years and over. Patients were randomised by types of treatment into 
three groups: prescription for antibiotics immediately for 10 days, no prescription, 
prescription for antibiotics if symptoms did not settle after three days. The proportion of 
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patients better by Day 3 did not differ significantly among the groups. There was also 
no difference in duration of illness, days off from work or school or proportion of 
patients satisfied.75 
The evidence is not conclusive about whether or not to prescribe antibiotics for sore 
throat. Since the signs and symptoms of pharyngitis associated with viral infection 
overlap substantially with those of streptococcal pharyngitis, it is difficult to diagnose 
pharyngitis caused by GAS based on clinical findings alone. However, age is the most 
important factor in predicting the causative agent of pharyngitis. In a study of febrile 
exudative tonsillitis, virus was found in 53% of patients younger than six years of age, 
whereas GAS were found in 46% of children older than six years of age. In fact, none 
of the children younger than three years of age had GAS." This fmding was supported 
by other studies as we11.76 While the large majority of pharyngitis in children under six 
is not caused by Group A streptococci, empiric antibiotic therapy would result in 
substantial over -treatment. Therefore, when streptococcal pharyngitis is suspected, 
appropriate therapy after confirming the etiology by a throat culture may help in 
reducing inappropriate antibiotic use.72 
Acute bronchitis 
Bronchitis is defined as an inflammation of the bronchial mucosa, resulting in 
productive cough. It is a self limiting condition most commonly caused by viral 
pathogens 22 Viral pathogens such as parainfluenza virus, respiratory syncytial virus and 
influenza virus account for the majority of agents identified among children with 
bronchitis.77 
In practice, physicians commonly prescribe antibiotics for this condition.78 In a study of 
1,398 children who visited a primary care practice with a chief complaint of cough, 
bronchitis was diagnosed in 33% children and 88% of these children were prescribed an 
antibiotic.79 In the National Ambulatory Care Survey in 1989,80 acute bronchitis was the 
ninth most common outpatient illness seen by physicians in the United States. In 
Australia, acute bronchitis is the fifth most common problem encountered by general 
practitioners.S1 
There are a number of substantial reviews which conclude that antibiotic treatment is 
not effective in bronchitis, but most of the studies involved adult patients. A meta - 
analysis by On et al. included six randomised controlled trials among adult patients.82 
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Four trials, including the two that were scored highest for methodologic soundness, 
demonstrated no difference in outcomes achieved by administering antibiotics as 
compared with placebo. The remaining two trials demonstrated improvement in 
duration of cough in the group treated by antibiotics. 
Another review included eight trials to determine the effectiveness of antibiotics on 
bronchitis in patients aged above 12 years. Six of the eight trials were included in the 
review by On et al.. The review showed that antibiotic treatment had no effect on the 
resolution of acute cough.83 
A Cochrane review84 included eight randomised controlled trials involving 750 patients 
aged from eight to over 65. Overall, patients who received antibiotics had slightly better 
outcome than those who received placebo. However, antibiotic- treated patients reported 
significantly more adverse effects such as nausea, vomiting, headache, skin rash and 
vaginitis. 
Few studies85,86 evaluated the use of antibiotics for acute bronchitis in children and none 
of these studies showed any benefit of antibiotic use for the cough. 
2.2.6. Consequences of antibiotic prescribing 
"Antibacterial drugs are powerful weapons when used reasonably against infectious 
targets, but when they are imprudently prescribed for nonspecific symptoms or infection that is 
probably viral, their use may only contribute to bacterial resistance" (Morton N. Swartz).87 
The benefits of prescribing antibiotics must be weighed against the costs. Routine 
prescribing encourages patients' dependence and re- attendance at the surgery, taking up 
valuable time of the doctor and patient for what is usually a self -limiting condition.88 
Antibiotic treatment in URI is not only ineffective, it may also be harmful. Large 
numbers of children are unnecessarily exposed to the potential side -effects of 
antibiotics: allergy, gastric upset, diarrhoea. Unnecessary antibiotic therapy also 
increases the economic cost of providing medical services. More importantly, routine 
therapy may delay the diagnosis of serious bacterial diseases. On the other hand, 
indiscriminate antibiotic use may select for resistant strains of bacteria and may thus 
lead to more rapid emergence of drug- resistant strains of bacteria.89,90 
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2.3. Antibiotics and Antibiotic- resistance 
Knowledge about different antibiotics that are commonly used in children and the 
mechanism by which they work on bacteria is essential to understand the reality of 
antibiotic -resistance. 
2.3.1. Antibiotics 
The term `antibiotic' was first used to define naturally occurring chemical substances 
which are produced by various microorganisms and which suppress the growth of 
bacteria. However, common usage of this term also includes synthetic agents, which 
were formerly known as antibacterial or antimicrobial agents. 
Types of antibiotics 
Antibiotics are commonly classified according to their chemical structure. Most 
antibiotics used in humans can be grouped into few major groups (Table 2.1). 
Table 2.1: Commonly used antibiotics in humans 
Family Commonly used antibiotic in humans 
Beta lactam 
Macrolide 
Aminoglycoside 
Tetracycline 
Sulfonomide- 
trimethoprim 
Glycopeptide 
Penicillin, cephalosporin, carbapenem and monobactam 
Erythromycin, roxithromycin, azithromycin, clarithromycin 
Neomycin, gentamicin, tobramycin, netilmicin, amikacin 
Tetracycline, doxycycline, minocycline 
Trimethoprim -sulfamethoxazole, trimethoprim, sulfadiazine 
Vancomycin 
Antibiotics can also be grouped according to their range of activity into a narrow - 
spectrum, effective against a particular organism only, and a broad -spectrum, effective 
against many different organisms. 
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Mechanism of action of antibiotics 
Antibiotics suppress the growth of bacteria either by arresting growth and preventing the 
multiplication of bacteria (bacteriostatic) or by killing the bacteria (bacteriocidal). 
These exert their bacteriostatic or bactericidal effects in various ways (Table 2.2). 
Table 2.2: Mechanism of action of commonly used antibiotics in humans 
Mechanism Family of antibiotics 
Inhibits cell wall synthesis Beta lactam, glycopeptide 
Inhibits protein synthesis Macrolide, aminoglycoside, tetracycline 
Inhibits metabolism Sulfonamide -trimethoprim 
Antibiotic use in humans 
Antibiotics are used in humans either for treatment or for prevention of infection 
(prophylaxis). Treatment may be empirical, which means start of therapy pending the 
results of culture and sensitivity results, or definitive, that is, start of therapy on the basis 
of culture and sensitivity test. Most antibiotics used for ARIs in children are prescribed 
empirically. 
It would seem that a great deal of empirical therapy in humans around the world is 
inappropriate. In one estimate, at least half of present antibiotics in United States are 
prescribed where they are not indicated at all or they are incorrectly prescribed as the 
wrong drug, the wrong dosage or the wrong duration.91 
Antibiotics when used for prophylaxis are usually used for a longer period than when 
used for treatment. Studies showed that administration of even a single antibiotic for 
two weeks or more leads to the selection of bacteria with resistance, not just to the 
antibiotic used, but to multiple structurally -unrelated antibiotics.92 Datta et al. reported a 
similar finding in fecal E. coli specimens collected from women taking prolonged 
courses of ampicillin for urinary tract infection.93 
2.3.2. Antibiotic -resistance 
The basic principle of antibiotic -resistance is survival of the fittest. Resistance is an 
adaptive response by microorganisms that enables them to tolerate increasing 
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concentrations of antibiotics that would normally inhibit them. Antibiotics cannot kill 
resistant bacteria and thus they survive and multiply, and may cause infection depending 
on the host's immunity. 
Bacterial resistance to antibiotics was observed soon after the introduction of 
antibacterial drugs. A new antimicrobial era started in the 1930s with the discovery of 
sulphonamide; sulphonamide- resistant organisms soon emerged, especially among the 
military population being treated prophylactically with this drug.94 The golden age of 
antimicrobial therapy, however, started with the advent of penicillin during the 1940s. 
Antimicrobials started emerging one after another; but resistance always followed 
almost immediately after the introduction of each new antibiotic. As a result, only 10 
years after the introduction of penicillin in practice, 59% of Staphylococci were reported 
as resistant to penicillin.92 
Newer drugs active against bacterial strains were increasingly available during the 1960s 
to 1980s, but the pace of new antibiotic development has markedly dropped over the 
1990s. The problem of antibiotic -resistance has recently become of serious concern as 
organisms resistant to multiple drugs became widespread, and there is little hope of new 
antibiotics in the near future.95'3'5'9e.97.98 Common antibiotics are now being reported as 
ineffective for the treatment of invasive infections caused by resistant 
organisms.99'100,101"102 In addition to potentially affecting patient morbidity and mortality, 
antibiotic- resistance in the community will significantly increase health care costs by 
increasing the number and duration of hospital admissions and increasing the 
requirement of higher doses of expensive antibiotics. Thus antibiotic- resistance has 
become a major public health problem both in Australia and throughout the world. 
2.4. Pneumococcal resistance to antibiotics 
The first clinical isolate of resistant pneumococcus was isolated in 1967.103 Between 
1967 and 1977, sporadic reports of penicillin- resistant pneumococci were reported from 
various parts of the world. The next dramatic event in the epidemiology of antibiotic - 
resistant pneumococci was the outbreak of pneumococcal disease caused by multidrug- 
resistant strains in South African hospitals in epidemics in 1977. In contrast to the first 
isolate, which was still susceptible to chloramphenicol, tetracycline, erythromycin, and 
sulfonamide -trimethoprim drugs, the multidrug- resistant South African strains 
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recovered in 1977 were shown to have greatly increased minimum inhibitory 
concentrations to all of these drugs.104 
2.4.1. Mechanisms of pneumococcal resistance to antibiotics 
Resistance to beta lactam antibiotics 
Beta lactam antibiotics (e.g. penicillin, cephalosporin) kill pneumococci by binding to 
PBPs present in the bacterial cell wall. They subsequently interfere with bacterial cell 
wall synthesis and activate the enzyme amidase, leading to autolysis of bacteria. Six 
PBPS are found in susceptible strains:1a, lb, 2x, 2a, 2b, 3. Binding to PBP 2b is 
essential for the lytic activity of beta lactams on pneumococci.105 Penicillin- resistant 
pneumococcal strains have one or more altered PBP that bind penicillin poorly, but are 
still able to perform their physiological function of cross -linking peptido -glycans. The 
resistant genes reside in the chromosome and are selected by heavy antibiotic use. 
Penicillin -resistance requires alteration of at least four distinct genetic elements. 
Cephalosporin resistance is acquired rapidly, as it needs at most, alteration of two 
genetic determinants.106 Highly resistant pneumococci may also acquire different 
mechanisms of resistance to other unrelated antibiotics. This resistance is transferred by 
mobile genetic elements such as plasmids and transposons.'°5 
Resistance to other antibiotics 
Some transposons can cause simultaneous resistance to many different classes of 
antibiotics. Transposon Tn1545 confers resistance to chloramphenicol, erythromycin, 
kanamycin, and tetracycline. Erythromycin resistance is due to the gene ermAM, the 
kanamycin resistance is due to aphA -3, and the tetracycline resistance is due to tetM. 
Chloramphenicol resistance in pneumococci is due to the production by resistant strains 
of inducible chloramphenicol acetyltranspherase enzyme. Resistance to tetracyclines 
and macrolides involves alterations of ribosomal target proteins. Alterations in folate 
and dihydrofolate metabolism and DNA gyrase structure result in resistance to 
cotrimoxazole and fluroquinolones respectively. 
2.4.2. Factors associated with carriage and spread of antibiotic - 
resistant pneumococci 
Serogroups: Serogroups 6, 14, 19, and 23 are the predominant serogroups of 
pneumococci manifesting antimicrobial resistance, and account for two- thirds of all 
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pneumococci isolated during the first two years of Iife.107 These serogroups are also 
commonly identified following antibiotic therapy107 and are carried for a longer period 
of time (mean 4.2 months versus 2.7 months for other serogroups; p <0.01).105 
Age: Carriage of, and infection with, resistant pneumococci is mostly associated with 
young children.108,109 Barry et al. compared two groups of children with acute otitis 
media infected with S. pneumoniae by controlling for sex, age at first attack and 
frequency of earlier attacks, and found a higher rate of isolation of penicillin- resistant 
strains in children under 18 months (p= .003).10 Gratten et al. studied 57 strains of 
pneumococci isolated from patients with pneumococcal infections in 1978 and found 
56% of the isolates from the children were penicillin -insensitive compared to 17% of 
the isolates from adults." In a multicentre prospective study, Clavo- Sanchez et al. 
found a significant association of resistance to multiple antibiotics with age younger 
than five years or older than 65 years.112 
Hospitalisation: In both children and adults, infection with resistant pneumococci is 
shown to be associated with hospitalisation.105 Duration of hospitalisation has been 
correlated with acquisition of penicillin- resistant strains, with patients colonised by 
susceptible strains having been hospitalised a median of less than one day and patients 
carrying resistant strains having been hospitalised a median of 5.5 days.113 
Day -care centre: Attendance at a day -care centre is a common source of spread of 
community -acquired resistant pneumococci.109 Several studies reported a higher level of 
carriage of resistant pneumococci by children in day -care centres. 114-116 Development 
and spread of multiply- resistant pneumococci after treatment for acute otitis media have 
been documented in day -care centres and surrounding communities.8 A resistant strain 
acquired by the children from the day -care centre may spread within the family. During 
the investigation of the first case of a community- acquired multiply- resistant 
pneumococcus, 27% of children in the same room as the index case were carrying the 
strain, compared with 11% of older children and staff. Five of 15 family contacts of 
colonised children acquired the resistant strain, compared with none of 19 contacts of 
children who did not carry the resistant strain.109 
Travel: Levy referred to antibiotics as `societal drugs' -the only class of therapeutics 
that can affect people around the individual being treated."? Bacteria are also social 
organisms and know no borders. Therefore, the emergence of a resistant strain in one 
30 
country is a potential problem in another.118 This spread became more common with the 
increasing volume of international travel. Investigators have documented the migration 
of a strain of multidrug- resistant pneumococcus from Spain to the UK, US, South Africa 
and elsewhere. "9,120 Strains of penicillin- resistant serotype 23F S. pneumoniae isolated 
from children attending a day -care centre in Cleveland were compared with those from 
Spain by electrophoretic analysis of PBP profiles and DNA restriction endonucleàse 
cleavage profiles of the PBP 2X and 2B genes amplified with the polymerase chain 
reaction and by multilocus enzyme electrophoresis. All strains from the two countries 
were identical by these criteria. The findings demonstrated that the Spanish and 
Cleveland isolates were clonally related and suggested that the antibiotic -resistant clone 
of serotype 23F S. pneumoniae has spread intercontinentally from Spain to the United 
States.120 
Antibiotic use: Exposure to antibiotics may contribute to carriage of resistant strains 
which may predispose to infection with resistant rather than susceptible strains.t05 The 
association between antibiotic use and resistance has been documented in both hospital 
and community settings.' °9,'21,122 Ecological studies have documented an association 
between the total amount of penicillin use in a defined area and the isolation of 
penicillin- resistant pneumococci.5,'22 Among 258 isolates of pneumococci obtained 
from 232 children, prior therapy with a beta lactam agent had occurred in 56% of 
patients with penicillin- resistant pneumococcal infections, compared with 14% of 
randomly selected children with susceptible pneumococcal infections (P = 0.009).123 In 
a separate study, 65% of the patients infected with resistant pneumococci received 
antibiotics in the previous three months compared with 17% of controls with susceptible 
pneumococcal infection.124 Duration of hospitalisation was not considered in any of the 
above studies; however, it is possible that exposure to hospital microflora had 
contributed to the acquisition of the resistant strain. Robins -Browne et al. found that 
acquisition of penicillin- resistant pneumococci was significantly related to exposure to 
beta lactam antibiotics even after controlling for young age and duration of 
hospitalisation.113 In a case -control study, Amitai and colleagues found that the duration 
of exposure to beta lactam antibiotics was 13.3 days in patients who had infections with 
penicillin- resistant pneumococci, compared to 4.2 days in patients with penicillin - 
susceptible infections (p <.02).125 The association of beta lactam antibiotic use and 
infection with penicillin- resistant pneumococci was consistent in a separate prospective 
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study by Clavo- Sanchez et al.112 Broad -spectrum antibiotics are of particular concern in 
increasing resistance because they provide selective pressure to increase the number of 
micoorganisms. 
Duration of exposure to antibiotics 
Several studies have reported an association between prior antibiotic use and antibiotic - 
resistance in pneumococci; most of these studies were either ecological or cross - 
sectional studies. The participants were commonly asked if they received an antibiotic 
during a given time period before the culture of resistant pneumococci. Type of 
antibiotic use was sometimes specified; however, most of the time, it was any antibiotic 
use during that period. The outcome was either penicillin- resistant (PRP) or multiply - 
resistant pneumococci (MRP). 
Table 2.3: Studies that found a positive association between prior antibiotic use 
in children with pneumococcal resistance to antibiotics 
Type of antibiotic Type of resistant Duration of study 
used pneumoccocci before culture 
Tan126 
Radetsky109 
Reichler$ 
Deeks127 
Ford128 
Melander129 
Arasons 
Any antibiotic 
Any antibiotic 
Any antibiotic 
Penicillin 
Beta lactam 
Any antibiotic 
Any antibiotic 
PRP 
MRP 
MRP 
PRP 
PRP 
PRP 
PRP and MRP 
1 month 
2 months 
3 months 
3 months 
3 months 
6 months 
12 months 
Very few studies monitored antibiotic use beyond three months before culture. Even the 
studies that looked at a longer period of antibiotic use, did not have enough information 
to specify a definitive period during which antibiotic use was associated with resistance 
development. However, Brook et al. studied 60 children to determine the effect of 
prophylactic antibiotic use on the recovery of penicillin- resistant bacteria.6 Twenty 
children were receiving amoxicillin and 20 were receiving sulfisoxazole for the 
prevention of otitis media. The rate of recovery of PRP increased only among patients 
32 
who received amoxicillin prophylaxis. The numbers of PRP increased from 0 to 25% 
during prophylaxis and returned to baseline within 3 -5 months after amoxicillin 
prophylaxis was discontinued. 
2.4.3. 
Penicillin- resistance 
Prevalence of antibiotic- resistance in pneumococci 
The first penicillin- resistant strain of pneumococcus was isolated from a 25 year old 
woman patient with hypo -gammaglobulinaemia in Sydney, Australia, who was 
previously treated with penicillin, tetracycline, erythromycin, chloramphenicol and 
sulfonamide.103 This strain was intermediately resistant to penicillin (MIC 0.6 mg/L) 
and tetracycline (MIC 5 mg /L). Subsequently, resistant strains were identified in New 
Guinea during a trial of penicillin prophylaxis for pneumonia in 1969.13° In this trial, a 
total of 15 isolates were penicillin -resistant and 11 of the 15 isolates were from the 
group receiving penicillin prophylaxis. However, the first insensitive strain was isolated 
from a three -year -old boy from the control group, who had suffered from pneumonia 
five months before and had been treated with penicillin. Subsequently an identical 
strain was isolated from 14 other people during a period of 14 weeks; all but one of 
them had recently received penicillin. In 1974, 12% of 518 isolates were penicillin - 
resistant in New Guinea,131 and by 1978 one -third of 57 strains isolated from patients 
with pneumococcal infections were resistant to penicillin." In the United States the 
first infection due to penicillin- resistant pneumococci was reported in 1974.132 This 
resistant strain was isolated from a three -year -old boy with sickle -cell disease. The 
child developed pneumococcal meningitis which relapsed despite high -dose penicillin 
therapy. The boy had had several courses of penicillin previously for upper respiratory 
infections. From 1974 to 1984, penicillin- resistant pneumococcal strains were reported 
from all over the world.133 
Erythromycin resistance 
The first pneumococcal strain resistant to erythromycin was reported in Canada in 1967 
from a 63- year -old man, who was known to have a bronchogenic carcinoma and 
subsequently developed lung abscess.134 Pneumococci isolated from the pleural aspirate 
were resistant to both erythromycin and lincomycin two weeks after starting treatment 
with oral erythromycin and intrapleural injection of lincomycin. The pneumococcal 
isolate was sensitive to these antibiotics before starting the treatment. Kislak reported 
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similar findings in a pneumococcus isolated from the throat culture of a 10- year -old boy, 
who had received erythromycin and intramuscular lincomycin for treatment of otitis 
media, one and a half months before this isolation.135 Erythromycin resistance is 
common in strains showing multiple resistance.108 Although multiply- resistant 
pneumococci are usually characterised by resistance to beta lactam antibiotics in 
addition to other agents, several case studies reported strains that were susceptible to 
beta lactam antibiotics but resistant to erythromycin, tetracycline, clindamycin and 
cotrimoxazole.136 All three children in the report had a history of prior treatment with 
antibiotics to which the pneumococci were resistant. 
Cotrimoxazole (TMP -SMZ) resistance 
A strain of pneumococcus resistant to TMP -SMZ was first identified in 1972 from the 
sputum of a 58- year -old woman.137 Klugman et al. reported a pneumococcal strain 
resistant to this antibiotic isolated from a 20- month -old baby with bacteremic 
pneumonia, who received cotrimoxazole during the week before isolation of 
pneumococci.136 A few other studies also found an association of cotrimoxazole use 
with subsequent isolation of cotrimoxazole- resistant pneumococci. 138,139 Resistance to 
TMP -SMZ is associated with multiply -resistant strains isolated from carriers in 
hospital108 and also from the healthy children in the community. 
Tetracycline resistance 
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The emergence of tetracycline resistance in pneumococci in the 1960s parallels the 
widespread use of this antibiotic for the management of acute exacerbations of chronic 
bronchitis.105 The first case of tetracycline resistance was isolated from the CSF of a 10- 
month -old child in Australia in 1963;141 subsequently an outbreak of tetracycline- 
resistant pneumococci was detected in a general hospital in the United Kingdom.'42 
Five of the ten patients had received tetracycline before the isolation of the resistant 
strain and all of them either failed to respond to tetracycline or relapsed after temporary 
improvement. Pneumococcal resistance to tetracycline in Great Britain declined from 
12.6% in 1975 to 6.8% in 1976,165 which may reflect a reduction in the use of 
tetracycline in that country. Tetracycline use in the United Kingdom dropped from 14.5 
million prescriptions in 1969 to 10.1 million prescriptions in 1976.'43 
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Chloramphenicol resistance 
Chloramphenicol- resistant pneumococci were first identified in Poland in 1970.144 
Pneumococcal strains showing chloramphenicol resistance are usually resistant to other 
antibiotics, usually including tetracycline and often including penicillin 105 
Multiple resistance 
Multiple resistance is defined in various studies as resistance to at least three different 
groups of antibiotics.108 The first multiply- resistant strain was isolated from a three - 
year -old child in Johannesburg in 1977,108 who developed pneumonia following repair 
of a ventricular septal defect. The strain was resistant to penicillin G, erythromycin, 
clindamycin, tetracycline, chloramphenicol and cotrimoxazole. The child was treated 
with several courses of penicillin and cephalothin within a month of developing 
pneumonia. After the recognition of this multiply- resistant pneumococcus, isolate from 
the children and adult patients and from the staff personnel at the hospital were surveyed 
for resistant pneumococci. Among the 427 isolates from patients, 51 isolates were 
multiply -resistant. All carriers of multiply- resistant pneumococci were child patients 
under three years of age; most of them had received multiple antibiotics for diseases like 
pneumonia)" 
Although multiply- resistant pneumococcus was first isolated from South Africa, Spain 
was subsequently identified as an area with a high prevalence of multiply- resistant 
pneumococci.148 The isolation of these strains in both South Africa and Spain was 
associated with antibiotic use in hospitalised children. Isolation of multiply- resistant 
strains from a person in Britain following a vacation in Spain suggested the potential for 
spread of these strains.146 
2.4.4. Australian perspective of pneumococcal resistance 
The prevalence of antibiotic -resistant pneumococci is growing rapidly in Australia. 
Although pneumococcal resistance to penicillin has been reported more frequently than 
to other antibiotics, resistance to other antibiotics is also common, sometimes even 
higher than penicillin- resistance.4 
The level of penicillin -resistance among S. pneumoniae isolates rose from 1.7% in 1989 
to 6.7% in 1994 in Australia.' This rate of rise in penicillin -resistance in Australia is 
similar to that seen in Spain in the 1980s and the United States in the 1990s. In the 
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United States, penicillin- resistant isolates rapidly rose from 1.3% in 1992 to 25% in 
1995.100 However, the rate of penicillin -resistance in 1997 was more than 20 %.4 High - 
level penicillin- resistance in pneumococci in Australia increased from 0.7% in 19943 to 
8.6% in 1997.4 
The resistance rates to erythromycin have also been rising rapidly, an increase from 
10.8% in 19943 to 16.3% in 1997.4 The resistance rate to cotrimoxazole in Australia has 
been consistently high for several years, although it dropped slightly from 42% in 19943 
to 33.4% in 1997.4 Resistance to tetracyclines appears to have been steady over the 
period from 1994 to 1997.4 
2.4.5. Impact of antibiotic- resistance 
The consequences of antibiotic -resistance include increased health care costs for more 
expensive and powerful drugs, additional hospital days, and on rare occasions, 
death.147,148 Morbidity and mortality increase because of delay in effective therapy for 
specific infections, when resistance emerges to the drug of choice for that particular 
infection. Resistance may lead to inappropriate empirical treatment which may delay 
recovery in critically ill patients. Alternative drugs, if they exist, may be more toxic, 
less effective, or more expensive. Multidrug resistance may lead to some conditions 
becoming untreatable. For comparison of the effects of infections due to antibiotic - 
resistant bacteria with those of infections due to antibiotic -susceptible strains of the 
same bacteria, data were evaluated from 175 published and unpublished reports of 
investigations of both nosocomial and community -acquired infections with selected 
bacteria.149 For both nosocomial and community -acquired infections, the mortality, the 
likelihood of hospitalisation, and the length of hospital stay were usually at least twice 
as great for patients infected with drug- resistant strains as for those infected with drug - 
susceptible strains of the same bacteria. Poor outcomes could be attributed both to the 
expected effects of ineffective antimicrobial therapy, and to the unexpected occurrence 
of drug- resistant infections complicated by prior antimicrobial therapy for other medical 
problems.149 One of the most important consequences of antibiotic -resistance is that 
resistance can lead to an increase in the incidence of the disease. For example, a person 
infected with a multidrug- resistant tuberculosis who is not effectively treated may 
transmit the infection to others. 
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2.4.6. Confronting antibiotic- resistance 
Decreasing unnecessary antibiotic use where it is not indicated, and treating with 
narrow- spectrum drugs where possible with appropriate doses, could reduce this 
problem. However, this needs a group effort from physicians, patients, microbiologists, 
public health officials and pharmaceutical industries. The problem of antibiotic - 
resistance should be recognised by all sectors and action should be taken to increase 
awareness in the public. General practitioners acknowledge that a variety of factors 
influence their prescribing behaviour, which includes patient expectation, workload and 
questions of litigation.'50,151 There is a widespread misconception among the general 
public that antibiotics are relatively harmless and can be used in cases of doubt or `just 
in case'. Routine prescribing for a viral infection like head cold, chest cold, or sore 
throat increases the expectation of many patients that antibiotics are the only answers for 
these infections. A survey of patients' expectations concludes that patients do not 
usually see the doctor for antibiotics, rather they want a clear explanation and 
information about the disease.152 However, it is difficult to explain the disease course, 
prognosis and treatment within the short period of consultation. Thus, it may be well to 
shift our attention towards patient education, to empower parents with basic knowledge 
about respiratory infections, and when antibiotics might help in these infections. This 
will reduce the number of patient visits to medical practitioners. Physicians will feel 
more comfortable explaining the reasons for not prescribing antibiotics in situations 
where they are not indicated. Evidence -based clinical practice guidelines for consumers 
and physicians might be helpful to reduce the antibiotic overuse if actively promoted 
and implemented. This new strategy will hopefully reduce antibiotic misuse. 
Experts in Australia recommended some guidelines to reduce the prevalence of 
pneumococcal resistance by reducing inappropriate antibiotic prescribing in children.'" 
The guidelines suggest that antibiotics should only be used for specific treatment, not as 
long -term prophylaxis for otitis media or tonsillitis. They also suggest not treating 
children with antibiotics for- probable viral infections, including non -toxic febrile 
children without a focus of infection. If an antibiotic is indicated, a narrow -spectrum 
agent would be preferable. 
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2.5. Discussion 
The higher use of antibiotics in children may lead to higher incidence of carriage of 
antibiotic -resistant pneumococci among them. Most of the antibiotic use in children is 
undoubtedly for ARls. The question is whether antibiotics are of any help in ARIs in 
children. Many studies have evaluated the effectiveness of antibiotic use on particular 
types of ARI, for example, sinusitis, otitis media. However, an episode of ARI in 
children is difficult to categorise to an exclusive type, simply on the basis of clinical 
signs and symptoms. For example, an episode of ARI which consists of runny nose, 
fever and earache may simply be a cold episode or an episode of otitis media. Grouping 
this episode to either of the two categories might create a bias in evaluating an 
antibiotic's effectiveness. It might therefore be better to examine the effectiveness of an 
antibiotic by considering all episodes of ARI as a general category, while also 
categorising them on their degree of severity. 
There is enough evidence to suggest an association between antibiotic use and 
antibiotic -resistance. Most of the studies that have documented this association are 
observational studies which had the potential to suffer from recall bias. The participants 
in these studies were commonly asked if they received any antibiotic during a specified 
period, commonly within the previous one to three months. Therefore, the association 
suggested in most of the studies is not suggestive of an association between a specific 
antibiotic use and resistance to that antibiotic. There is also lack of evidence to suggest 
detailed aspects of the association. Usually the studies considered prior antibiotic use in 
children for a short period of time, which was usually one to three months. Therefore, 
the relation of antibiotic -resistance with previous use can only be suggested for a short 
period of time. Even in studies where data about antibiotic use were gathered for a 
longer period, information is lacking regarding the specific period during which 
antibiotics were actually used. As a result, the elapsed time period after antibiotic use 
up to the development of resistance is not clear. The studies also did not evaluate the 
required time period for the resistant organisms to become sensitive again. Moreover, 
no study has yet documented if the duration of antibiotic use, rather than simply any 
antibiotic use, has an effect on increasing antibiotic -resistance. Although there is a 
widely held view that broad -spectrum antibiotics are more likely than narrow -spectrum 
to increase resistance, no study has evaluated this association comprehensively. 
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Given the fact that antibiotic use in children is associated with carriage of antibiotic - 
resistant pneumococci and a major portion of antibiotic use in children is for ARIs, we 
need to know if antibiotic use offers a benefit for these infections. We also need to 
know if use of the antibiotics that are commonly prescribed to children, for example, 
beta lactam antibiotics, is associated with carriage of pneumococci resistant to those 
antibiotics. If there is an association, the amount of exposure needed to develop 
resistance is also important. We also need to know the dynamics of pneumococcal 
resistance, for example, time needed to develop resistance after exposure and time 
needed to return the resistance to baseline. My research hypothesis was developed to 
reduce the gap in the evidence that less use of beta lactam antibiotics in childrens' 
respiratory illnesses can reduce the level of penicillin- resistance in pneumococci without 
compromising clinical care. 
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Chapter 3 Methods 
3.1. Overview 
A randomised controlled trial (RCT) of clinical practice guidelines for respiratory 
infections was conducted in the Australian Capital Territory (ACT), during the period 
September 1997 to November 1999. This study was part of that trial in which I 
followed all of the study participants as a cohort for 25 months from September 1997 to 
September 1999. The overall aim of the trial was to determine if development of 
clinical practice guidelines (CPGs) for acute respiratory infections could reduce the 
injudicious use of antibiotics in children. The impact of this intervention is the subject 
of another thesis by Eileen Wilson. The trial was conducted in a general practice setting 
involving general practitioners (GPs) and their patients under the age of two years. GPs 
were recruited and randomly allocated to the early -intervention or the late -intervention 
group for the purpose of the trial. Children were subsequently recruited by their GPs 
and were allocated to either of the two groups according to the intervention group status 
of their GPs. Surveillance of respiratory illness in children was conducted by a daily 
diary recorded by their parents throughout the trial. Antibiotic- resistance in 
pneumococci was monitored by collecting four nasal swabs from the children during the 
study. In this thesis I examine the impact of antibiotic use on respiratory symptoms 
from the parental diary and pneumococcal resistance in nasal swab isolates. 
40 
3.2. Study population 
General practitioners and their child patients constituted the study population. General 
practice is the first point of medical care for any disease; therefore, GP participation was 
essential to implement guidelines in clinical practice. 
We used three eligibility criteria for recruitment of children in the trial. First, children 
must have been under two years of age at 1 September 1997 and then would be followed 
for another 27 months. We selected this age group on the basis of evidence that 
children under five years of age have a higher rate of respiratory infections than older 
children.153 Therefore, we expected a higher number of respiratory episodes from these 
children, which would provide an adequate sample for us to answer the research 
questions. Secondly, we did not include a child if the parent did not consider the study 
GP as a regular GP for that child. The reason for selecting this criterion was to measure 
the effect of guidelines on antibiotic prescribing which would be implemented through 
the study GP. Thirdly, only one child from a family was considered eligible for the 
study. By including only one child from a family, we could avoid the influence of 
family cluster on the child's independence. 
3.2.1. Sample size estimation 
The project was primarily designed to detect the effect of clinical practice guidelines 
(CPGs) on antibiotic use for respiratory infections in children. Thus, for estimate of the 
required sample size, the outcome of interest was days of antibiotic use by children for 
respiratory infections. To determine the required sample for the study, we accounted for 
the following: the anticipated rate of respiratory episodes in children; the anticipated 
days of antibiotic use for respiratory infections in children; the anticipated effect of the 
intervention; and the impact of the cluster design. 
Rate of respiratory episodes in children 
The average Australian child under five years of age experiences five to eight 
respiratory infections in a year.14 The rate is even higher for younger children. For the 
purpose of sample size estimation, we anticipated a rate of a minimum five episodes of 
acute respiratory infection for a child per year. 
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Number of days of antibiotics 
About 60% of all acute respiratory infections in children are treated with an antibiotic., 
With an average of five days per antibiotic course for 60% of the five respiratory 
episodes per child -year, we anticipated a minimum 15 days of antibiotic use in children 
per year for acute respiratory infections. 
Effect of intervention 
There was no existing evidence which detected an effect of an intervention on antibiotic 
use. In the absence of evidence, a 20% reduction of antibiotic use was considered 
clinically worthy of detection. For example, a 20% reduction of 15 days would be 12 
days per year of antibiotic use by a child. 
Effect of cluster 
Children were allocated either to the early -intervention or to the late -intervention group 
depending on their GPs' group status. This, then, was a cluster design; each cluster 
being a GP; intervention was implemented through the GPs. For this cluster design, the 
effect of guidelines on the antibiotic use in a child would provide less information than 
if randomisation was done by individual children. As a consequence of this cluster 
design, the outcome of each child cannot be valued as statistically independent. The 
variation in antibiotic use would be greater among the children cared for by different 
GPs than it would be among children cared for by the same doctor. In the presence of 
variation among the GPs, the variance would be different in children between the 
clusters. For sample size estimation, we anticipated a reasonable variance as 0.5 and a 
maximum variance as 1.5 between the clusters. The variance of 0.5 means 50% 
overdispersion as proportional increase in variance between clusters of children. The 
sample size was calculated in a Poisson distribution model allowing for a cluster effect. 
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Table 3.1: Estimated sample size for detecting a 20% reduction of antibiotic use 
in acute respiratory infections in children allowing for cluster design 
Variance GPs Children Power 
0.5 20 15 92 
1 20 15 67 
1.5 20 15 50 
If the GPs are not very different in antibiotic prescribing, a sample size of 20 GPs and 
300 (15 /GP) children in each group would be sufficient to detect a 20% difference in 
antibiotic use for respiratory infections in children, with 80% power at an a level of 
0.05. But if there is a massive difference between GPs' prescribing, the sample size 
would not be sufficient; however, this seemed unduly pessimistic. 
Final target sample 
According to the calculation and with an anticipation of reasonable variance in GP 
prescribing, we decided for a target sample of 40 GPs and 600 children for the study. 
3.2.2. Sample frame 
We obtained two lists of general practices in the ACT, one from the Department of 
Health and Community Care (DHCC, which is currently known as Department of 
Health and Aged Care) and the other from the Division of General Practice (DGP). The 
list obtained from the DHCC consisted of the only practices in the ACT that 
administered immunisation for children. This list contained names and addresses of the 
practices, but it did not have the names of GPs working in the practices. On the other 
hand, the list from the DGP contained the name, address and phone number of their 
member GPs. We compiled a new list by manually matching the names of GPs'with the 
names of practices based on addresses mentioned in both lists. The new list was cross- 
checked with the 1997 telephone directory. We then removed the practices from the 
new list that were not dealing with paediatric patients, such as sports medicine, 
University health centres and geriatric practices. One hundred and twelve practices 
remained in the list containing 265 GPs' names, which constituted the sample frame. 
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The practices were then stratified into solo, small (2 -4 GPs) and large (more than 4 GPs) 
practices according to the number of GPs practising (Table 3.2). We planned to 
approach one GP from each practice to avoid contamination of information regarding 
intervention between the early and the late -intervention group. We anticipated that 
information could be disseminated between the GPs and the patients of the two groups 
if more than one GP was recruited from the same practice, but allocated to different 
groups. From a group practice, we randomly selected one GP within the practice by 
using a random number table. Thus, 112 GPS were identified for potential recruitment. 
Table 3.2: List of general practices in the ACT 
Type of practice No. of practices No. of GPs % of total GPs 
Solo 41 41 15.5 
Small 60 158 59.6 
Large 11 66 24.9 
Total 112 265 100 
3.3. Recruitment of study participants 
3.3.1. Recruitment of general practitioners 
GP recruitment commenced at the end of August 1997. There were three steps in this 
process. A letter was sent to each of the 112 randomly selected GPs describing an 
overview of the study. Every GP was then phoned by the chief investigator of the 
project (RMD) to further describe the purpose of the research and to seek their 
involvement in the study. If the GP expressed an interest, one of the researchers (DN, 
EJW) visited the practice. During the visit, the researcher explained in detail the design 
of the study and their required, involvement and also the involvement required from their 
patients. GPs who agreed to participate in the study signed a consent form at that 
meeting and were provided a study entry questionnaire (Appendix 3). They were then 
assigned a random number that classified them either in the early or in the late - 
intervention group. We developed a computer generated randomisation plan with a 
block size of ten, which had five zeroes and five ones. We used those numbers to assign 
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the GPs in either group: zero for the early- intervention and one for the late -intervention 
group. By the first week of November 1997, we completed the recruitment process for 
all the GPs contained in the list. However, the number of GPs recruited did not attain 
the target sample size number. Thus, we started a secondary recruitment in March 1998. 
We identified eleven GPs from the practices where another GP had been approached 
before, but had refused to be involved in the study. We repeated the same three steps as 
performed for the primary recruitment. Although during the recruitment process GPs 
knew that they could be assigned to either of the two groups, their actual group status 
was not disclosed to them untill after completing full GP recruitment. 
The primary recruitment of GPs was performed between August 1997 and November 
1997 and the secondary recruitment during March 1998. 
3.3.2. Recruitment of parents and children 
Recruitment of parents and children commenced in association with recruitment of GPs. 
At the time of recruitment, we asked each GP to recruit 15 patients from the practice 
who were under the age of two years at 1 September 1997. During the GP visit, we also 
visited the attending receptionists. We explained to them the design of the trial and 
sought their help in the recruitment of parents and children. We delivered child 
recruitment sheets and project information sheets to the receptionists(Appendix 3). 
When a child of under two years visited the GP, the receptionist would attach a 
recruitment sheet and an information sheet with the case note. During the consultation, 
the GP would explain briefly the trial and his or her involvement in the trial to the 
parent. If a parent agreed the GP would immediately send the name and telephone 
number of the parents to the researchers by fax or post. One of the researchers (EJW, 
DN) then contacted the parent by telephone and confirmed that the child met the 
eligibility criteria. If the child was eligible to participate, we explained the required 
involvement of the parent and the child for the project. If the parent expressed an 
interest in receiving more information about the project, we sent a package to the parent 
which contained a consent form, a study entry questionnaire, a diary for the first month 
and a refrigerator magnet with the ARIC study logo to secure the diary in a noticeable 
place (Appendix 3). A sample diary and an instruction sheet were also included in the 
first package to help the parent in filling out the diary (Appendix 3). Children were 
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automatically assigned to the early or late -intervention group according to the group 
status of their GPs. The GPs continued the recruitment process unless we asked them to 
stop recruitment after 15 parents agreed to participate. 
Recruitment of children continued from September 1997 to April 1998. 
3.4. Intervention by clinical practice guidelines (CPGs) 
3.4.1. Objective 
The objective of the intervention was to reduce antibiotic use for acute respiratory 
infections in children. 
3.4.2. Development of CPGs 
The GPs and a group of parents from the early- intervention group were actively 
involved in the development of clinical practice guidelines. The process of 
development of CPGs began with a parent focus group in November 1997. Information 
from the parent focus group was subsequently presented to a meeting with GPs. After 
six interactive sessions with GPs and parents, the clinical practice guidelines for parents 
and GPs were developed in April 1998 (Appendix 3). 
3.4.3. Implementation of intervention 
During May 1998, we provided clinical practice guidelines to all the GPs and parents of 
the early -intervention group. The guidelines were introduced to the participants of the 
late -intervention group in February 1999. 
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3.5. Data collection 
Data collection commenced with recruitment of the study participants. GPs and parents 
filled in a study entry questionnaire at the time of recruitment. This questionnaire 
provided information about the demographic details of the participants as well as past 
experience of participants in caring for ARI in children. A daily respiratory diary was 
employed to collect data on respiratory infections and treatment in children. These 
diaries were recorded by the parents and returned to us every month, which allowed us a 
prospective data collection. A nasal swab was collected from the children four times 
during the study to monitor the pneumococcal carriage and pneumococcal resistance to 
antibiotics. 
3.5.1. GP questionnaire 
The GP questionnaire was developed using a range of sources including a questionnaire 
previously used in a study in Adelaide (personal communication with RMD). The 
modified questionnaire was divided into four sections (Appendix 3): 
Section A: socio- demographic information about the GP. 
Section B: information regarding medical practice and involvement in different medical 
associations. 
Section C: information regarding clinical practice in treating acute respiratory 
infections. 
Section D: attitudes of GP towards clinical practice guidelines. 
3.5.2. Parent questionnaire 
The parent questionnaire was developed on the basis of the questionnaire used in a 
previous study in Adelaide (personal communication with RMD). This questionnaire 
was divided three sections (Appendix 3): 
Section A: socio- demographic information about the child. 
Section B: management of acute respiratory infections by the parent. 
Part C: parents' satisfaction with GP visit for their child. 
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3.5.3. Respiratory diary 
We developed a respiratory diary in a monthly calendar format, which was similar to the 
diary used by Roberts.154 Parents were supplied with an example -filled diary in the 
recruitment package to help them in properly recording the daily diary. The diary 
allowed parents to record symptoms of respiratory infections in children and treatment 
use by the children (Appendix 3). 
3.6. Outcome 
3.6.1. Surveillance of respiratory illness and its management 
Data from the respiratory diary were used for surveillance of respiratory illnesses and 
management of the illnesses. In the diary, parents recorded symptoms of respiratory 
illness and details of management of illness including antibiotic use and health service 
utilisation. At the end of each month they sent the diary back to the research office. To 
obtain the best possible data, we immediately checked the information on receipt. If we 
found any incomplete information in a diary, we rang the parent for clarification. In the 
middle of each month, a research assistant rang the parents who did not send diaries for 
the previous month. Sometimes she also completed diaries over the telephone for the 
parents who were unable to fill the diary for a month. 
Data derived from the respiratory diaries were: 
1. Symptoms of respiratory illness including runny nose, blocked nose, green nasal 
discharge, dry cough, moist cough, wheeze, sore throat, hoarse voice, earache, ear 
discharge, fever and cold. 
2. Health service utilisation including doctor or hospital visit, hospital admission with 
the reason. 
3. Medication used including duration of use. 
4. Any other illness. 
On the basis of parents' reporting of a respiratory illness I defined a respiratory episode. 
An episode was defined as the occurrence of at least two consecutive days of any of the 
12 symptoms: runny nose, blocked nose, green nasal discharge, dry cough, moist cough, 
wheeze, sore throat, hoarse voice, earache, ear discharge, fever and cold. The end of an 
episode was defined as the occurrence of at least two symptom -free days. This approach 
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to definition of a respiratory episode has previously been used by Samet et al. in a study 
of nitrogen dioxide and respiratory illness in infants.155 Samet used five symptoms to 
define a respiratory episode which included runny or stuffy nose, dry cough, wet cough, 
wheeze or trouble breathing. I included another five symptoms and signs (green 
discharge, earache, ear discharge, sore throat, hoarse voice) to define an episode because 
of their frequent occurrence in children in association with respiratory illnesses. 
3.6.2. Surveillance of pneumococcal carriage and antibiotic - 
resistance in pneumococci 
We collected a nasal swab from each child four times during the 25 months of the study 
period to determine the carriage rate of pneumococci and to monitor the level of 
antibiotic -resistance to pneumococci. To monitor the change of carriage and resistance 
over the study period, we planned to collect two swabs per year for the two years of the 
study at approximately the same seasonal period. Thus, the first and third set of nasal 
swabs were collected during autumn (March and April) 1998 and 1999 respectively and 
the second and fourth swabs were collected during winter (August and September) 1998 
and 1999 respectively. These particular periods were chosen to determine the carriage 
rate of pneumococcus before and after winter, as it was expected that children would 
have more respiratory episodes and more antibiotic prescriptions during winter. The 
procedure of the nasal swab collection is detailed in the appendix 3. 
Laboratory procedure 
The laboratory procedures were undertaken in the Canberra Hospital Microbiology 
Department. Collected specimens were immediately inoculated onto blood agar plates 
and incubated for 18 -24 hours at 35 degrees in an atmosphere with added 5% CO2. The 
media used were standard horse blood agar (HBA), standard horse blood agar with 
added 5 mg /L gentamicin (HBAG) and Mueller Hinton agar with 5% defibrinated sheep 
blood (MHASB). The media were prepared according to the National Committee for 
Clinical Laboratory Standards (NCCLS) guidelines. 
Isolation of Pneumococci: The medium used in the primary plates was HBAG. 
Suspicious colonies were selected from the primary plates and subcultured onto HBA 
for pure growth, with an optochin disc placed between the first and second streak lines 
in order to detect pneumococci. These subcultured plates were incubated for 18 -24 
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hours at 35 degrees C in an atmosphere with added 5% CO2. Suspicious colonies were 
those with the typical morphology of pneumococcus on blood agar. Small 
pneumococcal colonies are smooth, _transparent and low convex while larger colonies 
become flattened or depressed centrally, showing the `draughtsman form'. A partial 
clearing of blood and a greenish discolouration (a haemolysis) was produced 
underneath and in a narrow zone around the colonies. Primary plates with no suspicious 
colonies were also re- incubated in the same environment for the same duration. Isolates 
from secondary plates, which showed typical morphology of pneumococci and were 
sensitive to optochin, were frozen and stored for sensitivity testing by using Protect 
Beads. Organisms which showed atypical morphology and were resistant to optochin 
disc were discarded. Primary plates which developed suspicious colonies after 48 hours 
were subcultured for purity on HBA with an optochin disc and were incubated for 
reading the next day. The rest of the primary plates were discarded. On the third day, if 
the secondary plates showed typical morphology and sensitivity to optochin, those were 
stored with Protect Beads. Colonies which showed typical morphology, but resistance 
to optochin, were further tested by bile solubility test. Only the predominant colony of 
each isolate was tested for sensitivity to antibiotics. 
Sensitivity testing: Sensitivity testing was performed on isolates shown to be S. 
pneumoniae. One predominant colony for each isolate was selected to test. The 
following antibiotics were chosen for disc susceptibility testing: oxacillin, erythromycin, 
cotrimoxazole, tetracycline, chloramphenicol and cefotaxime. Susceptibility testing was 
performed on Mueller Hinton Agar with 5% defibrinated sheep blood (MHASB) and 
according to the National Committee for Clinical Laboratory Standards (NCCLS) 
guidelines. Plates were predried in air at 35 degrees C for 20 -30 minutes before use. A 
bacterial suspension was prepared from the culture plates into Mueller Hinton broth or 
0.9% saline, at a turbidity equivalent to a 0.5 McFarland standard. Plates were 
inoculated with bacterial suspension within 15 minutes of adjustment. A sterile swab 
was then dipped into the suspension, squeezed against the side of the tube to get rid of 
excess inoculum, then swabbed over the surface of the plate, making sure all sides of the 
swab touched all parts of the plates. After allowing the swabbed plate five minutes to 
dry, discs were placed on the plates. According to NCCLS guidelines, a maximum of 
four discs were placed on a 100 mm plate. Discs were pressed down onto the agar 
surface to ensure complete contact. Plates were inverted and incubated within 15 
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minutes of disc placement. Laboratory reference strains S. pneumoniae ATCC 49619 
and Staphylococcus aureus ATCC 25923 were used as controls. 
Minimum inhibitory concentrations (MICs) for penicillin and erythromycin by E- strips 
were also tested for each isolate. Sensitivity to cefotaxime was also tested using E- 
strips, but only for the isolates that were resistant to penicillin. The E -test consisted of 
strips, which were impregnated with gradients of varying antibiotics. The Minimum 
Inhibitory Concentration (MIC) was read where the `inhibition ellipse' intersected the 
scale of the strip and was always at the point of complete inhibition of growth. 
Interpretation of the ellipse was as follows: 
If the ellipse came into the scale between dilutions, the upper dilution was read as the 
MIC. 
If the ellipse came in unevenly at different intersections, the upper dilution was taken as 
the MIC. 
If there was any macro colony present, the MIC was read where it was completely 
inhibited on the scale. 
If there was a double zone, the higher dilution was taken as the MIC. 
If the ellipse suddenly dropped off near the strip, the MIC was determined by reading 
through the curve of the ellipse. 
Interpretation of sensitivity test 
The MIC breakpoints published by NCCLS Guidelines were used to define the isolate as 
sensitive to penicillin when minimal inhibitory concentration (MIC) was less than or 
equal to 0.064 mg/L, intermediate resistant when MIC was greater than 0.064 mg /L but 
less than or equal to 1 mg/L, and highly resistant when MIC was greater than 1 mg/L. 
All isolates were tested for cefotaxime susceptibility with a 30 lag disc and only the 
penicillin- resistant isolates were tested with an E -strip for cefotaxime MIC. 
Antibiotic- resistance was categorised as either intermediate or high level resistance. 
Multi -drug resistance was defined as the presence of intermediate or high level 
resistance to two or more antibiotics. 
The following table was made from NCCLS tables 2C, 3 and 3C; it was used for 
determining sensitivity patterns of S. pneumoniae, along with quality -control values. 
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Table 3.3: Zone sizes for antibiotics tested against S. pneumoniae 
Antibiotic Disc content 
(µg) R 
Zone diameter 
I S 
ATCC 
49619 
Zone 
ATCC 
25923 
Zone 
Cefotaxime 30 25 -31 
Chloramphenicol 30 < 20 >_ 21 23 -27 19 -26 
Cotrimoxazole 1.25/23.75 <_ 15 16 -18 > 19 22 -27 24 -32 
Erythromycin 15 <_ 15 16 -20 >_ 21 25 -30 22 -30 
Oxacillin 1 >_ 20 24 -30 18 -24 
Tetracycline 30 <_ 18 19 -22 >_ 23 27 -31 24 -30 
There were no data for cefotaxime as third -generation cephalosporins are usually 
extrapolated from oxacillin zone size and penicillin MIC value. 
Table 3.4: MIC values for S. pneumoniae against erythromycin and penicillin 
(NCCLS tables 2C and 3C) 
Antibiotic MIC (µg/ml) ATCC 49619 
S I R Range 
Erythromycin <_ 0.25 0.5 >_ 1.0 0.03 -0.12 
Penicillin < 0.06 0.12 -1.0 >_ 2 0.25 -1.0 
3.7. Data management 
A database was established in Microsoft Access software. The database contained fields 
for the diary, questionnaire, and tracking forms to track every datum received from the 
participants. Each time we received a diary the date was immediately noted in the 
tracking form of the database. After the end of each month we made a list of the parents 
who did not send the diary of that month. We recruited a research assistant who 
reminded the parents at the middle of the following month to send the diary at the 
earliest possible time. 
Every month we sent birthday cards to the children whose birthdays were in that month 
(Appendix 3). It seemed encouraging to the parents, as sometimes parents reminded us 
in the diary that the next particular date was the child's birthday. We also sent seasons' 
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greetings and Christmas wishes to the children and parents. We sent regular newsletters 
to parents and GPs informing them of different aspects of the study (Appendix 3). 
During each set of nasal swab collections, a research assistant and I rang every parent to 
remind them on the evening before the date of swab collection. During that telephone 
reminder we also asked parents about any confusion or any problem regarding the study. 
That conversation helped both parents and researchers to know each other and also 
helped parents to feel involved in the study; it also helped us to track the changes of 
address and telephone number for parents. 
Most of the data were entered into the database by a professional data -entry firm and 
data about nasal swab collections were entered into Excel 4 by a research assistant in 
Canberra Hospital Pathology. 
3.8. Analysis 
I exported data from Microsoft Access to SPSS by using Excel -4. I then performed 
descriptive analysis by using SPSS 7.5 for Windows. However, for multivariate 
analysis, I transported the data from SPSS to Stata by using Stata transfer. I created 
graphs using Microsoft Excel. 
3.8.1. Respiratory illness and antibiotic use 
Crude rates were calculated for respiratory symptoms, respiratory episodes and 
antibiotic use for all children. Total observation days for a child in the study were used 
as a denominator in defining the rate. The period of observation for children was based 
on the daily diary returned by parents. In fact, the day of diary record was taken as the 
day of observation for a child. 
An episode was defined as the occurrence of at least two consecutive days of any of the 
12 reported symptoms in the diary; the end of an episode was defined as the occurrence 
of at least two symptom -free days. Duration of an episode was calculated from the 
onset of symptoms to the last day on which symptoms occurred before the occurrence of 
two symptom -free days. 
The 12 symptoms and signs were grouped into four major groups depending on their 
association with the specific illnesses: ear symptoms, throat symptoms, lower 
respiratory and upper respiratory symptoms. Ear symptoms included earache and ear 
discharge; throat symptoms were sore throat and hoarse voice. Moist cough and wheeze 
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constituted lower respiratory symptoms and runny nose, blocked nose, green nasal 
discharge, dry cough and `cold' were included as upper respiratory symptoms. 
The episodes were classified into five types depending on the type of symptoms present 
in the episode. The types were: ear episode, throat episode, lower respiratory, upper 
respiratory and fever episodes. 
The rate of a specific symptom for a child was calculated by dividing the total number 
of days of that symptom in the children by the total number of days of observation for 
children in a year. The episode rate, the rate of total and each specific antibiotic use 
were also calculated in the same way. 
I used multivariate modelling in Stata to test the effect of antibiotic use on the severity 
of respiratory episodes. The outcome of severity was measured as the average number 
of symptoms per day from the point of doctor visit up to the end of the episode. The 
data used for this variable were continuous -type. I anticipated that the episode of a child 
might not be independent of other episodes in the same child; I therefore used a random 
effect linear regression model that allowed adjustment for the impact of clustering 
within child. My goal was to obtain a valid estimate of the effect of exposure to 
antibiotic use on the severity of respiratory episodes after controlling for potentially 
confounding factors. I followed the stages to develop a multivariate model suggested by 
Kleinbaum, where the stages are variable specification, interaction assessment and 
assessment of confounding.156 
Variable specification 
I selected potentially confounding variables that could be biologically associated with 
respiratory illness or that had been shown in previous studies to be related to respiratory 
illness. As the severity was measured from symptoms reported by the parents, I also 
considered the factors that could influence parents' reporting of severity. The variables 
were selected from the diaries and the questionnaires completed by parents and GPs. 
The details of the modelling strategy and the final model accepted are provided in 
Chapter 7. 
Adjustment for clustering 
The episodes experienced by the same child cannot be regarded as independent 
regarding the severity of illness. By using a random effect linear regression model I 
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made a robust estimate of coefficient and standard errors. The robust estimator relaxes 
the assumption of independence of the observations by producing corrected standard 
errors for correlated observations within child. 
The command I used in STATA for linear regression to determine the effect of single 
exposure of antibiotic use on the severity of respiratory episode was: 
regress severity antibiotic, cl(idno) 
severity = logarithm of average number of symptoms per day after the doctor visit up to 
the end of the episode 
antibiotic = episode associated with antibiotic use 
cl(idno)= clustered by child identification number (adjust for multiple episodes from the 
same child) 
3.8.2. Antibiotic- resistance and antibiotic use 
Pneumococcal carriage was monitored in children by collecting a nasal swab four times 
during the 25 months of study as described above. The descriptive analysis of 
pneumococcal carriage and resistance to six antibiotics during four collections is 
presented in Chapter 5. 
To detect the effect of antibiotic use on antibiotic -resistance, I limited my analysis to 
beta lactam antibiotic use and its effect on penicillin- resistance in pneumococci. I 
analysed the data using a multiple logistic regression model in Stata that adjusted for 
cluster effect within child. I started modelling with specification of the variables, 
followed by interaction assessment and completed with confounding assessment. The 
details of the modelling strategy and the final model are presented in Chapter 6. 
3.9. Ethics 
The Ethics Committee of the Australian National University approved the trial. Nasal 
swab collection was approved separately by the Ethics in Human Experimentation 
Committee. We informed the GPs and the parents of the children about the details of 
the trial by providing an information sheet at recruitment (Appendix 3). Written consent 
was obtained from each of them during recruitment (Appendix 3). In the consent form, 
it was made clear to the participants that they would be free to withdraw at any stage of 
the study and the information about them would be kept confidential. Confidentiality 
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was maintained by using a unique identification numbering system for each child and 
each GP. 
3.10. Pilot studies 
We did not pilot the diary and the questionnaires used in the study as they had been used 
in previous studies. 
3.10.1. Piloting the process of intervention 
During June 1997, we arranged a meeting with a group of GPs and a meeting with a 
group of parents to pilot the process of intervention. The pilot studies are described by 
Eileen Wilson in her thesis. 
3.10.2. Piloting nasal swab collection 
In March 1998, the surgery of a study GP was used as a pilot site for nasal swab 
collections from children. The objective was to test the swab stick, agar plate and 
collection technique. A total of nine child patients of that GP and their parents 
participated in this pilot. Three research assistants were involved in swab collection. 
They were practically taught the procedure of swab collection and the process of 
inoculation on agar plate by a laboratory scientist from Canberra Hospital Pathology. 
The swab collectors alternately collected a swab. The swabs collected by each collector 
were kept separated. 
The procedure of swab collection and the size of swab stick seemed quite acceptable to 
the children, as well as to their parents. A pneumococcus was isolated from 30% of the 
swabs as was expected, which proved that the agar plates were satisfactory. There was 
no difference of result among the swabs collected by three collectors. 
3.11. Discussion 
Although my part of the project treated the children as a prospective cohort, the study 
was also designed as a randomised controlled trial, which itself minimised a number of 
potential problems associated with other study designs. We considered the impact of 
clustering in sample size calculation and also in methods of analysis. The process of 
random selection of the GPs was designed to maximise generalisability and was also 
intended to eliminate the chance of contamination of information between two 
intervention groups. Although this would not create a problem for the pneumococcal 
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resistance study, it could have resulted in a reporting bias by parents, which would 
definitely affect the analysis of severity of respiratory illness in the cohort. 
Loss to follow -up is the biggest problem for any study of such long duration. We 
undertook a number of strategies to maintain a good participation rate as outlined above. 
A research assistant rang the parents every month to remind them about the previous 
month's diary. She also filled in diaries for the parents who claimed not to have 
received a diary for that month or failed for some other reason to return the diary. We 
regularly sent birthday cards for children, and seasonal greetings to the children and the 
parents. We also sent regular newsletters to the parents informing them of the progress 
of the study and expressing appreciation of their enthusiastic participation. A reminder 
call before each swab collection also helped in enhancing a sense of involvement in the 
parents to the study. 
We also sent regular newsletters to the GPs informing them of different aspects and 
progress of the study, and posted them the most current evidence -based information 
regarding the management of ARIs in children. Information regarding antibiotic - 
resistance from international conferences was also part of the newsletters. 
The study design had a few limitations. 
Limitations in GP recruitment: The majority of the study GPs (58/63) were recruited 
strictly by a random process in primary recruitment, which we could not maintain during 
secondary recruitment. During primary recruitment, we approached only one GP from a 
practice in the sample frame. We anticipated that 15 children would easily be recruited 
by each GP within two months. Although some of the GPs could recruit 15 children in 
a week, in reality most of the GPs were not able to recruit even half of the expected 
number of children even after six months in the study. At this stage, we thought about 
the feasibility of recruiting more children from the GPs who completed recruitment first. 
However, because of the GP- cluster effect, even a large number of children from one 
GP would not have greatly enhanced the power of the RCT part of the study. We 
therefore decided to approach some more GPs, which would be likely to increase the 
power by increasing clusters as well as the total number of children. However, during 
primary recruitment, we had approached one GP from each of the practices in the 
sample frame. We therefore selected a few additional names of GPs from the list of 
practices. These selected GPs were practising in group practices where another GP had 
57 
been approached before, but where that GP had declined to participate. This subset of 
additional GP recruitment could lead to selection bias of the GP sample. However, as 
with the primary group, we randomly allocated them to the early or late -intervention 
group. 
Problems in child recruitment: The recruitment of children took much longer than 
anticipated. We expected two weeks to be enough time to recruit 15 children from a 
GP's surgery. However, even after repeated reminders and encouragement from us, it 
took several months for most of the GPs to recruit even half of the children. One of the 
reasons for this slow recruitment was the timing of recruitment. We started recruitment 
of study participants in late September, when rates of colds and coughs are declining. 
These symptoms are usually the main reasons for GP visits for children. 
Apart from that, even after we provided a written recruitment protocol and several 
reminders, a few GPs misunderstood the first step of the recruitment process. They 
approached only the children who visited them for some sort of respiratory infection. 
During the Christmas and summer holiday in December -January 1998, the recruitment 
became even slower; it was very difficult to contact parents during that period. At that 
point, the number of recruited children was far below the estimated target. We sent a 
letter to all study GPs asking them to continue to recruit more patients over the next two 
months. A few GPs asked if they could select children from their patient lists rather 
than waiting for children to visit surgeries, which seemed to be the easier and quicker 
way to recruit the required children. We agreed with them at that point and offered the 
same strategy to other GPs as well. We also offered assistance in selecting patients 
from the list. During March 1998, the number of children increased because a good 
number of children were recruited by the secondary recruitment of GPs. It took the 
general practitioners eight months to recruit 502 children in the study, whereas we had 
hoped to get 600 children within the first few weeks. 
The prolonged recruitment also partly resulted from the workload in general practice. 
GPs were asked to approach the parents of every child under two years of age, who 
came to visit them. In reality, GPs did not always maintain the recommended criteria 
for children recruitment. A few GPs selected patients from their practice lists rather 
than approaching all subsequent eligible patients in the surgery. GPs might have 
selected parents whom they considered competent to maintain diaries for a long study 
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period. GPs also excluded parents who could not speak English well, as they 
anticipated problems in recording diaries. This eliminated an opportunity to see whether 
a cultural difference could make a difference in management of respiratory infections. 
We also received some names from GPs of children who were not their regular patients. 
We could control this problem by asking parents whether they considered the GP as the 
child's regular GP. Overall, the selection of children probably resulted in a bias in the 
sample, as we observed a social and educational profile of the families in the study 
compared to average Australian families. 
In retrospect, I think it would have been easier and quicker to recruit the sample if the 
receptionists had been given the primary responsibility, to attach the recruitment sheet to 
the case history of each successive eligible child. Alternatively, a research assistant 
could have been involved with each GP for a certain period to establish adequate 
recruitment. We were dependent however on the goodwill of GPs, who were somewhat 
idiosyncratic in their approach to recruitment. 
The setting of the study itself introduced some limitations. The people of the ACT are 
different from average Australians in respect to their higher level of education and 
income. Higher socio- economic status might influence the incidence of illness, health 
care utilisation and antibiotic use. Most of the children in the study were in families 
where both parents were working: this might affect their management strategy for 
children's respiratory infection. The GPs in the ACT are frequently involved in research 
which could result in a difference in their treatment strategy from their counterparts in 
other parts of Australia. 
3.11.1. Effect of the limitations on the issues explored in this thesis 
We would have preferred a fully random sample of GPs and patients for this project. 
Lack of randomness could compromise the generalisability to the Australian population 
as a whole of the findings. Nevertheless the questions that are explored in this study 
remain relevant and pertinent to the recruited population and the growing body of 
knowledge on the issue of antibiotic use in the Australian population. 
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Chapter 4 Results: The cohort 
4.1. Overview 
This chapter describes the details of the enrolment process and the baseline 
characteristics of study participants. General practitioners (GPs) and a group of children 
from their practices participated in the study. The characteristics of the study 
participants are based on the analysis of study entry questionnaires completed by the 
GPs and parents at recruitment. I also describe the dynamics of the cohort with the rate 
of diary return for every month, and loss to follow -up. 
4.2. Recruitment of study participants 
4.2.1. GP recruitment 
Recruitment of GPs took six months, from September 1997 to February 1998. Details 
of the recruitment procedure were described in Chapter 3. Of the 112 eligible GPs from 
the original list, seven GPs were not able to be contacted at the address given. We 
contacted 11 more GPs at the later stage of recruitment. Thus we approached a total of 
116 GPs from the ACT, and 63 (54 %) participated. The results of GP recruitment are 
shown in Figure 4.1. 
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Figure 4.1: GP recruitment 
A. Primary recruitment 
B. Secondary recruitment 
112 GPs -eligible for 
potential recruitment 
105- contacted 
72- agreed to 
meet 
58- accepted 
to participate 
11- contacted 
7-not 
contactable 
33- refused 
to meet 
14- declined 
6- declined 
5- accepted 
63 -total GPs 
recruited for 
the trial 
We randomly allocated 3.1 GPs to the early- intervention group and 32 GPs to the late - 
intervention group. 
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4.2.2. Recruitment of children 
Recruitment of children was conducted from September 1997 to April 1998. We 
received a total of 728 recruitment forms back from the GPs with the name and contact 
number of the parents: 697 were considered eligible by the GPs. The eligibility criteria 
of children have been described in Chapter 3. Of the 697 parents, we could not contact 
12 because of disconnected or wrong telephone numbers. Parents of a total of 592/697 
(86 %) children agreed to participate in this trial (Figure 4.2). 
Figure 4.2: Recruitment of study children 
697 -considered 
eligible by GP 
685- contacted 
12-not 
contactable 
592- agreed to receive a 
recruitment package 
300 -early 
intervention 
group 
292 -late 
intervention 
group 
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Rate of recruitment of children per month 
Recruitment of children began in September 1997 and continued to April 1998. During 
the Christmas and New Year holiday in December1997 and January 1998, the 
recruitment process was very slow because of unavailability of the parents. At that time 
the number of recruited children was far below the estimated target. At that time, we 
sent a letter to all study GPs asking them to recruit more patients within a month or two. 
We also offered assistance in the recruitment process by providing a research assistant 
for the surgery if needed. During March 1998, the recruitment rate improved because of 
the large number of patients recruited by the second recruitment of GPs. The whole 
process of recruitment was completed by the first week of April 1998. 
Figure 4.3: Number of children recruited per month, September 1997 -April 1998 
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4.3. Non -participants 
4.3.1. Reasons for non -participation of GPs 
It was difficult to determine the reason for non -participation of the 33 GPs who refused 
to be contacted by a researcher. Twenty GPs declined to participate in the study after a 
meeting with a researcher. They offered one or all three of the following reasons: 
1. Inadequate number of child patients. 
2. Lack of time, already involved in other studies. 
3. Lack of interest in the study. 
4.3.2. Reasons for non -participation of children 
Of the 685 parents of the children contacted, 93 (14 %) did not participate in the study. 
Although these 93 children were considered eligible by GPs, three of them were older 
than two years, thus were not eligible for the study. The reasons for non -participation 
are given in Table 4.1. 
Table 4.1: Reasons for non -participation of the children in the trial 
Reasons Number ( %) 
Study GP was not the primary GP 27 (29) 
Not interested in the study 24 (26) 
Decided to move from ACT 17 (18) 
Another sibling was recruited in the study 12 (13) 
Time pressure for record keeping 10 (11) 
Child older than 2 years (not eligible for the study) 3 (3) 
Total 93 (100) 
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4.4. Active participants 
Nine of the 63 recruited GPs had withdrawn from the study before the completion of the 
total recruitment process in April 1998; 7 of them were from the intervention group. 
Eight of the nine GPs gave inadequate numbers of child patients in the practice as a 
reason for withdrawing from the study. One GP, who suddenly decided to retire, had 
recruited only one patient for the trial. 
Of the 592 parents who agreed over the telephone to receive a recruitment package, 90 
did not reply when the package was sent. 
At the end of recruitment in April 1998, 54 GPs and 502 children remained active in the 
study. Of the 54 GPs, 24 were in the early -intervention arm and 30 in the late - 
intervention group. Among the 502 active children, 257 were recruited by the GPs of 
the early- intervention group and 245 by the GPs of the late -intervention group. 28 GPs 
recruited 10 or more patients, 15 recruited 6 -9 patients and 11 had 5 or less. 
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4.5. Baseline characteristics 
4.5.1. GP characteristics 
Fifty -two of the 54 active GPs (96 %) sent a study entry questionnaire back to us; 58% of 
them were male. Half of the GPs had graduated from medical school after 1977, three 
of them had graduated between 1987 and 1995. The average period of clinical practice 
for the GPs was 16 years (standard deviation 8, range 1 -33 years). Most of the GPs 
(75 %) worked in a group practice. Half of the GPs work 40 hours per week in the 
surgery. The GPs spent an average of 3.5 hours per week (standard deviation 3, range 1- 
15 hours) in reading background materials. All the study -GPs were vocationally 
registered. The vocational training program is conducted by the Royal Australian 
College of General Practitioners to prepare the medical graduates for entry into 
unsupervised general practice. Most of the GPs (92 %) in the study were members of the 
ACT Division of General Practice either alone or in conjunction with RACGP, AMA 
and other medical associations. 
Most of the GPs (77 %) who worked in solo practices were male, whereas the sex ratio 
was equal in group practices. Among the GPs who worked part-time ( < =30 
hours /week), 75% were female. Male GPs worked significantly longer in the surgery 
than the female GPs (90% of male GPs worked more than 30 hours per week compared 
to 59% of the female GPs, p= .009). The characteristics of study GPs are tabulated in 
Table 4.2. 
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Table 4.2: Characteristics of general practitioners (n =52) 
Characteristics (Number of respondents) Number ( %) 
Sex (52) 
Male 30 (58) 
Female 22 (42) 
Year of graduation (52) 
Before 1972 13 (25) 
1973 -1977 11 (21) 
1978 -1982 15 (29) 
After 1982 13 (25) 
Years of clinical practice (51) 
<12 years 15 (29) 
12 -15 years 12 (23.5) 
16 -21 years 11 (22) 
>21 years 13 (25.5) 
Number of GPs per practice (52) 
1 GP 13 (25) 
2 -3 GPs 28 (54) 
>3 GPs 11 (21) 
Hours in the surgery per week (52) 
1 -30 hours 12 (23) 
31-40 hours 16 (31) 
41 -45 hours 11 (21) 
>45 hours 13 (25) 
Hours of background reading /week (51) 
2 hours 28 (55) 
>2 hours 23 (45) 
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4.5.2. Characteristics of children 
477 of 502 (95 %) parents of the participating children returned the study entry 
questionnaire. These questionnaires contained demographic, environmental and health - 
related information about the children. 
The mean age of the children at recruitment was 11.8 months with a range from two 
weeks to two years. Thirty -five per cent of the children were the only child of their 
parents during recruitment and another 40% had only one sibling. Most of the children 
were breastfed for at least some time and 26 children were being breastfed at study 
entry. The mean duration of breastfeeding at that point was seven months with standard 
deviation of 5.5 months. Half of the children were breastfed for more than six months. 
The characteristics of the children are shown in Table 4.3. 
68 
Table 4.3: Characteristics of children at recruitment (n =477) 
Characteristics (number of respondents) Number ( %) 
Age (476) 
Sex (477) 
Male 
Female 
Number of siblings (474) 
No sibling 
1 or more siblings 
Ever breastfed (460) 
Never 
Breastfed 423 (92) 
Immunisation for the age (468) 
Not immunised 18 (4) 
Immunised 450 (96) 
Types of day -care (472) 
Care by parents 283 (60) 
Private care by Nanny or a relative 38 (8) 
Family day -care 27 (6) 
Day -care centre 124 (26) 
Duration of day -care per week (472) 
No day -care 283 (60) 
1 -20 hours 79 (17) 
21 -40 hours 73 (15) 
>40 hours 36 (8) 
Any major illness (472) 
No 396 (84) 
Yes 76 (16) 
Mean 11.8 months, 
range 2 wks -2 yrs 
217 (45.5) 
260 (54.5) 
166 (35) 
308 (65) 
37 (8) 
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4.5.3. Characteristics of parents 
Over 30% of the parents in the study had either a graduate or a postgraduate degree from 
university. Thirty -five per cent of parents earned more than A$60,000 per annum. The 
characteristics of parents and family are tabulated in Table 4.4. 
Table 4.4: Characteristics of parents and family (n =477) 
Characteristics (number of respondents) Number 
Age of father (462) Mean 33 years 
(range 18 -52 years) 
Age of mother (465) Mean 31 years 
(range 16-44 years) 
Education of father (456) 
High school 138 (30) 
Trades or TAFE 148 (33) 
University graduate 106 (23) 
Postgraduate 64 (14) 
Education of mother (466) 
High school 163 (35) 
Trades or TAFE 144 (31) 
University graduate 115 (25) 
Postgraduate 44 (9) 
Family income (446) 
<30,000 86 (19) 
31,000- 45,000 93 (21) 
46,000- 60,000 109 (24) 
>60,000 158 (35) 
Smoking by a family member (458) 
No smoking 315 (69) 
Smoke 143 (31) 
Duration of pregnancy for the child (469) 
36 weeks or less 31 (7) 
>36 weeks 438 (93) 
Type of delivery of the child (469) 
Normal vaginal delivery 325 (69) 
Other than normal vaginal delivery 144 (31) 
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4.6. Loss to follow -up 
At the end of recruitment in April 1998, a total of 502 children were active in the study. 
Of the 502 children, 71% (355/502) remained active at the end of the study in 
September 1999. The involvement of the children in the study was mainly determined 
from the monthly diary return by the parents; the number of diary returns was variable 
throughout the period (Figure 4.4). 
Figure 4.4: Diary return by the parents between May 1998 and September 1999 
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The period of observation for the children was based on the number of daily diaries 
returned by the parents. There was a total of 251,051 observation days from 502 
children during the 25 months with a mean of 501 days. The period of diary observation 
varied between children, ranging from 28 days to 760 days. A total of 303 children 
were observed for more than 70% (540/760) of the total study period (Figure 4.5). 
Figure 4.5: Days of observation for 502 children within the 760 days of study 
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A total of 147 children left the cohort at some time between May 1998 and September 
1999; we failed to determine the exact time when these children actually dropped out 
from the study. In spite of all the efforts to maintain a good participation rate, diaries 
were not returned every month; this was a particular problem when we lost contact with 
parents as they moved to a new place without informing us or their GPs of a new 
address. However, we removed a child from the study if we did not receive a diary for 
the child for six consecutive months. The major dropout of children was observed six 
months after the completion of recruitment in April (Figure 4.6). 
Figure 4.6: Number of active children in the study between April 1998 and 
September 1999 
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Interestingly, a few parents started sending a diary after a prolonged silence and 
apologised for misplacing diaries, mostly during the difficulties of moving house. We 
did not ask them to return a diary if the gap was more than two months, in order to 
minimise a recall bias. However, we probably could have checked the reason for 
restarting diary return, which we did not. Therefore, it could be an episode of illness 
which reminded parents about.the study and thus to return a diary. This may have led to 
overestimation of respiratory illness and treatment in this study. 
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4.7. Generalisability 
The study GPs were representative of Australian GPs regarding clinical practice. The 
majority of Australian GPs work in group practices, as in the study population.157 The 
average hours of work in the surgery per week were a little shorter for the study GPs 
compared to the average Australian GPs (40 hours versus 43 hours).158 However, this 
difference was probably due to there being more female GPs in the study than the 
national average (42% versus 31 %), because female GPs work shorter surgery hours 
than their male counterparts. 
The demographic details of the study children and their parents were compared to the 
1996 Census of Population and Housing by the Australian Bureau of Statistics (ABS). 
There were more girls in the study compared to the national average and ACT average: 
54.5% of the study children compared to 49% of the ACT population were females. 
Parents in the study had higher education compared to the ACT population: 27% of the 
ACT population had a degree or higher education, whereas approximately 35% of the 
study parents had graduated from an university or had a postgraduate degree. The level 
of education of the study parents was much higher than that of the average Australian. 
In 1996, 40% of Australians aged 15 to 64 years had qualifications above high- school 
level, which mainly included vocational qualifications and undergraduate or associate 
diploma, and only 14% had a degree or higher education.159 The rate of post- school 
education was higher in the ACT in 1996, at 50 %.159 However, in the study population, 
over 65% of the parents had post -school qualifications and 35% had a university degree 
or a postgraduate degree. The family income of the study population compared well 
with the average family income of the ACT. The median gross income of couples with 
dependent children in the ACT was A$57,000 per annum in 1996, which was higher 
than the national average income.159 
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4.8. Discussion 
The final sample of children in the study was smaller than had been intended and the 
recruitment process took much longer than had been anticipated. The reality of general 
practice is that it not only serves sick people, but is now also an important area for 
clinical research. During the recruitment stage of this study, several GPs indicated that 
they were already participating in other research trials. The slow recruitment of children 
may have been partly due to the pressure of GP commitments. We anticipated this 
problem in the design phase and aimed to involve the receptionist as the first point of 
child recruitment. It was proposed that the receptionist would attach a recruitment form 
with the case file of each successive child aged under two years, until 15 children from 
the practice were recruited. We hoped that this would reduce the work of recruitment 
for the GP, as well as being a reminder to the GP. However, most of the GPs decided to 
keep all the responsibilities themselves to reduce the pressure on the receptionists. As a 
result, we found that GPs apparently did not approach every successive child under two 
years of age who came to their practices. Sometimes, they selected patients from their 
practice lists. These facts lead obviously to some selection biases in the recruitment of 
patients, as seen from the social and educational profile of the parents. 
A consequence of the longer child recruitment period that is particularly detrimental to 
the issues explored in this thesis was that we had a short data -collection phase before the 
first round of nasal swabs, in March -April 1998. The resulting small number of diaries 
reduced the power of the study to detect a significant association between antibiotic use 
before swab collection and antibiotic -resistance. However, despite the small number of 
diaries before the first swab, definitive results were obtained (Chapter 6). 
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Chapter 5 Surveillance of respiratory illness, antibiotic use 
and antibiotic -resistance 
5.1. Overview 
This chapter reports the descriptive analysis of respiratory illness and treatment in 
children during the study period. It also presents the pneumococcal carriage and 
pneumococcal resistance to antibiotics in the cohort over the time period. Respiratory 
illness was monitored by a daily diary recorded by the parents. Parents also recorded the 
detailed management of illness which included antibiotic use by the children. 
Pneumococcal carriage was monitored by a nasal swab collection from the children four 
times during the study. Pneumococcal isolates were tested for their sensitivity to six 
commonly used antibiotics to determine antibiotic- resistance. 
5.2. Respiratory illness and management 
5.2.1. Methods 
Surveillance of respiratory illness was carried out for a total of 760 days (25 months) 
extending from September 1997 to September 1999. Parents maintained a respiratory 
health record for their children by completing a daily diary during the 25 months. The 
diary allowed parents to record the presence of 12 respiratory symptoms and signs: 
runny nose, blocked nose, green nasal discharge, dry cough, moist cough, wheeze, 
hoarse voice, sore throat, earache and ear discharge, cold and fever. `Cold' was used by 
the parents as a summary description of respiratory illness rather than one specific 
symptom.160 We therefore decided to keep `cold' as a separate item for parents to 
report. In the daily diary, parents also reported the detailed management of respiratory 
illnesses in children including any doctor or hospital visit with the reason for the visit 
and treatment and duration of treatment of the children. 
5.2.2. Respiratory illness 
At the end of recruitment we had a sample of 502 children whose parents had agreed to 
participate in the study (Chapter 4). There was a total of 251,051 observation days from 
502 children during the 25 months. 
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Respiratory symptoms 
Days of a symptom per child -year were computed for each child by dividing the total 
number of days on which that symptom was observed by the total days for which diary 
records were available. For the whole population of children a mean was obtained from 
the estimates for individual children. The most common symptom experienced by the 
children was runny nose (Table 5.1). 
Table 5.1: Days of respiratory symptoms for 502 children observed for 251,051 
days between September 1997 and September 1999 
Respiratory symptoms Total number of days with 
symptom 
Days per child -year 
Runny nose 38257 54.2 
Blocked nose 5941 8.1 
Green nasal discharge 10572 15.2 
Dry cough 10702 14.8 
Moist cough 15562 22.3 
Wheeze 5681 9.0 
Hoarse voice 2182 3.3 
Sore throat 2320 3.3 
Earache 4332 6.7 
Ear discharge 265 0.6 
Fever 5567 8.0 
Cold 23373 33.2 
Runny nose accounted for 15% of the total observation days for children with a rate of 
54 days per child -year. Children also had a high incidence of `cold', at a rate of 33 days 
per child -year. 
76 
Figure 5.1: Number of days of symptoms per child -year 
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Respiratory episodes 
A respiratory episode was defined as the presence of any of the above mentioned 
symptoms for at least two consecutive days, and an episode ended when there were two 
symptom -free days. Children recorded a total of 6,824 respiratory episodes during the 
25 months with a rate of 9.9 episodes per child -year. Episodes per child -year were 
computed in the same way the symptom rate per child -year was computed. Children 
most commonly suffered from upper respiratory episodes which constituted 45% of all 
respiratory episodes (Table 5.2). 
Table 5.2: Incidence of different types of episodes in 502 children observed for 
251,051 days 
Episode Number Episodes /child -year 
Total respiratory episodes 6824 9.9 
Upper respiratory episode 3062 4.4 
Lower respiratory episode 1554 2.2 
Throat episodes 856 1.2 
Ear episode 1127 1.7 
Fever only episodes 225 0.4 
77 
5.2.3. Management of respiratory illness 
Of the 6,824 respiratory episodes, 35% (2,373/6,824) of episodes had at least one visit 
to a doctor or a hospital. There was more than one consultation during the episode in 
10% (680/6,824) of episodes. 
Overall, 20% (1,383/6,824) of all respiratory episodes were treated by antibiotics. Fifty - 
two per cent (1,243/2,373) of the episodes with at least one consultation received an 
antibiotic. Although antibiotics in Australia cannot be purchased without a prescription, 
3% (140/4,451) of the episodes with no doctor visit during an episode also reported 
receiving an antibiotic. It is possible that parents used antibiotics left over from the 
previous prescription, or a doctor visit was not mentioned in the diary by parents. 
Highest antibiotic use was recorded for ear episodes: 51% (572/1127) of all ear episodes 
were treated with antibiotics compared to 31% (264/856) of throat episodes and 19% 
(297/1554) of lower respiratory episodes. Seven per cent (221/3,062) of upper 
respiratory episodes also received antibiotics. The episodes that consisted of only fever 
were mostly diagnosed and treated as ear infections with 13% (29/225) receiving 
antibiotics. 
Figure 5.2: Overview of respiratory episodes experienced by the children between 
September 1997 and September 1999 
Total 
episodes =6824 
No visit =4451 (65 %) 
At least one visit to a 
doctor =2373 (35 %) 
Received 
antibiotic =1243 (52 %) 
Not received 
antibiotic =1130 (48 %) 
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5.2.4. Total antibiotic use by the children 
Children in the study commonly received one of three types of antibiotics: penicillin, 
cephalosporin or a macrolide. Commonly used penicillins in children were 
phenoxymethylpenicillin (Abbocillin) and amoxycillin (Amoxil, Alphamox, Cilamox); 
however some children also received a broader -spectrum penicillin like amoxycillin 
with potassium clavulanate (Augmentin). In this thesis, the term `penicillin group' is 
used to refer to the entire group of penicillin used by the children. Commonly used 
cephalosporins in children were cephalexin (Keflex, Ibilex) and cefaclor (Ceclor). 
Cephalosporins as a group have a broader -spectrum of antibacterial activity than the 
penicillin group of antibiotics. Children also received cotrimoxazole, which was mostly 
used for prevention of urinary tract infection. Chloramphenicol was also used in 
children as a topical anti -infective preparation for eye or ear. Among the other 
antibiotics used in children, metronidazole (Flagyl) was the commonest. 
There were six children in the study who received antibiotics for more than half of their 
observation period. These six children received antibiotics for an average 237 
days /child -year compared to 17.6 days /child -year for other children. I considered these 
six children different from average children regarding total antibiotic use and therefore, 
excluded them from the following analysis. 
Of the remaining 496 children, 114 (23 %) did not receive an antibiotic during the period 
for which their parents provided diaries. In children who received an antibiotic, the days 
of antibiotic use ranged from 1 to 221 days. There was a total of 12,309 days of 
antibiotic use for the children with a rate of 17.6 days per child -year. Antibiotic use per 
child -year was computed for each child by dividing the number of days when antibiotic 
was used by the total days for which diary records were available. The average of the 
estimates of all children determined the rate for the whole population of children. The 
most commonly used antibiotic group in children was the penicillin group followed by 
cephalosporin and macrolide groups. The rate of use of penicillin group was 6.5 
days /child -year compared to 6.1 days /child -year of cephalosporin use. The rate of 
macrolide use was 3.1 days /child -year (Figure 5.3). Only 44 children received 
cotrimoxazole and 85 children received chloramphenicol at some time during the period 
of their observation. 
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Figure 5.3: Rate of antibiotic use (days per child -year) in 496 children 
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5.3. Pneumococcal carriage and antibiotic- resistance 
5.3.1. Methods 
To monitor the pneumococcal carriage and antibiotic -resistance level in the study 
children, we collected a nasal swab from each study child four times during the two 
years of study. I described the detailed protocol of swab collection and laboratory 
procedure for culture of pneumococci in Chapter 3. Pneumococcal isolates collected 
from the children were tested for susceptibility to penicillin, erythromycin, 
cotrimoxazole, tetracycline, cholramphenicol and cefotaxime by disc diffusion tests. 
The minimum inhibitory concentrations (MIC) of penicillin, erythromycin and 
cefotaxime were also determined by the E -test. The interpretive criteria of the 
NCCLS161 were used for susceptibility categorisation of E -test values. Antibiotic - 
resistance was defined as decreased susceptibility to antibiotics, which included both 
intermediate and high -level resistance. Multi -drug resistance was defined as decreased 
susceptibility to two or more antibiotics. 
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5.3.2. Nasal swab collection 
Of the 502 study children, 96% (484) attended at least one of the four nasal swab 
collections and 60% (303) attended all four. A total of 1,576 nasal swabs were collected 
from 484 children in four collections during the two years of study. Four hundred and 
sixty -one swabs were collected in the first collection during March -April 1998, another 
405 were collected in the second round during August- September 1998, 369 during 
March 1999 in the third collection and 341 in the last collection during August - 
September 1999. The first and third swabs were collected during autumn, whereas the 
second and fourth swabs were collected during late winter to early spring in Canberra. 
5.3.3. Pneumococcal carriage 
Pneumococcus was isolated from 654 of 1576 (41.5 %) swabs. The pneumococcal 
carriage rate was higher during the winter collections compared to those collected in 
autumn. 
Figure 5.4: Pneumococcal carriage rate in 484 children in four swabs 
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Of the 303 children who attended all four swab collections, a pneumococcus was 
isolated at least once from 85% (257) of them. Among these 257 children, 48% (124) 
carried pneumococci on two or more successive collections and 9% (22) carried a 
pneumococcus on all four occasions. However, as we did not test for serotyping of the 
isolates, it is not possible to decide if the children had a prolonged carriage of the same 
strain or if they acquired new strains. 
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Figure 5.5: Pneumococcal carriage in children who attended all four swab 
collections 
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5.3.4. Antibiotic- resistance in pneumococci 
A total of 654 pneumococcal positive swabs were collected from 484 children and were 
tested for their sensitivity to six commonly used antibiotics in humans. Of the 654 
isolates, 53% (348) were resistant to at least one of the six antibiotics. The overall rate 
of penicillin- resistance was 14 %, with high -level resistance in 1 %. Resistance to some 
other antibiotics was even higher than that to penicillin. For example, the rate of 
cotrimoxazole resistance was 49% in the isolates and 42% of them were highly resistant 
to cotrimoxazole.(Figure 5.6) Nineteen per cent of all isolates were resistant to two or 
more antibiotics (multi -resistant) and five isolates (1 %) were resistant to all six 
antibiotics. 
Figure 5.6: Overall antibiotic- resistance in 654 pneumococci, isolated from 484 
children during the study 
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Nasal swabs were collected twice in 1998 and twice in 1999. The percentage of 
pneumococcal isolates that were sensitive to all of the six antibiotics decreased from 
about 50% in 1998 to 40% in 1999. Conversely, the percentage of pneumococci 
resistant to at least one antibiotic increased from approximately 30% in 1998 to 40% in 
1999 (Figure 5.7). 
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Figure 5.7: Pneumococcal isolates resistant to the number of antibiotics in four 
swabs 
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The rate of resistance to most of the antibiotics did not change significantly over the two 
years. However, the rate of resistance to cotrimoxazole increased by about 10% from 
1998 to 1999 which might increase the total resistance.(Figure 5.8) 
Figure 5.8: Pneumococcal resistance to six antibiotics in four swabs 
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5.4. Discussion 
Children in the study, in general, had fewer days of symptoms than those in other 
published studies, although the rate of respiratory episodes was similar to other 
published rates. For example, the days of runny nose in a study of children by Robertsl54 
were 89 days per child -year compared to 56 days per child -year in this study. The rate 
of blocked nose and cough was also lower in this study compared to that of Roberts. 
However, in her study Roberts studied children in day -care settings, where the incidence 
of respiratory illness and morbidity is high. 
The rates of respiratory illness in children aged 0 -5 years vary widely in different 
studies, from as low as 6.1 per child -year up to 15.7 per child- year.33,153.162 -164 Although 
we used more symptoms to define a respiratory illness in this study, the incidence of 9.9 
per child -year is still comparable with other studies. 
The increase in the rate of pneumococcal resistance to antibiotics has been reported in 
Australia and around the world.4,165 In the present study, resistance to one antibiotic 
increased by 10% within only one year from 1998 to 1999. 
Resistance to the antibiotics that are not commonly prescribed for children, e.g. 
tetracycline, suggests that resistance is being spread and maintained by mechanisms 
other than a direct selective pressure of the specific antibiotic use. It is consisted with 
the process of coselection by other antibiotic use, that is due to sharing of the same 
resistance mechanisms for several drugs in the same organism.'22 
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Chapter 6 Penicillin -resistance in pneumococci 
6.1. Overview 
This chapter presents the results of the effect of antibiotic use on antibiotic -resistance in 
pneumococci. Children in this study commonly received beta lactam antibiotics 
(penicillin, cephalosporin). Pneumococcal resistance to all beta lactam antibiotics is 
believed to be entirely due to the development of altered penicillin -binding proteins 
(PBPs),105 so that resistance to one beta lactam antibiotic tends to follow resistance to 
the other. In this chapter, I explored the association between the use of beta Iactam 
antibiotics in children and the isolation of penicillin- resistant pneumococci. I performed 
two steps in the analysis. 
First, I explored if there was any association between use of any beta lactam antibiotic 
during periods preceding isolation of a penicillin- resistant pneumococcus. Antibiotic 
use in children could be monitored for a maximum of 24 months before a swab 
collection. This 24- months period was split into 12 two -month periods to explore the 
temporal association of beta lactam use with penicillin- resistance. I separately explored 
the relationship of penicillin group use, cephalosporin use and combined use of 
penicillin group and cephalosporin with penicillin- resistance during those periods. 
Second, I explored if duration of use of beta lactam antibiotic in children was related to 
the likelihood of a pneumococcus to be resistant to penicillin. For this analysis, I used 
total beta lactam antibiotic use in children during the six months before collecting a 
positive pneumococcal swab. This association was also explored for use of penicillin 
group and cephalosporin separately during that period. 
I also paid particular attention to the antibiotic -resistance profile of the pneumococcal 
isolates collected from the children who received long -term antibiotics during the study. 
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6.2. Methods 
To detect the effect of use of beta lactam antibiotics on penicillin- resistance, I included 
the data collected throughout the study period extending from September 1997 to 
September 1999. Information regarding children's health and treatment was determined 
from the daily diary recorded by the parents. Pneumococcal resistance to penicillin was 
monitored by testing nasal swabs from the study children four times during the two 
years. The procedure of nasal swab collection is detailed in Appendix 3. Pneumococcal 
isolates were identified by colonial morphology, a- haemolysis on blood agar plates, 
susceptibility to optochin and/or bile solubility. Only the most predominant colony of 
each pneumococcal isolate was tested for susceptibility to penicillin, erythromycin, 
cotrimoxazole, tetracycline, chloramphenicol and cefotaxime. The isolates were defined 
as sensitive to penicillin when minimal inhibitory concentration (MIC) was less than or 
equal to 0.064 mg/L, intermediate- resistant when MIC was greater than 0.064 mg/L but 
less than or equal to 1 mg/L, and highly resistant when MIC was greater than 1 mg/L. 
The detailed laboratory procedures for isolation of pneumococcus and sensitivity test to 
antibiotics are described in Chapter 3. 
6.2.1. Inclusion criteria 
A total of 654 swabs positive for pneumococcus were isolated from 484 children in four 
collections. I excluded 17 of the 654 pneumococcal isolates collected from the children 
for whom we did not receive any diary. Another six pneumococcal positive swabs were 
collected from the children who received prophylactic antibiotics during the study. I 
defined prophylaxis as antibiotic use for more than half of the observation period before 
collection of a nasal swab. Children who were on prophylaxis received antibiotics for 
an average of 237 days /child -year compared to 18 days /child -year for other children. I 
considered the isolates collected from these children as a separate entity regarding their 
resistance status. Therefore, the main analysis was performed with 631 pneumococcal 
isolates (654 -23 =631). However, the six isolates were analysed separately. 
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6.2.2. Period of observation before swab collection 
Children had a maximum of six months of observation before the first swab, 12 months 
before the second swab, 18 months before the third swab and 24 months before the 
fourth swab collection. The time period before the date of each swab collection was 
split into 12 two -month periods. I wanted to determine if there was any specific period 
before the isolation of pneumococcus during which beta lactam antibiotic use was 
particularly likely to be associated with penicillin- resistance. Because not all children 
returned all diaries, we had variable information for each of the 60 day periods. The 
available diary observation for children ranged from a minimum of 27 days to a 
maximum of 60 days within each two- monthly period. In Figure 6.1 I have grouped the 
pneumococcal isolates into those for which less than 75% of days were documented (27- 
44 days) and those for which 75% or more of days (>=44 days) were documented. 
Eighty -eight per cent (555/631) of the isolates were collected from the children who had 
some observation during the first two months before swab collection. Among the 555 
isolates, 94% (522/555) were isolated from children who were observed for at least 75% 
of the first 60 days before the swab. The number of isolates for which observation was 
available gradually reduced as I sought to discover the effects of beta lactam use at up to 
two years before the isolation. A few children had more than 18 months of observation 
before a swab. For example, 16% (100/631) of the isolates were collected from the 
children who had some observation during 19 -20 months before swab collection and 92 
of these isolates had information about antibiotic use for more than 44 days (Figure 6.1). 
To limit the likelihood of misclassification of exposure to antibiotics, I excluded from 
the analysis pneumococcal isolates that were collected from children who were observed 
for less than 75% of the 60 days ( <44 days) during the two monthly time period. Thus 
for the 19 -20 month period my analysis was based on the 92 isolates for which 75% or 
more of days were observed in that period. 
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Figure 6.1: Days of observation within each two months associated with positive 
pneumococcal swabs 
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6.3. Association of beta lactam antibiotic use with isolation of penicillin - 
resistant pneumococci 
Of the total 631 eligible pneumococcal isolates, 14% (86/631) were resistant to 
penicillin. Beta lactam antibiotic use during a period implied either use of penicillin 
group or use of cephalosporin or both penicillin group and cephalosporin use during that 
period. In this section, first, I assessed if there was an association between any beta 
lactam use during a period and the rate of isolation of penicillin- resistant pneumococci. 
Then the risk was assessed separately for penicillin group use, cephalosporin use and 
use of both penicillin group and cephalosporin during a period. 
6.3.1. Effect of any beta lactam antibiotic use with isolation of 
penicillin- resistant pneumococci 
Exposure variable 
The exposure variable was use of a beta lactam antibiotic during a particular period 
(beta). The variable was a dichotomous variable, which indicated any beta lactam use 
versus no beta lactam use during a period. 
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Outcome variable 
The outcome variable was pneumococcal resistance to penicillin (pen); resistance 
included either intermediate or high resistance to penicillin. The variable was a 
dichotomous variable, which indicated if an isolate was sensitive or resistant 
(intermediate or highly) to penicillin. The different levels of sensitivity are defined in 
Chapter 3. 
Selection of the model 
My aim was to obtain a valid estimate of the effect of beta lactam use on penicillin - 
resistance. Therefore, I selected an exposure- disease model, using multivariate 
regression analysis. The appropriate multivariate model was multiple logistic 
regression, as both the outcome and the exposure variables were dichotomous. 
Adjustment for clustering 
A pneumococcal isolate was collected from a child as many as four times during the 
four collections over the two years. The pneumococcal isolates of a child are not 
necessarily independent, regarding their resistance status. Therefore, the isolates from 
the same child cannot be regarded as independent for the purpose of analysis. Thus I 
performed both univariate and multivariate analysis by using logistic regression in 
STATA, that allowed adjustment for the impact of clustering within a child. I estimated 
robust standard error, which relaxes the assumption of independence of the observations 
for correlated observations within a child. 
The command I used in STATA for univariate analysis to detect the effect of use of any 
beta lactam antibiotics on penicillin- resistance was: 
Logistic pen beta, cl(idno) 
where 
pen= resistance to penicillin (yes /no) 
beta =use of beta lactam antibiotics during the period(yes /no) 
cl(idno) = clustered by child identification number. 
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Univariate analysis 
The risk of penicillin- resistance was compared for each period between the isolates 
collected from the children who received beta lactam antibiotics and those collected 
from the children who did not receive any. Beta lactam use was grouped as either use of 
beta lactam antibiotic at least for a day, or no beta lactam use at all during the period. 
Penicillin- resistance was also a dichotomous variable, and grouped as either sensitive or 
resistant to penicillin. Of the total 631 pneumococcal isolates, 86 (14 %) were resistant 
to penicillin. The number of isolates would be different in different time periods 
depending on the corresponding number of days of observation in that period. The use 
of beta lactam antibiotics during each two monthly period was tested for its association 
with penicillin- resistance. However, a child might receive beta lactam antibiotics in 
more than one period of time. If there was a significant association observed between 
penicillin -resistance and beta lactam use in a period, I examined if the association was 
affected by the use of beta lactam in an earlier period. The risk of having a penicillin - 
resistant pneumococcal isolate was 1.8 times higher in those who used beta lactam 
antibiotics during the immediate two months period before the swab was collected (RR 
1.8, p =0.01) (Table 6.1). A significant risk was also observed for the beta lactam use 
during the 19 -20 months before swab collection (RR 2.9, p =0.02) (Table 6.1). 
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Table 6.1: Crude relative risk of penicillin- resistance among the exposed 
compared to those non -exposed by 2- months period 
Time before 
swab collection 
Penicillin- resistant 
isolates /total isolates 
with beta lactam 
Penicillin -resistant 
isolates /total isolates 
with no beta lactam 
RR p (2 sided 
Fisher's 
exact) 
0 -2 months 22/98 53/424 1.8 0.01 
3-4 months 18/111 54/407 1.2 0.43 
5 -6 months 19/110 50/349 1.2 0.45 
7 -8 months 10/73 45/293 0.9 0.72 
9 -10 months 11 /100 40/253 0.7 0.25 
11 -12 months 9/78 32/217 0.8 0.48 
13 -14 months 7/62 23/151 0.7 0.45 
15 -16 months 8/63 23/143 0.8 0.53 
17 -18 months 3/40 23/125 0.4 0.10 
19 -20 months 6/17 9/75 2.9 0.02 
21 -22 months 1/14 11/55 0.4 0.26 
23 -24 months 2/8 3/17 1.4 0.67 
I measured the effect of beta lactam use on penicillin -resistance in a logistic regression 
model adjusting for the cluster effect of repeated positive swabs in a child (Appendix 
6.1). The adjusted results were qualitatively similar to the crude effect that is shown in 
table 6.1. In the adjusted model, the odds of penicillin- resistance was double for those 
who used beta lactam during the previous 2 months (OR 2.03, 95% CI 1.15 -3.56, 
p= 0.01). The adjusted odds of penicillin- resistance for beta lactam use during the 19 -20 
months was also significantly high, but because of the small number of exposed isolates 
in this period the association had an wide confidence interval (OR 4.00, 95% CI 1.18- 
13.56, p =0.03) (Appendix 6.1). 
The risk of penicillin -resistance gradually decreased as the duration from time of beta 
lactam use to the date of swab collection became longer (Figure 6.2). 
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Figure 6.2: Odds ratio of penicillin- resistance for children with any beta lactam 
use at different periods before swab collection, adjusted for repeated 
pneumococci from the same child 
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The point estimate of having penicillin- resistant pneumococcal isolate was greater than 
1 for the children who used beta lactam antibiotics during the 0 -6 months before swab 
collection (Figure 6.2). However, the association between beta lactam use and isolation 
of penicillin- resistant isolate was only significant for the period of 0 -2 months before 
swab collection. The point estimate was also high for the association during 19 -20 
months, but with a wide confidence interval. 
Because of the consistency of the finding for the particular period of 19 -20 months, the 
association was further explored. A total of six penicillin -resistant isolates were 
collected from children who had received beta lactam antibiotics 19 -20 months before 
the swabs. They were collected from six different children and a penicillin- resistant 
pneumococcus was isolated from all of them during the fourth swab. All six isolates 
were resistant to penicillin and cotrimoxazole, and five of them were also resistant to 
erythromycin and tetracycline; only one isolate was resistant to chloramphenicol. All 
six children had also received a beta lactam antibiotic during more recent periods and 
three of them received it during the six months before the swab collection. Although 
these children were not included in the group of children with prophylaxis by definition, 
they were high antibiotic users compared to other children. For example, these six 
children had a mean of 77 days (SD 60 days) of antibiotic use during the study 
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compared to a mean of 18 days (SD 24 days) for all children from whom a 
pneumococcal isolate was collected, except those with prophylactic antibiotic use. The 
most commonly used antibiotic in these six children was beta lactam antibiotic with a 
mean of 52 days (SD 48 days) and macrolide with a mean of 25 days (SD 25 days). 
Cephalosporin was the most commonly used beta lactam antibiotic by these children, 
with a mean of 34 days (SD 33 days) compared to mean of 18 days (SD 25 days) 
penicillin group use. Therefore, at least three explanations can be made for the strong 
association observed between beta lactam use and penicillin- resistance during 19 -20 
months before the swab collection. One, the cumulative exposure of antibiotics by the 
children during the two years before the fourth swab had an effect on the carriage of 
penicillin- resistance. Two, the use of beta lactam antibiotics, particularly the use of 
cephalosporin, exerted a selection pressure. Third, the use of beta lactam antibiotics 
during the recent periods before the swab was responsible for the association. 
Multivariate analysis 
I set out to obtain an overall estimate of the effect of beta lactam use during the two 
months before swab collection on penicillin- resistance, after adjusting for a range of 
confounding factors. I followed the stages of developing a multivariate model 
suggested by Kleinbaum.156 I started modelling with specification of the variables, 
followed by interaction assessment, and completed with assessment of confounding. 
Variable specification 
I selected potentially confounding variables that could be biologically associated with 
penicillin- resistance or that had been shown in previous studies to be related to 
penicillin -resistance. These included demographic and environmental variables, and 
variables related to health and treatment of children (Tables 6.2 -6.4). 
Age was included because several studies reported that younger children are more likely 
to carry a resistant strain of pneumococcus than older children.8,129 Gender was included 
because Melander et al. found that the carriers of penicillin- resistant pneumococci were 
more often of male sex than the non- carriers.129 However, another study found no 
association between sex of the child and carriage of resistant pneumococci.8 
Day -care attendance is frequently reported as an important factor to influence the 
epidemiology of resistant bacteria. Henderson found that a higher proportion of 
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pneumococci recovered from children in a day -care centre were resistant to beta lactam 
antibiotics and also to trimethoprim -sulphamethoxazole, compared to the organisms 
isolated from patients at a tertiary care hospita1.114 
A visit to a doctor or hospital was considered as a potential confounding variable 
because of the likelihood of a child being exposed to other patients in the waiting room, 
which may increase the chance of acquiring a resistant bacteria. The more often a child 
visited a doctor, the more likely that she/he would receive an antibiotic. However, if a 
child did not visit a doctor or hospital at all, she/he is not likely to take an antibiotic. 
Therefore, this variable was not included in the model. 
Type of respiratory episode was also considered as a potential confounder. However, 
the type of episode is unlikely to be related to antibiotic- resistance independently of its 
association with antibiotic use. The antibiotic use in an episode depends on the type of 
episode. For example, if a child had an ear episode she /he was more likely to receive 
antibiotics than another child who had no ear episode. Therefore, this variable was also 
excluded as it was also not used in the model. 
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Table 6.2: Demographic characteristics of children 
Variable description Form of the variable 
Age of child at the time of swab collection Continuous 
Dichotomous 
M =0, F =1 
Sex of child 
Table 6.3: Environmental variables 
Variable description Form of variable 
Type of day -care attended by the child at the Categorical 
l= single care by parent or by nanny 
2 =small group care (2 -6 children/care) 
3 =large group care ( >6 children/care) 
Duration of day -care Categorical 
0 =no day -care 
1 =1 -20 hr /wk 
2 =21 -40 hr /wk 
3 = >40 hr /wk 
Number of siblings Categorical 
0 =no sibling 
1 =1 sibling 
2 =2 -5 siblings 
Presence of older siblings Dichotomous 
0 =no older sibling 
1 =1 or more older siblings 
Season of swab collection Dichotomous 
time of swab collection 
1= autumn 
2= winter /early spring 
Table 6.4: Health and treatment -related variables 
Variable description Form of variable 
Any hospital admission during the period Dichotomous 
0 =no, l -yes 
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Assessment of interaction 
All the variables except any hospital admission (Tables 6.2 -6.4) were tested by using 
logistic regression to determine if there was evidence of effect modification. Hospital 
admission could not be tested for evidence of effect modification because of the very 
low number of admissions. Ten of the 522 isolates had a hospital admission, six of 
them had some beta lactam use and one of them was resistant to penicillin. I tested 
other variables for interactions with the beta lactam use during the two months using the 
Likelihood Ratio test. The test assessed the deviation between the model with the 
interaction term and the confounder, and the model with only confounder. None of the 
interaction terms was statistically significant by the Likelihood Ratio test (Table 6.5). 
Table 6.5: Impact of interaction terms by using Likelihood Ratio test in logistic 
regression model 
Interaction terms P value in Likelihood Ratio test 
Beta lactam use *age 
Beta lactam use *sex 
Beta lactam use *number of siblings 
Beta lactam use *presence of older sibling 
Beta lactam use *type of day -care 
0.55 
0.67 
0.69 
0.98 
0.60 
Beta lactam use *duration of day -care 0.89 
Beta lactam use *season of swab collection 0.48 
Assessment of confounding 
I assessed confounding by using logistic regression. To determine if a variable was a 
confounder I first obtained a crude overall estimate of the association between exposure 
and outcome, adjusting for repeated positive swabs isolated from a child. Then I 
controlled the association for each variable at a time and observed if the addition of a 
variable altered the estimate of the association between the exposure and the outcome. 
A potential confounder would be considered a confounder if adjustment for the variable 
resulted in a meaningful change of the association between the exposure and the 
outcome.166 A 10% or greater distortion of odds ratio from the crude was considered as 
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a meaningful distortion. The results of this confounding assessment are shown in Table 
6.6. 
Table 6.6: Evaluation of confounding for distortion of effect of any beta lactam 
use during two months immediately before swab 
penicillin- resistance (n =522 isolates) 
collection on 
Variables OR Evaluation 
Crude OR between penicillin- resistance and beta lactam 2.03 
use 
Adjusted for age 
Adjusted for sex 
Adjusted for number of siblings 
Adjusted for presence of older sibling 
Adjusted for type of day -care 
Adjusted for duration of day -care 
Adjusted for season of swab collection 
Adjusted for any hospital admission in two months 
2.01 Not a confounder 
2.00 Not a confounder 
2.00 Not a confounder 
2.08 Not a confounder 
2.11 Not a confounder 
2.08 Not a confounder 
1.98 Not a confounder 
2.02 Not a confounder 
None of the variables meaningfully distorted the relationship between penicillin - 
resistance and use of beta lactam antibiotic during the two months immediately before 
swab collection. 
Final model 
The final multivariate model was adjusted for the cluster effect of repeated 
pneumococcal positive swabs in the same child. Children who received beta lactam 
antibiotics during the two months immediately before the swab collection were twice as 
likely to carry a penicillin- resistant isolate as children who did not (OR 2.03, 95% CI 
1.15 -3.56, p <0.01) (Table 6.7). 
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Table 6.7: Final multivariate model between penicillin- resistance and any beta 
lactam use during the two months immediately before the swab 
collection, adjusted for cluster effect of child (n =522 pneumococcal 
isolates) 
Variable OR Robust Lower Upper P 
St error 95% CI 95% CI value 
Beta lactam use in 2 months 2.03 0.58 1.15 3.56 0.01 
I tested to see if beta lactam use during the 3 -4 months had affected the finding of the 
relationship in the two months immediately before swabbing. Thirty-three 
pneumococcal positive swabs were collected from the children who received beta 
lactam antibiotics during the first two months, as well as during the 3 -4 months. The 
association between beta lactam use during the two months immediately before swab 
collection and penicillin -resistance was still significant even after excluding the 33 
isolates that had beta lactam use during both periods (OR 2.10, CI 1.09 -4.06, p= 0.03). 
Of the 522 isolates that were included in the analysis of beta lactam use during the two 
months before the swab, 81% (424/522) were collected from children who did not 
receive any beta lactam and 19% (98/522) were from children who received a beta 
lactam antibiotic. Of the 98 isolates collected from the children who received a beta 
lactam, 38% (37/98 isolates) received penicillin group, 52% (51/98 isolates) received 
cephalosporin, and 10% (10/98 isolates) received both penicillin group and 
cephalosporin during that period. The risk of penicillin- resistance for each of these 
three groups of beta lactam use was examined separately to determine the effect of each 
particular pattern of beta lactam use on penicillin- resistance. The highest risk of 
penicillin -resistance was associated with the pneumococci isolated from the children 
who received both penicillin group and cephalosporin during that period and the 
association was statistically significant (Table 6.8). The risk of penicillin- resistance was 
1.7 times higher in isolates collected from children who had only cephalosporin use and 
1.5 times higher in the isolates from children who had only penicillin group use, than 
the isolates that did not have any beta lactam antibiotics during that period, however 
neither reached statistical significance (Table 6.8). 
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Table 6.8: Crude relative risk of penicillin- resistance in three groups of isolates 
with only penicillin group use, only cephalosporin use and both 
penicillin group and cephalosporin use during the two months before 
swab collection 
Types of beta lactam Penicillin- resistant Penicillin -resistant RR P (2 sided 
use isolates /total isolates isolates /total isolates Fisher's 
exposed not exposed exact p) 
Only penicillin group 7/37 53/424 1.5 0.27 
Only cephalosporin 11/51 53/424 1.7 0.07 
Both penicillin group 4/10 53/424 3.2 0.01 
and cephalosporin 
After adjusting for the cluster effect of repeated positive swabs from the same child, the 
association of penicillin- resistance was still significant for the isolates collected from 
the children who received both penicillin group and cephalosporin during the two 
months period (OR 4.67, 95% CI 1.27 -17.09, p =.02) (Appendix 6.2). Although the 
odds ratio was almost 5, the 95% confidence interval was wide because of small 
numbers of isolates from children who had been exposed to both antibiotics. 
6.3.2. Effect of penicillin group use on the isolation of penicillin - 
resistant pneumococci 
Univariate analysis 
The risk of penicillin -resistance for the isolates collected from the children who received 
only penicillin group in different time periods before swab collection was compared to 
those who did not receive any beta lactam antibiotics. The risk of penicillin- resistance 
for the penicillin group use during the four months immediately before the swab was 1.5 
times higher and for the use during 5 -6 months was 1.4 times higher compared to no 
beta lactam use during those periods. None of the associations was statistically 
significant (Table 6.9). 
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Table 6.9: Crude relative risk of penicillin- resistance in the isolates that were 
exposed to only penicillin group compared to those not exposed to any 
beta lactam antibiotics in different periods before swab collection 
Time before 
swab collection 
(months) 
Penicillin- resistant 
isolates /total isolates 
with penicillin group 
only 
Penicillin -resistant 
isolates /total isolates 
with no beta lactam 
RR P (2 sided 
Fisher's 
exact p) 
0-2 7/37 53/424 1.5 0.27 
3-4 8/40 54/407 1.5 0.24 
5-6 10/49 50/349 1.4 0.27 
7-8 4/37 45/293 0.7 0.46 
9-10 5/51 40/253 0.6 0.27 
11-12 6/46 32/217 0.9 0.77 
13-14 2/26 23/151 0.5 0.31 
15-16 2/25 23/143 0.5 0.29 
17-18 0/20 23/125 0 
19-20 2/9 9/75 1.9 0.39 
21-22 1/9 11/55 0.6 0.53 
23-24 1/5 3/17 1.1 0.90 
The association of penicillin group use during each two months with penicillin - 
resistance was adjusted for the repeated positive swabs collected from the same child. 
The adjusted risk of penicillin -resistance was about 1.5 times higher for the isolates 
collected from the children who had only penicillin group use during the 0 -6 months 
before swab collection (Appendix 6.3). However, no association was statistically 
significant. The number of penicillin- resistant isolates from children who had received 
penicillin group was small in all periods. The smaller sample size might have reduced 
power to show a significant association. There was hardly any isolate in the resistant 
group after the 15 -16 months period (Table 6.9). The direction of effect of penicillin 
group use on penicillin- resistance over time is suggestive of a dose response as shown in 
Figure 6.3. 
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Figure 6.3: Risk of penicillin- resistance for children with exclusive penicillin 
group use at different periods before swab collection, adjusted for 
repeated positive swabs from the same child 
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The point estimate of having a penicillin- resistant pneumococcus was greater than 1 for 
penicillin group use alone during the first six months before swab collection. A similar 
pattern of risk was also observed for any beta lactam use for the same period (Figure 
6.2). 
Multivariate analysis 
I followed the same strategy to develop a multivariate model as I did for any beta lactam 
use during the two months before swab collection and penicillin- resistance. None of the 
variables (Tables 6.2 -6.4) modified or confounded the effect of penicillin group use 
alone on penicillin- resistance. Therefore, the final model was adjusted only for repeated 
pneumococcal isolates collected from the same child. Children who received only 
penicillin group during the two months before collecting a swab were more likely to 
carry a penicillin- resistant isolate than the children who did not receive any beta lactam 
antibiotic; however, the association did not reach statistical significance (OR 1.63, 95% 
CI 0.66 -4.01, p =0.29) (Appendix 6.3). 
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6.3.3. Effect of cephalosporin use alone on the isolation of 
penicillin- resistant pneumococci 
Univariate analysis 
The risk of penicillin- resistance for the isolates collected from the children who received 
cephalosporin alone in different periods before the swab collection was examined 
against those who did not receive any beta lactam antibiotics. The association between 
the use of cephalosporin alone during the two months before the swab collection and 
penicillin -resistance was of borderline significance (RR =1.7, p =0.07) (Table 6.10). 
Table 6.10: Crude relative risk of penicillin- resistance in the isolates that were 
exposed to only cephalosporin compared to those not exposed to any 
beta lactam antibiotics in different periods before swab collection 
Time before 
swab collection 
(months) 
Penicillin- resistant 
isolates /total isolates 
with cephalosporin 
Penicillin -resistant 
isolates /total isolates 
with no beta lactam 
RR P (2 sided 
Fisher's 
exact p) 
0 -2 11/51 53/424 1.7 0.07 
3 -4 7/58 54/407 0.9 0.80 
5 -6 7/53 50/349 0.9 0.83 
7 -8 6/29 45/293 1.3 0.45 
9 -10 2/36 40/253 0.4 0.10 
11 -12 1/24 32/217 0.3 0.15 
13 -14 3/29 23/151 0.7 0.49 
15 -16 5/29 23/143 1.1 0.88 
17 -18 1/16 23/125 0.3 0.22 
19 -20 4/7 9/75 4.8 0.002 
21 -22 0/5 11/55 0 
23 -24 0/1 3/17 0 
The association was also highly significant for cephalosporin use alone during the 19 -20 
months before the swab collection (Table 6.10). A similar association was also 
observed for any beta lactam use and penicillin- resistance during the same period (Table 
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6.1) and the isolates were also common in both analyses. The antibiotic use and the 
resistance pattern related to the exposed isolates during the 19 -20 months before swab 
collection have been described previously. 
The effect of cephalosporin use on penicillin- resistance was adjusted for cluster of 
repeated pneumococcal isolates collected from a child (Appendix 6.4). After adjusting 
for cluster effect in children, cephalosporin use during the two months before the swab 
was again associated with a borderline increase in penicillin- resistance (OR 1.93, 95% 
CI 0.93 -3.98, p =0.08) (Appendix 6.4). 
The point estimate of having penicillin- resistant pneumococcal isolates was greater than 
1 for cephalosporin use alone during the 0 -2 months and about 1 for the use during the 
3 -6 months before the time of swab collection (Figure 6.4). Apart from a slight rise in 
odds ratio for exposure 7 -8 months before swabbing, the pattern of association was 
similar to that of any beta lactam use (Figure 6.2) and penicillin group use alone (Figure 
6.3). The smaller sample size of exposed isolates resulted in a very wide confidence 
interval, which is difficult to plot in the graph. In figure 6.4, therefore, I limited the 
association up to 16 months before swab, to be consistent with Figure 6.3. I believe the 
significance observed at 19 -20 months is explained on other grounds. 
Figure 6.4: Odds of penicillin- resistance for children with exclusive cephalosporin 
use at different periods before swab collection, adjusted for repeated 
pneumococci from the same child 
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Multivariate analysis 
None of the variables (Tables 6.2 -6.4) modified or confounded the effect of exclusive 
cephalosporin use on penicillin- resistance. Therefore, the final model was only adjusted 
for repeated positive swabs collected from the same child. Children who received only 
cephalosporin during the two months before swab were more likely to carry a penicillin - 
resistant isolate than the children who did not receive any beta lactam antibiotic during 
that period (OR 1.93, 95% CI 0.93 -3.98, p =0.08) (Appendix 6.4). 
6.3.4. Effect of combined use of penicillin group and cephalosporin 
on the isolation of penicillin- resistant pneumococci 
Univariate analysis 
The risk of penicillin -resistance for the isolates collected from the children who received 
both penicillin group and cephalosporin in different periods before the swab collection 
was examined against those who did not receive any beta lactam antibiotics (Table 
6.11). A total of 10 isolates were collected from the children who received both 
penicillin group and cephalosporin during the 0 -2 months before the swab collection. 
Eight of the 10 children had suffered from one or more ear episodes either alone or with 
some other respiratory episodes during the two- months period. These children received 
a total of 97 days of penicillin group and 73 days of cephalosporin during the period. 
Children usually received one of the two antibiotics on most of the above days except 
for three days when both penicillin group and cephalosporin were used on the same day. 
Interestingly, 8 of the 10 children received cephalosporin before penicillin group, 
whereas the opposite might have been expected. The risk of penicillin- resistance was 
three times higher for the combined use of both antibiotics during the preceding two 
months compared to no beta lactam use during the period (Table 6.11). 
105 
Table 6.11: Crude relative risk of penicillin- resistance among the isolates that 
were exposed to both penicillin group and cephalosporin compared to 
those that were not exposed to any beta lactam antibiotics in each 
period 
Time before 
swab collection 
(months) 
Penicillin- resistant 
isolates /total isolates 
with both beta lactams 
Penicillin -resistant 
isolates /total isolates 
with no beta lactam 
RR P (2 sided 
Fisher's 
exact p) 
0-2 4/10 53/424 3.2 0.01 
3-4 3/13 54/407 1.7 0.31 
5-6 2/8 50/349 1.7 0.40 
7-8 0/7 45/293 0 
9-10 4/13 40/253 1.9 0.16 
11-12 2/8 32/217 I.7 0.43 
13-14 2/7 23/151 1.9 0.34 
15-16 1/9 23/143 0.7 0.69 
17-18 2/4 23/125 2.7 0.12 
19-20 0/1 9/75 0 
21-22 0/0 11/55 0 
23-24 1/2 3/17 2.8 0.29 
The effect of combined penicillin group and cephalosporin use on penicillin- resistance 
was adjusted for cluster of repeated pneumococcal isolates from the same child. 
Children who received both penicillin group and cephalosporin during the two months 
before swab collection were more likely to carry a penicillin -resistant isolate than those 
who did not receive any beta lactam (OR 4.67, 95% CI 1.27- 17.09, p =0.02) (Appendix 
6.5). The numbers of total isolates and exposed isolates were not adequate to examine 
the effect beyond 16 months. The point estimate for penicillin- resistance was greater 
than 1 for combined penicillin group and cephalosporin use during most of the time 
periods. However, the lower number of isolates in each period resulted into wide 
confidence intervals around the point estimate (Figure 6.5). 
106 
Figure 6.5: Odds of penicillin- resistance for children with both penicillin group 
and cephalosporin use at different periods before swab collection, 
adjusted for repeated isolates from the same child. 
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Multivariate analysis 
After adjusting for repeated pneumococcal isolates from the same child, the use of both 
penicillin group and cephalosporin during the two months increased the risk of 
penicillin- resistance by about 5 times (Appendix 6.5). 
The summary of the analyses undertaken in Section 6.3 indicated that use of beta lactam 
antibiotics during the two months immediately before swab collection was significantly 
associated with the risk of isolation of penicillin- resistant pneumococci (Table 6.1). It 
also suggested that recent use is more important than use at a distant period from the 
swab. The effect on penicillin- resistance associated with independent penicillin group, 
independent cephalosporin and use of both antibiotics during the two months further 
suggested a dose -response effect of beta lactam use. The risk was higher for 
cephalosporin use alone than for penicillin group use alone (OR 1.93, 95% CI 0.93 -3.98 
for cephalosporin use alone and OR 1.63, 95% CI 0.66 -4.01 for penicillin group use 
alone), but use of both antibiotics exerted a synergistic effect (OR 4.67 and 95% CI 
1.27 -17.09 for use of penicillin group and cephalosporin) on the isolation of penicillin - 
resistant pneumococci (Table 6.10). 
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6.4. Association of duration of beta lactam use with isolation of penicillin - 
resistant pneumococci 
In what follows, I have explored the effect of duration of beta lactam antibiotic use on 
isolation of penicillin- resistant pneumococci. The swabs were collected approximately 
six months apart from each other, and most of the children with a positive 
pneumococcus provided diaries for 75% or more of the observation during the six 
months before swab collection (Figure 6.1). For this analysis, I used beta lactam 
antibiotic use by the children during the six months before the swab collection. 
6.4.1. Effect of duration of any beta lactam use on the isolation of 
penicillin- resistant pneumococci 
A total of 456 pneumococcal isolates were collected from the children who had at least 
75% of days of observation during the six months before the swab, and 15% (68/456) of 
them were resistant to penicillin Of the 456 isolates, 44% (199/456) had at least one 
day of beta lactam use and 13% (61/456) had beta lactam use for more than 14 days. 
The duration of beta lactam use in these children ranged from 0 to 85 days within the six 
months. The duration of beta lactam use during the six months was grouped into four 
categories on the basis of average length of an antibiotic course, which is usually seven 
days. The categories were: `0 days (no beta lactam)' `1 -7 days (1 course)' `8 -14 days (2 
courses)' ` >14 days ( >2 courses)' (Appendix 6.6). 
The percentages of penicillin- resistant isolates were equal in the group that had no beta 
lactam use (12 %) and the group that had 1 -7 days use (11 %) within six months before 
swab; the percentage increased as the total days of beta lactam use increased beyond 
seven days (Figure 6.6). 
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Figure 6.6: Percentage of penicillin- resistance among the isolates with different 
beta lactam use during the six months before swab collection 
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I tested the association in a logistic regression model by taking cluster effect of children 
into account. Although the children who received beta lactam antibiotics for more than 
seven days within the six months before swab collection were at higher risk of carrying 
a penicillin- resistant pneumococcus than the children who never received beta lactam 
during that period, the association was statistically significant only if children had more 
than 14 days of beta lactam use (Table 6.12). 
Table 6.12: Effect of duration of beta lactam use during the six months before 
swab collection on penicillin- resistance (n =456 isolates) 
Days of penicillin group Odds Robust Std Lower Upper P value 
use in 6 months before 
swab 
ratio error 95% CI 95% CI 
1 -7 days 0.86 0.37 0.37 2.02 0.73 
8 -14 days 1.50 0.55 0.73 3.06 0.27 
>14 days 2.50 0.84 1.30 4.82 0.006 
The association between duration of beta lactam use and penicillin- resistance was 
further explored by using duration of use as a continuous variable rather than 
categorising it. I used a logistic regression model in STATA that allowed adjustment 
for the effect of clustering within children. For each single -day increase in beta lactam 
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use during the six months before the swab collection, the risk of a child carrying a 
penicillin -resistant pneumococcus increased by 4% (Table 6.13). 
Table 6.13: Effect of days of beta lactam use during the six months before swab 
collection on penicillin- resistance, adjusting for cluster effect of 
children (n =456) 
Odds ratio Robust St Lower 95% Upper 95% P value 
error CI CI 
Beta lactam 
use 
1.04 0.01 1.01 1.06 0.001 
6.4.2. Effect of duration of penicillin group use alone on the 
isolation of penicillin- resistant pneumococci 
Of the 199 pneumococcal isolates collected from the children who received a beta 
lactam antibiotic during the six months before swab collection, 38% (76/199) had only 
penicillin group use. The duration of penicillin group use in these children ranged from 
one to 45 days during the six months. The rate of penicillin- resistance was compared 
against the duration of penicillin group use alone with no beta lactam use (Appendix 
6.7). The rate of penicillin- resistance increased as the duration of penicillin group use 
increased within the six months (Figure 6.7). 
Figure 6.7: Percentage of penicillin- resistant pneumococci among the isolates with 
different duration of only penicillin group use during the six months 
before swab collection 
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After adjusting for the cluster effect of repeated swabs from the same child, there was a 
dose -response effect observed in the association of penicillin group use alone with 
isolation of penicillin- resistant pneumococci (Table 6.14). Children who received 
penicillin group alone for more than 14 days within the six months before the date of 
swab collection were more likely to carry penicillin -resistant pneumococci (OR 3.20, 
95% CI 1.10 -9.27, p =0.03) (Table 6.14). 
Table 6.14: Effect of duration of penicillin group use alone during the six months 
before swab collection on penicillin- resistance, adjusted for cluster 
effect of repeated pneumococcal isolates from the same child 
Duration of penicillin group 
use in 6 months 
OR Robust Std 
error 
Lower 
95% CI 
Upper 
95% CI 
P value 
1 -7 days 1.00 0.57 0.33 3.05 0.99 
8 -14 days 1.53 0.82 0.53 4.40 0.43 
>14 days 3.20 1.74 1.10 9.27 0.03 
Duration of penicillin group use within the six months before swab collection was also 
tested as a continuous variable against penicillin- resistance. For a single increase in 
days of penicillin group use alone during the six months, the risk of a child carrying a 
penicillin- resistant pneumococcal isolate increased by 4% (OR 1.04, 95% CI 1.00 -1.09, 
p =0.03) (Appendix 6.8). 
6.4.3. Effect of duration of cephalosporin use alone on the isolation 
of penicillin- resistant pneumococci 
A total of 86 isolates were collected from the children who had only cephalosporin use 
during the six months before swab collection. The rate of penicillin- resistance was 
compared between the duration of cephalosporin use only during the six months and no 
beta lactam antibiotic use (Appendix 6.9). The percentage of penicillin -resistance 
increased as the duration of cephalosporin use increased more than seven days within 
the six months (Figure 6.8). 
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Figure 6.8: Percentage of penicillin- resistant pneumococci among the isolates with 
different duration of cephalosporin -only use during the six months 
before swab collection 
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After adjusting for repeated pneumococcal isolates collected from the same child, a 
dose -response effect was observed similar to that observed with any beta lactam use and 
penicillin group use alone (Table 6.15). 
Table 6.15: Effect of duration of cephalosporin use alone during the six months 
before swab collection on penicillin- resistance, adjusted for cluster 
effect of repeated pneumococcal isolates from the same child (n =343 
pneumococcal isolates) 
Duration of cephalosporin 
use in 6 months 
OR Robust Std 
error 
P 
value 
Lower CI Upper CI 
1 -7 days 0.78 0.49 0.69 0.23 2.67 
8 -14 days 1.49 0.68 0.38 0.61 3.67 
>14 days 1.62 1.09 0.47 0.44 6.02 
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6.5. Effect of number of penicillin courses on the isolation of penicillin - 
resistant pneumococci 
The analysis suggested that children who used any beta lactam antibiotics during the 
two months before the swab were more likely to carry penicillin- resistant pneumococci. 
The analysis further suggested that for each single -day increase in any beta lactam 
antibiotics during the six months before swab collection, the risk of a child carrying 
penicillin -resistant isolate increased by 4 %. A similar increase in risk was also observed 
if penicillin group was used alone during the period. Children who received penicillin 
group alone for more than 14 days during the six months were significantly more likely 
to carry a penicillin- resistant pneumococcus. However, it was not clear if this 
association between the duration of penicillin group use and penicillin- resistance was 
irrespective of continuous or intermittent use. To explore the association between 
continous or intermittent penicillin group use and penicillin- resistance, isolates from the 
children who received only penicillin group during the six months before swab were 
considered. 
Of the 456 pneumococcal isolates with at least 75% of the six months observed, 76 had 
only penicillin group use during the period. The duration of penicillin group use for 
these 76 isolates ranged from one day to 45 days. A penicillin course was defined as 
penicillin group use for two or more consecutive days and if there was a gap of even a 
day, I considered it a new course. There was only one day of penicillin group use during 
that period associated with one isolate; I excluded that isolate from the following 
analysis. Of the remaining 75 isolates, 55 (73 %) had only one course and 7 (9 %) had 
more than two courses during the six- months period. The percentage of penicillin - 
resistance increased with increase in number of penicillin courses used in that period 
(Table 6.16). 
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Table 6.16: Percentage of penicillin- resistance among the four groups, grouped by 
the number of penicillin courses used during the six months before 
swab collection (n =75 pneumococcal isolates) 
Penicillin 
sensitivity 
1 course (% within 
column) 
2 courses (% within 
column) 
>2 courses (% 
within column) 
Total 55 13 7 
Sensitive 47 (85) 10 (77) 4 (57) 
Resistant 8 (15) 3 (23) 3 (43) 
After adjusting for repeated pneumococci isolated from the same child, there was a 
dose -response effect observed between the number of penicillin courses used within the 
six months before the time of swab collection and the isolation of penicillin- resistant 
pneumococci (Table 6.17). Children who used more than two penicillin courses during 
the six months were 4.4 times more likely to carry penicillin- resistant pneumococci; 
however, the association was not statistically significant (Table 6.17). 
Table 6.17: Odds of penicillin- resistance for different groups, grouped by the 
number of penicillin courses used during the six months before the 
swab collection and adjusted for the repeated pneumococci isolated 
from a child (n =75 pneumococcal isolates) 
Number of penicillin courses in 6 OR Robust std Lower Upper P value 
months (1 course referrent) error 95% CI 95% CI 
2 courses 1.76 1.34 0.40 7.85 0.46 
>2 courses 4.41 4.11 0.71 27.40 0.11 
Although the rate of penicillin -resistance increased with increase in number of penicillin 
courses during the six months, the duration of use might affect this association. The 
duration of penicillin group use was longer in isolates with more than one penicillin 
course than in isolates with only one course (mean 21 days and sd 9.9 days versus mean 
7 days and sd 2.9 days) during the six -months period. We already established that the 
risk of a child to carry penicillin- resistant pneumococci increased with each day increase 
in the duration of penicillin group use alone during the six months, and children who 
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received penicillin group alone for more than 14 days within the six months were 
significantly more likely to carry penicillin- resistant pneumococci (OR 3.20, 95% CI 
1.10 -9.27, p =0.03). Therefore, I further explored if the duration of use affected the 
relationship between number of penicillin courses used by the children and the rate of 
penicillin -resistance. Most of the single penicillin courses (98 %) were 2 -14 days long, 
and 75% of the isolates with more than 14 days of penicillin group use received two or 
more penicillin courses (Table 6.18). 
Table 6.18: Length versus duration of penicillin courses (n =75 pneumococcal 
isolates) 
Duration of penicillin group 
use in 6 months 
1 penicillin course in 6 
months 
>1 penicillin courses in 6 
months 
Total 55 20 
2 -14 days 54 (98) 5 (25) 
>14 days 1 (2) 15 (75) 
The distribution of penicillin- resistant isolates was different in the groups depending on 
the number and duration of penicillin courses (Table 6.19). 
Table 6.19: Distribution of penicillin- resistant isolates among the groups, grouped 
by number of penicillin courses and duration of penicillin group use 
within six months before the time of swab collection (n =75 
pneumococcal isolates) 
Penicillin sensitivity 2 -14 days of penicillin group >14 days of penicillin group 
use in 6 months use in 6 months 
1 course >1 course 1 course >1 course 
Number ( %) Number ( %) Number ( %) Number ( %) 
Sensitive isolates 
Resistant isolates 
46 (85) 4 (80) 1 (100) 10 (67) 
8 (15) 1 (20) 0 (0) 5 (33) 
Among the isolates that had 2 -14 days of penicillin group use during the six months, the 
isolates that had more than one course had higher resistant isolates (20% versus 15 %) 
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compared to those with only one course. There was only one isolate that had one 
penicillin course within six months with a duration of more than 14 days, which was 
sensitive to penicillin. However, 33% of the pneumococcal isolates that had penicillin 
group use of more than 14 days duration with more than one course within the six 
months were resistant to penicillin. 
6.6. Complete versus incomplete penicillin course and the isolation of 
penicillin- resistant pneumococci 
Thirty pneumococcal isolates had a penicllin course of 1 -7 days duration. I grouped the 
30 penicillin courses into an `incomplete course (1 -4 days) and a `complete course' (5 -7 
days). Twenty -five per cent of the isolates collected from the children who had an 
incomplete penicillin course carried a penicillin -resistant isolate compared to 5% of the 
isolates from children who had a complete penicillin course (Table 6.20). However, 
there was only one isolate with a complete course that was resistant. Therefore, it was 
difficult to draw a conclusion from this finding. 
Table 6.20: Percentage of penicillin- resistance among the isolates with complete 
and incomplete penicillin course (n =30 pneumococcal isolates) 
Penicillin sensitivity Incomplete course Complete course P value 
Number ( %) Number ( %) 
Total 8 22 
Sensitive isolates 6 (75) 21 (95) 
Resistant isolates 2 (25) 1 (5) 
0.10 
Overall, the analysis in this section suffered from very small sample size and a definite 
conclusion could not be reached from this analysis. 
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6.7. Effect of prophylactic antibiotic use on the isolation of penicillin - 
resistant pneumococci 
Six children received antibiotics for more than half of the observation days before the 
corresponding swab collection. Three of these children did not have a positive 
pneumococcal swab. A total of 11 swabs were collected from the other three children 
and a positive pneumococcus was isolated from six swabs. These children had been 
receiving prophylactic antibiotics for kidney reflux; one of them received cephalosporin 
and the other two received cotrimoxazole as prophylaxis. Three pneumococci were 
isolated from the child who received cephalosporin prophylaxis; two of them were 
resistant to both penicillin and cotrimoxazole. Another three pneumococci were 
isolated from the children with cotrimoxazole prophylaxis; all of them were resistant to 
five of the six antibiotics tested except cefotaxime. All the six isolates were resistant to 
at least one antibiotic and 83% (5/6) were resistant to more than one antibiotic (Table 
6.21). 
Table 6.21: Sensitivity status of the six isolates, isolated from the children who had 
prophylaxis 
Total ( %) 
n =6 
Resistant to at least one antibiotic 6 (100) 
Resistant to penicillin 5 (83) 
Resistant to cotrimoxazole 5 (83) 
Resistant to erythromycin 4 (67 %) 
Resistant to tetracycline 3 (50 %) 
Resistant to chloramphenicol 2 (33) 
Resistant to cefotaxime 0 (0) 
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6.8. Discussion 
The data allowed me to explore three theories about the association between antibiotic 
use and pneumococcal antibiotic -resistance: first, that antibiotic use is associated with 
antibiotic -resistance; second, that greater antibiotic use will increase the likelihood of 
pneumococcal antibiotic -resistance; third, that the use of a broad -spectrum antibiotic is 
more likely than narrow -spectrum antibiotic use to be associated with a high rate of 
antibiotic- resistance in pneumococci. 
These theories, however, have not previously been tested in prospective human studies. 
An association between antibiotic use and pneumococcal penicillin- resistance has been 
reported in a number of cross -sectional human studies. I am unaware of any similar 
study where a group of individuals were followed for a time period to establish this 
association between beta lactam use and penicillin -resistance in pneumococci. In this 
study, a total of 502 children were followed up for 25 months and antibiotic use by these 
children was monitored in detail, together with duration and reason for use. Antibiotic - 
resistance of nasally carried pneumococci in these children was also monitored four 
times during the period. 
The first theory has been supported by my findings. Any beta lactam antibiotic use 
during the two months before swab collection was associated with a significant increase 
in the isolation of penicillin -resistant pneumococci (OR 2.03, 95% CI 1.15 -3.56, 
p= 0.01). Although this association was also evident for beta lactam use during the six 
months before swab collection with an odds ratio of greater than one, statistical 
significance was only achieved for use in the two months immediately before the swab. 
The declining sample size after two months reduced the capacity to attain statistical 
significance. A study with a larger sample size might further explore this association. 
The second theory was also firmly supported in this study. For each day increase in beta 
lactam use during the six months before the swab collection, the risk of a child carrying 
a penicillin- resistant isolate increased by 4% (OR 1.04, 95% CI 1.01 -1.06, p= 0.001). In 
fact, children who used beta lactam antibiotics for more than 14 days during the six 
months before swab collection were significantly more likely to carry a penicillin - 
resistant pneumococcus than the children who did not use any beta lactam antibiotic 
during the period (OR 2.50, 95% CI 1.30 -4.82, p= 0.006). This association was also true 
when penicillin group use alone was considered. The results support the theory that the 
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more the bacteria carried by children are exposed to an antibiotic, the greater the 
likelihood that the organism will be selected for developing resistance to that antibiotic. 
The results also support the third theory but are not statistically significant. 
Cephalosporin use alone during the two months before swab collection was associated 
with higher risk of penicillin- resistance (OR 1.93, 95% CI 0.93 -3.98, p =0.08) than use 
of penicillin group only (OR 1.63, 95% CI 0.66 -4.01, p= 0.29). However, the risk 
difference between the two antibiotics did not achieve statistical significance. 
I also explored the effect of incomplete antibiotic courses on carriage of penicillin - 
resistant pneumococci. Twenty-five per cent of the pneumococcal isolates collected 
from the children who had an incomplete course of penicillin of 1 -4 days long, were 
resistant to penicillin, compared to 5% of the isolates collected from the children who 
had a completre course of 5 -7 days long (Table 6.20). However, the difference was not 
statistically significant. 
Finally, the study brought to light some important implications for prophylactic 
antibiotic use. Three pneumococcal positive swabs were isolated from a child who 
received cephalosporin for 520 days as a prophylaxis for urinary reflux and two of them 
were resistant to both penicillin and cotrimoxazole. The other isolate was not resistant 
to penicillin, but was resistant to erythromycin. The isolates received from the two 
children who received cotrimoxazole as prophylaxis were resistant to penicillin and 
other antibiotics tested except cefotaxime. Thus, all six isolates from these children 
reveal evidence of antibiotic- resistance. 
The evidence from this prospective study is clear and consistent. Use of beta lactam 
antibiotic increases the probability of carriage of penicillin- resistant pneumococci in the 
short term. A reduction in the rate of prescription of beta lactam antibiotics in 
childhood would probably arrest the rate of growing antibiotic -resistance. If it can be 
shown that the heavy use of antibiotics in childhood infections is not producing 
discernible benefits to the recipients, the case for greater conservatism in antibiotic use 
is even clearer. 
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Chapter 7 Effects of antibiotic use on respiratory illness 
7.1. Overview 
This chapter explores the effects of antibiotic treatment on the respiratory illness 
episodes in children that presented to a doctor. Parents reported daily on the presence of 
12 respiratory symptoms in their children over the study period: these 12 symptoms 
were used to define a respiratory episode. I calculated the duration and the total number 
of symptoms in an episode using them as measures of severity. 
To answer the question `Does the use of antibiotics in these episodes make a difference 
to the severity of illness ?', I selected for study 981 respiratory episodes which resulted 
in one or more doctor visits in the children in the late - intervention group' during the 
period September 1997 to February 1999. Neither doctors nor parents in this group had 
been exposed to the clinical practice guidelines during the period. I classified all 
episodes into a `less severe' and a `more severe' group. Then I compared episodes 
which received antibiotics with those that did not. I performed the univariate analysis in 
SPSS and multivariate analysis by using a multiple linear regression model in STATA. 
7.2. Definition of respiratory episode 
Parents reported the presence of 12 respiratory symptoms and signs in a daily diary. 
These were: runny nose, blocked nose, green nasal discharge, dry cough, cold, moist 
cough, wheeze, sore throat, hoarse voice, earache, ear discharge, and fever. 
An episode was defined as the occurrence of at least two consecutive days of any of the 
above reported symptoms. The end of an episode was defined as the occurrence of at 
least two symptom -free days. Duration of an episode was calculated from the onset of 
symptoms to the last day on which symptoms occurred before the occurrence of two 
symptom -free days. This approach to definition of a respiratory episode has previously 
been used by Samet et al. in a study of nitrogen dioxide and respiratory illness in 
infants.155 Samet used only five symptoms to define a respiratory episode which 
included runny or stuffy nose, dry cough, wet cough, wheeze or trouble breathing. I 
included seven other symptoms and signs (green nasal discharge, earache, ear discharge, 
sore throat, hoarse voice, cold and fever) to define episodes. 
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7.2.1. Types of respiratory episode 
The 12 symptoms and signs were allocated to one of the four groups: ear symptoms, 
throat symptoms, lower respiratory and upper respiratory symptoms. Ear symptoms 
included earache and ear discharge. Throat symptoms were sore throat and hoarse 
voice. Moist cough and wheeze constituted lower respiratory symptoms and runny 
nose, blocked nose, green nasal discharge, dry cough and cold were included as upper 
respiratory symptoms. 
The episodes were classified into five types depending on the type of symptoms present 
in the episode (Table 7.1). The types were ear episode, throat episode, lower 
respiratory, upper respiratory and fever episodes. The order of classification was based 
on the severity and on the rate of antibiotic prescribing.).64 Among the acute respiratory 
infections, the highest antibiotic prescribing was suggested for ear illnesses and the 
lowest was for upper respiratory illnesses. The presence of fever in the absence of any 
other sign or symptom was kept as a separate category, because it could be due to any of 
the other four types of episodes or even due to a non -respiratory illness. 
The presence of at least one day of earache or ear discharge during an episode was 
considered as an ear episode. If there was no ear symptom, but a throat- related 
symptom (sore throat or hoarse voice) was present in an episode, the episode was 
considered as a throat episode. Presence of at least one day of moist cough or wheeze in 
the absence of an ear -or throat- related symptom was considered as a lower respiratory 
episode. If the episode did not contain any of the ear or throat or lower respiratory 
symptoms, but contained one of the upper respiratory symptoms, the episode was an 
upper respiratory episode. If an episode consisted of only fever and was not included in 
either of the above classifications, then the episode was considered as a `fever only' 
episode. 
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Table 7.1: Classification of respiratory episodes 
Type of episode Primary symptoms in association with 
any other symptoms 
Ear episode Earache or discharge 
Throat episode Sore throat or hoarse voice in absence of 
ear symptoms 
Lower respiratory episode Moist cough or wheeze in absence of ear 
and throat symptoms 
Upper respiratory episode Upper respiratory symptoms in absence of 
ear, throat and lower respiratory symptoms 
Fever episode Only fever, in absence of any other 
symptom 
7.3. Inclusion criteria 
For this part of the study, I included the data received from the children of the late - 
intervention group during the period from September 1997 to February 1999. Clinical 
practice guidelines for acute respiratory infections were given to the GPs and the parents 
of the early -intervention group during May 1998 (Chapter 3). Since this intervention 
was not blinded, it had the potential to create a bias in reporting of symptoms by 
parents. To eliminate such bias, analysis of the effect of antibiotics on morbidity was 
restricted to the data received from the late -intervention group only. The children in the 
late -intervention group experienced a total of 2,653 respiratory episodes during the 
period between September 1997 and February 1999. 
Of the 2,653 respiratory episodes, 63% (1,672/2,653) did not have a visit to a doctor or 
to a hospital during the episode (visit). Among the remaining 981 episodes with at least 
one visit during an episode, the number of visits ranged from one to eight within an 
episode. The duration and the number of symptoms in an episode varied with the 
number of visits within an episode (Table 7.2). 
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Table 7.2: Episode characteristics grouped by the number of visits in an episode 
No visit 1 visit 2 visits >2 visits 
Total 1672 670 212 99 
Type of episode 
Fever only 60 (4 %) 31 (5 %) 7 (3 %) 1 (1 %) 
Upper 980 (59 %) 147 (22 %) 28 (13 %) 3 (3 %) 
Lower 365 (22 %) 177 (26 %) 53 (25 %) 18 (18 %) 
Throat 131 (8 %) 142 (21 %) 43 (20 %) 16 (16 %) 
Ear 136 (8 %) 173 (26 %) 81 (38 %) 61 (62 %) 
Total length 
Mean ±SD 7 days ±5 10 days ±8 15 days ±11 26 days ±18 
Median 5 days 9 days 12 days 20 days 
Total symptoms 
Mean ±SD 11 ±12 21 ±17 33 ±24 65 ±49 
Median 7 18 28 50 
Symptoms /day 
Mean ±SD 1.6 ±0.7 2.0 ±0.8 2.1 ±0.8 2.5±0.8 
Median 1.4 1.9 2.2 2.5 
Antibiotic use 77 (5 %) 324 (48 %) 127 (60 %) 88 (89 %) 
Antibiotic use was minimal in the episodes that did not have a visit to a medical 
practitioner. However, there were 77 episodes that received antibiotics without a 
reported visit; 34 of these episodes were in children who had been receiving 
prophylactic antibiotics during that period. I did not have any information about the 
acquisition of antibiotics in the rest of the episodes without a visit. It might be that 
either the parent did not report a visit or used antibiotics left over from a previous 
prescription. 
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The episodes that were associated with at least one visit in an episode were considered 
for analysis. Since a prescription is needed in Australia to obtain antibiotics, it was 
necessary to restrict the analysis to those episodes involving at least one visit to a 
medical practitioner. This allowed a comparison to be made of severity up to the doctor 
visit and the subsequent use or non -use of antibiotics. Therefore I excluded from the 
analysis 1,672 episodes with no visit in an episode. 
A total of 981 episodes had at least one visit during the episode. Of the 981 episodes, 
68% (670/981) had only one visit in an episode. The episodes with only one visit were 
less severe in duration and number of symptoms in the episode than the episodes that 
had more than one visit (Table 7.2). In fact, the higher the number of visits in an 
episode, the more severe the episode was: mean symptoms /day was 2.0 for episodes 
with one visit, 2.1 for episodes with two visits, 2.5 for episodes with more than two 
visits (Table 7.2). 
Since the episodes with only one visit constituted the major portion of respiratory 
episodes in the children, and also those episodes were less severe than the others, I 
decided to analyse those episodes separately. I therefore grouped all the respiratory 
episodes with at least one visit into `less severe' (episodes with only one visit) and 
`more severe' episodes (episodes with more than one visit). To have a valid estimate of 
the effect of antibiotics on respiratory illness, I performed analysis on the less severe and 
the more severe episodes separately. 
7.4. Effect of antibiotics on less severe episodes 
The children had a total of 670 less severe respiratory episodes during the 18 months. 
These episodes were associated with a single visit and 48% of the episodes received an 
antibiotic prescription. 
7.4.1. Methods of statistical analysis 
Data from the daily diary recorded by the parents, parent questionnaires and GP 
questionnaires were entered into an Access data base. Univariate analyses were 
performed in SPSS and multivariate analyses were performed by using STATA to 
address the issue of cluster effect of repeated episodes in the same child. 
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7.4.2. Exposure variable 
The exposure variable was antibiotic use during a respiratory episode, which was a 
dichotomous variable (antibiotic). 
7.4.3. Outcome variable 
Severity was measured as the average number of symptoms per day from the point of 
visit up to the end of the episode (severity). The average number of symptoms in a day 
was calculated by dividing the total number of symptoms after the visit by the duration 
of the episode after the visit. The data collected for this variable were continuous. The 
distribution of severity was positively skewed. The episodes had a mean of two 
symptoms (standard deviation 0.8) in a day after the visit. To make the distributions 
more symmetrical, the average number of symptoms per day after the visit were log 
transformed and used as the outcome variable. 
7.4.4. Selection of the model 
My goal was to obtain a valid estimate of the effect of antibiotic use on the severity of 
respiratory episodes. Therefore I selected an exposure- disease model to answer this 
question, using multivariate regression analysis. The appropriate multivariate model for 
this question was multiple linear regression, as the outcome variable `severity' (average 
number of symptoms per day after the first visit) was a continuous variable. However, I 
performed descriptive analysis before performing a multivariate analysis. 
7.4.5. Descriptive analysis 
Of the 670 respiratory episodes that were associated with only one visit during the 
episode, 48% (324/670) received antibiotics. The severity of the entire episode was no 
different between those treated with an antibiotic and those not treated, in respect to 
total length and total number of symptoms present in an episode (Table 7.3). The 
episodes that received an antibiotic prescription were more severe before the visit than 
the other group: average symptoms per day were 2.24 for antibiotic -treated episodes and 
2.08 for episodes with no antibiotic (Table 7.3). However, after the visit, the severity 
was not significantly different between the two groups (Table 7.3). 
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Table 7.3: Comparison of severity between the episodes that received antibiotics 
and those that did not (n =670 episodes) 
Total length 
(mean) 
Total symptoms 
(mean) 
Symptoms /day 
(mean) 
Entire episode 
Antibiotic group (n =324) 
Non -antibiotic group (n =346) 
*P value 
Episode before visit 
Antibiotic group (n =324) 
Non -antibiotic group (n =346) 
*P value 
Episode after visit 
Antibiotic group (n =324) 
Non -antibiotic group (n =346) 
*P value 
10 
10 
0.78 
5.11 
5.21 
0.49 
4.86 
5.29 
0.62 
20.87 
20.92 
0.81 
11.16 
10.79 
0.72 
9.71 
10.13 
0.39 
2.03 
1.92 
0.09 
2.24 
2.08 
0.02 
1.74 
1.57 
0.06 
*Difference between antibiotic and non -antibiotic episodes by the Mann -Whitney test 
To determine the effect of antibiotics on severity, I measured the severity of the episode 
after the visit where the first antibiotic was prescribed in an episode. 
7.4.6. Adjustment for clustering 
The characteristics of an episode in a child are not necessarily independent of 
characteristics of other episodes in the same child. Therefore the episodes experienced 
by the same child cannot be regarded as independent regarding severity of illness. I 
used a random effect linear regression model in STATA that allowed adjustment for the 
impact of clustering within a child by estimating robust estimate of coefficient and 
standard errors. The robust estimator relaxes the assumption of independence of the 
observations by producing corrected standard errors for correlated observations within a 
child. 
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The command I used in STATA for linear regression was: 
regress severity antibiotic, cl(idno) 
severity = logarithm of average number of symptoms per day after the visit up to the end 
of the episode 
antibiotic = episode associated with antibiotic use 
cl(idno)= clustered by child identification number (adjust for multiple episodes from the 
same child) 
Univariate analysis taking cluster effect of children 
After adjusting for multiple episodes in the same child, there was no difference in 
severity after the first doctor visit between the antibiotic- treated episodes and the 
episodes that were not treated with antibiotics. The episodes that were treated with 
antibiotics had 4% more symptoms per day after the doctor visit than the episodes that 
were not treated with antibiotics (coeff= 0.042, p =0.25) (Table 7.4). 
Table 7.4: Univariate analysis of severity after the first visit between episodes 
that were treated with antibiotics and those that were not, adjusting 
for the cluster effect of children 
Beta Robust Lower Upper P value 
coeff st error 95% CI 95% CI 
Episodes associated with 0.042 0.04 -0.03 0.11 0.25 
antibiotic 
7.4.7. Multivariate analysis 
The goal of the analysis was to obtain a valid estimate of the effect of use of antibiotics 
in an episode on the post- doctor -visit severity of respiratory episodes, after adjusting for 
confounding factors. I followed the stages to develop a multivariate model suggested by 
Kleinbaum, where the stages are variable specification, interaction assessment and 
assessment of confounding.156 
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Variable specification 
I selected potentially confounding variables that could be biologically associated with 
respiratory illness or that had been shown in previous studies to be related to respiratory 
illness. As the severity was measured from symptoms reported by the parents, I also 
considered the factors that could influence parents' reporting of severity. The variables 
were related to episodes, children, parents and environment (Table 7.5 -8.8). 
The type of respiratory episode was considered both as a confounder and as an effect 
modifier. Severity may be different depending on the type of episode, and antibiotics 
may have benefit in some types but not in others. The average number of symptoms per 
day before the doctor visit was included, because severity after the visit could have an 
association with the severity before the visit. The use of medicines other than 
antibiotics could confound the effect of antibiotics by changing the severity of the 
episodes (Table 7.5). 
Child variables such as age and sex were included because of reported increased 
susceptibility to respiratory illness in younger children and in males.167 Parents reported 
in the questionnaire if the child had any major illness which included asthma, 
pneumonia and bronchiolitis. The variable was included as a confounding variable 
because of their possible biological association with respiratory illness and antibiotic 
treatment (Table 7.6). 
Parents' age and education were considered as possible confounders because these 
factors could influence reporting the severity of an illness and being prescribed 
antibiotics in an episode (Table 7.7). 
Attendance at day -care centre increases the risk of illnesses because of crowding and 
transmission of organisms among children.33 The proneness of these children to more 
infections may result in a greater likelihood that they will receive antibiotics. Duration 
of care was considered because of its biological plausibility with development of 
respiratory illness. The more the exposure to other children the more likely it is that the 
child will carry an infection (Table 7.8). 
128 
Table 7.5: Episode variables 
Variable description Form of variable 
Types of episode 
Average number of symptoms /day before 
visit 
Duration of other medicine use (other than 
antibiotic) in an episode 
Categorical 
Type 1 =fever only 
Type2 =upper respiratory 
Type3 =lower respiratory 
Type4= throat 
Types =ear 
continuous 
continuous 
Table 7.6: Child variables 
Variable description Form of variable 
Sex of child 
Age of child at the start of trial 
Any major illness 
Dichotomous 
M =O, F =l 
Continuous 
Dichotomous 
No =0, yes =1 
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Table 7.7: Parent characteristics 
Variable description Form of variable 
Age of father in years Continuous 
Age of mother in years Continuous 
Education of father Categorical 
Fatherl =high school or less, 
Father2 =Trade or TAFE, 
Father3=Uni graduate, 
father4= Postgraduate 
Education of mother Categorical 
Motherl =high school or less, 
Mother2 =Trade or TAFE, 
Mother3=Uni graduate, 
mother4= Postgraduate 
Table 7.8: Environmental variables 
Variable description Form of variable 
Type of child care during the day Categorical 
Carel= parent/private care 
Care2= Family day -care 
Care3= Day -care centre 
Duration of care outside home (hour /week) Categorical 
1 =no care 
2 =1 -20 hours 
3 =21-40 
4 = >40 
Having sibling or not Dichotomous 
No =0. Yes =1 
Interaction assessment 
I assessed interaction before assessing confounding. The variables (Table 7.5 -Table 7.8) 
were tested to determine if there was any effect modification involved with any of the 
variables. I included an interaction term between antibiotic use and each variable in the 
model between exposure, outcome and all potential confounders. I considered keeping 
130 
an interaction term in the model if the impact of the interaction term was significant at 
the level of p <0.05 by Wald test (Table 7.9). 
Table 7.9: Impact of interaction by Wald test on model with all variables 
Interaction terms p value in Wald test 
Antibiotic *types of respiratory episode 0.61 
Antibiotic*symptorn/day before first visit 0.20 
Antibiotic *sex of child 0.42 
Antibiotic *age of child 0.19 
Antibiotic *any major illness of child 0.07 
Antibiotic *age of father 0.30 
Antibiotic *age of mother 0.26 
Antibiotic *father's education 0.11 
Antibiotic *mother's education 0.81 
Antibiotic *type of day -care 0.63 
Antibiotic *duration of day -care 0.52 
Antibiotic *number of sibling 0.40 
None of the interaction terms appeared to be significant at the level of p <0.05 by the 
Wald test. 
Assessment of confounding 
I assessed the potential confounders to determine if the presence of a variable distorted 
the relationship between the explanatory variable (antibiotic) and the outcome (severity) 
(Tables 7.10- 7.13). I used linear regression to assess confounding by adjusting for the 
cluster effect of repeated episodes in the same child. At first I fitted a linear regression 
model with only the explanatory variable against the outcome and calculated a crude 
beta -coefficient of severity associated with antibiotic use against no antibiotic use. The 
crude coefficient was 0.042. Then the same calculation was done adding one potential 
confounder in the model at a time. The resulting beta coefficient was compared with the 
crude beta -coefficient to determine if the variable was a confounder. A distortion of 
coefficient over 10% ( <0.038 or >0.046) was considered as a meaningful change. The 
results of the assessment of confounding are shown in Tables 8.11 -8.14. For example, 
adding type of episode in the model resulted in a coefficient of 0.004, which was more 
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than a 10% distortion from the crude coefficient (Table 7.10). Therefore, I accepted that 
the type of episode confounded the relationship between antibiotic use and severity. 
Table 7.10: Evaluation of episode variables for distortion of effect of antibiotic use 
on severity 
Variables B coeff Interpretation 
Crude co- efficient 0.042 
Adjusted for types of episode 0.005 Confounder 
Adjusted for number of symptoms /day 0.006 Confounder 
before first visit 
Adjusted for duration of other medicine 0.045 *Not confounding 
use 
*not confounding because beta coefficient did not alter 10% from.042. 
Table 7.11: Evaluation of child variables for distortion of effect of antibiotic use 
on severity 
Variables B coeff Interpretation 
Crude co- efficient 
Adjusted for sex of child 
Adjusted for age of child 
Adjusted for major illness 
0.042 
0.055 
0.050 
0.056 
Confounder 
Confounder 
Confounder 
Table 7.12: Evaluation of parent variables for distortion of effect of antibiotic use 
on severity 
Variables B coeff Interpretation 
Crude co- efficient 
Adjusted for age of father 
Adjusted for age of mother 
Adjusted for father's education 
Adjusted for mothers education 
0.042 
0.053 
0.050 
0.047 
0.053 
Confounder 
Confounder 
Confounder 
Confounder 
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Table 7.13: Evaluation of environmental variables for distortion of effect of 
antibiotic use on severity 
Variables B coeff Interpretation 
Crude co- efficient 0.042 
Adjusted for type of day -care 0.052 Confounder 
Adjusted for duration of day -care 0.055 Confounder 
Adjusted for presence of sibling 0.051 Confounder 
Of the episode variables, type of respiratory episode and average number of symptoms 
per day before first visit meaningfully distorted the relationship between antibiotic use 
and severity. Most of the variables related to children and parents also confounded the 
relationship between antibiotic use in an episode and the severity of the episode. 
Final model 
The final multivariate model thus contained 12 confounders and allowed for the cluster 
effect of children. The coefficients for the dichotomous exposure variable estimate the 
mean difference between the logarithm of severity for antibiotic -treated episodes and for 
non -antibiotic episodes. After adjusting for confounding, antibiotic use in an episode 
did not show an association with the subsequent severity of that respiratory episode 
(coeff= 0.008, p =0.78) (Table 7.14). 
Table 7.14: Effect of antibiotic use on severity in less severe respiratory episodes, 
fully adjusted for confounding and the cluster effect of children 
(n =528 episodes) 
Beta Robust* P value Lower 95% Upper 95% 
coeff standard cI cI 
error 
Antibiotic use 0.008 0.027 0.78 -0.05 0.06 
in an episode 
*Standard error adjusted for clustering episodes in the same child 
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7.5. Effect of antibiotics on more severe episodes 
A total of 311 episodes were associated with more than one visit during the episode and 
215 (69 %) of these received an antibiotic. Antibiotics were prescribed at different time 
in different episodes (Figure 7.1). 
Figure 7.1: Visit where antibiotic was prescribed in severe episodes 
Severe episodes 
( >1 visit in an 
episode), n =311 
V 
Received 
antibiotic, n =215 
Did not receive 
antibiotic, n =96 
Received 
antibiotic on 1s` 
visit, n =110 
Received 
antibiotic on 2nd 
visit, n =71 
Received antibiotic 
on 3rd or a later 
visit, n =34 
I performed the analysis in two stages to determine the effect of antibiotics on severe 
episodes. The first analysis was performed including the 96 episodes that did not 
receive antibiotics in the episode and the 110 episodes that received antibiotics on the 
first visit, and severity was measured from the first visit to the end of the episode for 
both groups. 
Of the 96 episodes that did not receive antibiotics, 89% (85/96) had two visits in an 
episode. I performed the second analysis including the same 96 episodes with no 
antibiotic and the 71 episodes that received antibiotics on the second visit. However, 
this time, severity was measured from the second visit to the end of the episode for both 
groups. The effect of antibiotics could not be measured on the 34 episodes that received 
134 
antibiotics on the third or a later visit because of the inadequate number of comparable 
episodes. 
73.1. Episodes that were treated with antibiotics on the first visit 
Descriptive analysis 
A total of 206 respiratory episodes were included in the analysis: 110 (53 %) received 
antibiotics on the first visit and 96 (47 %) episodes did not receive antibiotics. The 
antibiotic -treated episodes were more severe in their entirety than the episodes that were 
not treated by antibiotics, in respect to duration and number of symptoms present in an 
episode (Table 7.15). The antibiotic -treated episodes were also more severe before the 
visit than the episodes that were not treated by antibiotics (Table 7.15). However, 
antibiotics did not reduce the severity of the episodes after the doctor visit, as more 
severe symptoms were reported by the treatment group (Table 7.15). 
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Table 7.15: Comparison of severity between the episodes that received antibiotic 
and those that did not (n =206 episodes) 
Total length 
(mean) 
Total symptoms 
(mean) 
Symptoms /day 
(mean) 
Entire episode 
Antibiotic group (n =110) 
Non -antibiotic group (n =96) 
*P value 
Episode before visit 
Antibiotic group (n =110) 
Non -antibiotic group (n =96) 
*P value 
Episode after visit 
Antibiotic group (n =110) 
Non -antibiotic group (n =96) 
*P value 
20 
15 
0.002 
5.65 
4.81 
0.72 
14.40 
10.15 
0.001 
47.61 
32.83 
<0.001 
13.82 
10.35 
0.03 
33.79 
22.48 
0.002 
2.33 
2.04 
0.005 
2.76 
2.19 
<0.001 
2.24 
2.01 
0.03 
*Difference between antibiotic and non -antibiotic episodes by the Mann- Whitney test 
Univariate analysis taking cluster effect of children 
The severity of episodes after the first doctor visit was compared between the episodes 
that received antibiotics on the first visit and those that did not receive antibiotics. The 
episodes in a child are not necessarily independent of each other. After adjusting for 
multiple episodes in the same child, the antibiotic treated episodes had 16% more 
symptoms per day after the first visit than the episodes that were not treated with 
antibiotic (coeffz0.16, p =0.01) (Table 7.16). 
Table 7.16: Univariate analysis of severity after the first visit between episodes 
that were treated with antibiotics and those that were not, adjusting 
for the cluster effect of children (n =206 episodes) 
Beta Robust P value Lower Upper 
coeff st error 95% CI 95% CI 
Episodes associated with 0.16 0.06 0.01 0.04 0.27 
antibiotic 
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Multivariate analysis 
The impact of interaction was assessed before considering confounding. The effect of 
interaction was tested for the variables (Tables 7.5 -7.8) with interaction with the 
exposure of antibiotic -treated episodes using the Wald test. Two interaction terms were 
significant (p <0.05) by this test: average number of symptoms per day before first visit, 
and age of mother; each interacted with antibiotic use in an episode (Table 7.17). 
Table 7.17: Impact of interaction terms by Wald test on model with all variables 
Interaction terms p value in Wald test 
Antibiotic *types of respiratory episode 0.66 
Antibiotic *symptoms /day before first visit 0.003 
Antibiotic *sex of child 0.85 
Antibiotic *age of child 0.14 
Antibiotic *any major illness of child 0.63 
Antibiotic *age of father 0.89 
Antibiotic *age of mother 0.03 
Antibiotic *father's education 0.22 
Antibiotic *mother's education 0.30 
Antibiotic *type of day -care 0.17 
Antibiotic *duration of day -care 0.27 
Antibiotic *number of siblings 0.55 
In the presence of interaction, confounding assessment requires subjective decisions. To 
avoid making subjective decisions, the safest approach is to keep all potential 
confounders in the model.156 This would ensure the proper control of confounding but 
may lack precision. 
Both of the variables (average symptoms per day and age of mother) were continuous, 
and therefore the overall estimate would be for a child who had no symptom before visit 
and whose mother is 0 years, which would not be meaningful. To have a meaningful 
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estimate, the variables were transformed towards central by subtracting the mean from 
the actual value. The mean age of mothers was 31 years and children had on average 
two symptoms per day before the visit. The final multivariate model contained two 
interaction terms: average number of symptom per day before first visit *antibiotic - 
treated episode, and age of mother *antibiotic- treated episode (Table 7.18). 
Table 7.18: Effect of antibiotic use on more severe respiratory episodes that 
received antibiotics on the first visit, fully adjusted for confounding 
and the cluster effect of children (n =186 episodes) 
Beta Robust P Lower Upper 
coeff std error value 95% CI 95% CI 
Antibiotic use in an episode 0.07 0.06 0.22 -.04 0.18 
Antibiotic use did not change the severity even in more severe respiratory episodes that 
received antibiotics on the first visit. 
7.5.2. Episodes that received antibiotics on the second visit 
Descriptive analysis 
A total of 71 respiratory episodes received antibiotics on the second visit. The severity 
of these episodes were compared with the 96 episodes that did not receive antibiotics 
even after having two or more visits in an episode. For this analysis, severity was 
measured from the point of second visit in the episode. The severity was greater for the 
entire episodes in the antibiotic -treated group than the non -antibiotic group (Table 7.19). 
The antibiotic- treated episodes were also more severe both before and after the second 
visit compared to the episodes that were not treated with antibiotics (Table 7.19). 
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Table 7.19: Comparison of severity between the episodes that received antibiotics 
and those that did not (n =167 episodes) 
Total length Total symptoms Symptoms /day 
(mean) (mean) (mean) 
Entire episode 
Antibiotic group (n =71) 
Non -antibiotic group (n =96) 
*P value 
Episode before visit 
Antibiotic group (n =71) 
Non -antibiotic group (n =96) 
*P value 
Episode after visit 
Antibiotic group (n =71) 
Non -antibiotic group (n =96) 
*P value 
17 
15 
0.16 
9.73 
10.27 
0.68 
6.56 
4.69 
0.007 
38.14 
32.83 
0.06 
23.38 
23.30 
0.19 
14.76 
9.53 
0.005 
2.29 
2.04 
0.05 
2.55 
2.23 
0.05 
2.00 
1.44 
0.002 
Difference between antibiotic and non -antibiotic episodes by the Mann -Whitney test 
Univariate analysis 
After adjusting for repeated episodes in the same child, the severity of the episodes after 
the second visit was not different between the antibiotic -treated episodes and the 
episodes not treated with antibiotics (Table 7.20). 
Table 7.20: Effect of antibiotic on severity in episodes that were prescribed 
antibiotic on the second visit (n =167 episodes) 
Beta Robust P Lower Upper 
coeff std error value 95% CI 95% CI 
Antibiotic use in an episode 0.02 0.03 0.57 -0.04 0.07 
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Multivariate analysis 
None of the interaction terms was significant (p <0.05) by the Wald test. I tested 
confounding after interactions were assessed. A total of 10 variables meaningfully 
distorted the relationship between antibiotic use and severity (Table 7.21). 
Table 7.21: Evaluation of variables for distortion of effect of antibiotic use on 
severity 
Variables B coeff Interpretation 
Crude co- efficient 
Adjusted for types of episode 
Adjusted for symptoms /day before 2 "d visit 
Adjusted for duration of other medicine use 
Adjusted for sex of child 
Adjusted for age of child 
Adjusted for major illness 
Adjusted for age of father 
Adjusted for age of mother 
Adjusted for father's education 
Adjusted for mother's education 
Adjusted for type of day -care 
Adjusted for duration of day -care 
Adjusted for presence of sibling 
0.015 
-0.003 
0.006 
0.016 
0.008 
0.007 
0.004 
0.006 
0.005 
0.017 
0.013 
0.010 
0.008 
0.008 
Confounder 
Confounder 
Not confounding 
Confounder 
Confounder 
Confounder 
Confounder 
Confounder 
Not confounding 
Not confounding 
Confounder 
Confounder 
Confounder 
Final model 
The final multivariate model was adjusted for 10 confounders and for cluster effect of 
children (Table 7.22). After fully adjusting for confounding and cluster, antibiotic use 
in an episode did not significantly reduce the severity of the episode after the doctor 
visit. 
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Table 7.22: Effect of antibiotic on respiratory episodes that received antibiotic on 
the second visit, fully adjusted for confounding and the cluster effect 
of children (n =134 episodes) 
Beta Robust P Lower Upper 
coeff std error value 95% CI 95% CI 
Antibiotic use in the episode -0.005 0.02 0.83 -0.05 0.04 
7.6. Discussion 
Antibiotic use did not show a beneficial effect on respiratory episodes, even when the 
episode was more severe. These results support the bulk of reviews that showed no 
beneficial effect of antibiotics on acute respiratory illness (Chapter 2). However, 
antibiotics are routinely prescribed for these illnesses, for example, about half of the 
less severe episodes and over 60% of the more severe episodes were treated with 
antibiotics (Table 7.2). Most of the respiratory illnesses are of viral origin and 
antibiotic use does not make a difference in viral illnesses. Complications from acute 
respiratory illness are not common in developed countries; complications from sore 
throat are rarely seen.168 Complications from acute otitis media are also rare, for 
example, in the Netherlands, among 4,860 consecutive patients with acute otitis media 
who were not given antibiotics, only two experienced mastoiditis. However, both 
patients responded to the oral antibiotics.66 
I could not analyse the effect of antibiotics on the episodes that received antibiotics on 
the third or a subsequent visit because of inadequate number of comparable episodes. 
If these episodes are the ones that developed complications, antibiotics could have a 
different effect on those. 
Because of the low prevalence of complications in developed countries, antibiotics can 
be avoided as a routine practice for acute respiratory infections. If antibiotic use could 
be withheld and used only for the complicated respiratory infections, we would see a 
substantial reduction in antibiotic use. However, the implications will be different for 
developing countries, where the complications from ARI, for example, rheumatic fever 
and acute glomerulonephritis, are common. 
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Chapter 8 Discussion and conclusions 
8.1. Introduction 
Since the late 1960s, strains of antibiotic- resistant pneumococci have been isolated with 
increasing frequency around the world.169 As penicillin has been the antibiotic of choice 
for pneumococcal infections, the emergence of penicillin- resistance has made the choice 
of empiric therapy for these infections more difficult.95 
The collection of longitudinal data on antibiotic use and respiratory symptoms in this 
prospective cohort study permitted me to explore the likely effects of antibiotic use on 
pneumococcal antibiotic -resistance and on the outcomes of the illnesses. In view of the 
growing concern at the rate of increase in antibiotic -resistance, an exploration of the 
likely benefits and costs of reducing antibiotic use seemed to be highly desirable. 
This chapter summarises the effect of antibiotic use on respiratory illness and on 
antibiotic -resistance in the cohort. It also discusses the limitations of the study and 
considers future needs in this field of work. 
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8.2. Use of beta lactam antibiotics was associated with an increase in 
pneumococcal resistance to penicillin 
The primary research question was whether antibiotic use in children affects antibiotic- 
resistance in pneumococci. I concentrated my analysis on beta lactam antibiotic use in 
children and its association with pneumococcal resistance to penicillin. The study 
provided support for two theories of antibiotic -resistance (Chapter 6). 
First, children who received a beta lactam antibiotic during the two months before swab 
collection were more likely to carry a penicillin- resistant pneumococcus (PRP) than 
children who did not (OR 2.03, 95% CI 1.15 -3.56, p= 0.01). Although this association 
was also suggestive for beta lactam use during the previous six months (Odds ratio >1), 
statistical significance was only reached for beta lactam use during the two months 
before swab collection. A study with a larger sample size would be needed to explore 
this association beyond two months. 
Secondly, the likelihood that a child carried a resistant pneumococcus increases with an 
increase in duration of antibiotic use. The total beta lactam antibiotic use by the 
children during the six months before swab collection was evaluated against the rate of 
isolation of PRP. The risk of a child carrying a penicillin- resistant pneumococcus 
increased by 4% for each extra day of beta lactam antibiotic use during the previous six 
months (OR 1.04, 95% CI 1.01 -1.06, p= 0.001). The risk of carriage of PRP was 
significantly higher in children who used beta lactam antibiotics for more than 14 days 
during the six months compared to the children who did not receive any beta lactam 
(OR 2.50, 95% CI 1.30 -4.82, p= 0.006). This association was also true when the 
penicillin group of antibiotics alone was considered. 
The results also suggest, but do not establish, that use of broader -spectrum antibiotics 
(cephalosporin) was more likely to increase penicillin- resistance than use of narrower - 
spectrum antibiotics (penicillin group). I found that cephalosporin use during the two 
months before swab collection was associated with higher risk of penicillin -resistance 
than the risk associated with penicillin group use (OR 1.93 versus OR 1.63). The 
difference was not statistically significant. 
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8.3. Antibiotic use did not reduce the severity of respiratory illness 
The second linked question that this study aimed to answer was whether the use of an 
antibiotic for acute respiratory infection in children had demonstrably altered the 
severity of illness. Here a comparison was made between the respiratory episodes that 
were treated with antibiotics and the episodes that were not. The effect of antibiotic 
treatment was examined separately on less severe and more severe respiratory episodes. 
Less severe episodes had a mean of two symptoms per day, the severe episodes had a 
mean of 2.3 symptoms per day. Forty -eight per cent of the less severe respiratory 
episodes received an antibiotic compared to 69% of the more severe episodes. In the 
less severe group, antibiotics were prescribed more often for children who had more 
symptoms before the visit to the doctor (average symptoms per day 2.24 for episodes 
with antibiotic versus 2.08 for episodes with no antibiotic, p= 0.02). However, there was 
no difference observed between the two groups after the doctor visit (fully adjusted beta 
coefficient 0.01, p= 0.73). The results suggest that antibiotic use did not reduce the 
severity of respiratory illness in children who presented with less severe illness. There 
was also no demonstrable difference in outcome of severity between the more severe 
episodes that were or were not treated with an antibiotic (Chapter 7). 
These findings cannot be seen as evidence that the use of antibiotics did not alter 
outcome. But they do provide some support for a more conservative approach to 
antibiotic use, especially when considered in conjunction with evidence from recent 
overviews of randomised controlled trials (Chapter 2). 
8.4. Strengths and limitations of the study 
The study was designed to minimise the potential problems of a cohort study. Loss to 
follow -up is the biggest problem for a study of this duration. We undertook a number of 
strategies to maintain a good participation rate. 
A research assistant was employed to ring all the parents who failed to send the previous 
month's diary back by the middle of the following month. During each set of nasal 
swab collections, a research assistant and I rang every parent to remind them on the 
evening before the date of swab collection. This short telephone conversation actually 
helped both parents and us to know each other, and also helped parents to feel involved 
in the study. That also helped us to track the change of address and telephone number 
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for parents. We also sent out repeated newsletters to both parents and GPs informing 
them of different aspects of the study. 
Notwithstanding these efforts to maintain compliance there was significant 
incompleteness in diary data. Therefore I had to express all the study events as days per 
child -year, where the number of child -days in the denominator varied across the study 
population. I was unable to ascertain the nature and extent of bias that resulted from 
this limitation; however, it is possible that the study results represent an over estimation 
of respiratory illness in children. As I mentioned in Chapter 5, a few parents sent a diary 
after a prolonged interval of non -return. At that time, we did not check the reason for 
recommenced diary recording: it could be an episode of illness in children which 
reminded parents about the diary. However, the rate of respiratory illness in the study 
children is still comparable with the reported rate in children in day -care centres in the 
ACT.154 
Although the majority of the study GPs were recruited strictly by the protocol in primary 
recruitment, we could not maintain this random process during secondary recruitment. 
We approached one GP from each of the practices in the sample frame during primary 
recruitment. In the secondary recruitment we selected a few names of the GPs from 
group practices where another GP was approached before, but that GP declined to 
participate. Although only a total of five GPs were recruited in this recruitment, this 
subset of GP recruitment could lead to a selection bias of the sample: they might 
overrepresent the GPs practising in a group practice. However, the demographic details 
of the study GPs were representative of Australian GPs (Chapter 5). GPs practising in a 
group practice might prescribe fewer antibiotics because of the likelihood of 
dissemination of scientific information between the GPs. The lower prescribing by the 
GPs subsequently could affect the antibiotic -resistance level in the children. However, 
this factor should not affect the association of antibiotic use with antibiotic -resistance or 
with outcome of respiratory illness in children. 
The recruitment of children took much longer than anticipated. We anticipated two 
weeks would be needed to recruit fifteen children from a GP's surgery. However, even 
after repeated reminders and encouragement from us, it took several months for most of 
the GPs to recruit even half of the target number of children. A consequence of the 
longer recruitment was a shorter period of data collection before the first round of swab 
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collection. Consequently only a small proportion of pneumococci isolated in the first 
swab could be used for the analysis of antibiotic use versus antibiotic -resistance. 
Although the study was able to show a significant association between antibiotic use and 
antibiotic -resistance, it sometimes suffered from problems associated with inadequate 
sample size. For example, there was insufficient power to explore thoroughly the 
association between pneumococcal penicillin -resistance and beta lactam antibiotic use 
for the 2 -6 months window before carriage of a resistant organism. For the same reason, 
the effect of prophylactic antibiotic use on antibiotic- resistance could not be adequately 
explored. 
Despite these limitations, the results are consistent with current theories regarding 
antibiotic -resistance. The higher risk of PRP carriage associated with broader -spectrum 
antibiotics (cephalosporin) against narrower -spectrums (penicillin group), though 
suggestive, was not however statistically proved. Nor could the theory regarding 
complete versus incomplete antibiotic courses and antibiotic -resistance be explored 
sufficiently, because of the limited sample size. 
Selection bias may have occurred when parents and children were selected for the study 
by their GPs as seen from the higher educational and income profile of the study 
parents. The higher socioeconomic profile of the study children could affect the 
generalisability of the study findings. Once an antibiotic was given to a child, the 
severity of illness or carriage of PRP should not differ between the children with parents 
having different levels of education or income. However, reporting of symptoms, thus, 
of the severity of illness, could be different depending on the level of parents' education. 
For this reason, I considered the socioeconomic variables related to parents as potential 
confounders in the analysis of antibiotics' effect on severity. 
Recall bias is probably an issue in this study. The daily diary was sent to the parents as 
a monthly calendar. Parents were asked to record respiratory symptoms and treatment 
of their children every day. In reality, it seemed that daily completion of the diary was 
probably not possible for most of the parents, some parents completed the calendar at 
the end of each month and sometimes the recall was even longer. By that time, they 
could forget some symptom or treatment, especially when it was trivial. This might be 
an explanation for having some records of antibiotic treatment from children without a 
record of a medical consultation. In future work, the problem of recall bias could be 
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reduced by a fortnightly telephone interview with every parent along with a calendar 
report, which could be used as a counter check as well as a reminder. 
There was a possibility that symptoms of respiratory illness and management may have 
been underreported. This study was a part of a RCT of clinical practice guidelines, and 
parents were aware that an objective of the study was to reduce doctor visits and 
antibiotic use in ARIs. Some parents might have tended to report fewer doctor visits. In 
some respiratory episodes, we found that there was abrupt disappearance of respiratory 
symptoms after the day of commencement of antibiotic treatment in an apparently 
severe episode before the doctor visit. It might well be a real effect or a coincidence; 
however, it might also be that some parents reported fewer symptoms after antibiotic 
prescription to validate antibiotic use in that episode. Parents could also have forgotten 
the events once the child started feeling better, or they did not feel it important to report 
the symptoms. A fortnightly telephone interview with parents could reduce this 
problem as well. 
The funding for this study allowed us to test only one pneumococcal isolate from each 
child during each round of swab collection. We therefore tested only the predominant 
isolate from each child in each collection. As we could not test all pneumococcal 
isolates, the rate of resistance may be underreported in this study. Funding limitations 
meant that the pneumococcal isolates could not be serotyped. It was not therefore 
possible to test whether repeated pneumococcal carriage in a child was due to prolonged 
carriage of the same strain of pneumococci or acquisition of a new strain. 
147 
8.5. Recommendations for the future 
My findings on antibiotic -resistance add to the growing evidence in the literature that 
decreasing unnecessary antibiotic use is the primary step to reduce the emergence of 
antibiotic -resistance. They also suggest that when antibiotic use is indicated, a shorter 
duration, adequate to eradicate the organisms is less likely to induce antibiotic - 
resistance. The results further suggest that treatment with a narrow -spectrum agent may 
be less likely to promote carriage of resistant organisms. 
There is emerging evidence that antibiotics can safely be withheld in most childhood 
respiratory illnesses. My own analysis cannot be seen as definitive but it certainly 
suggests that even for the severe illnesses presented at the time of doctor visit, the 
respiratory outcomes were not appreciably different in the two groups, whether they 
were treated with or without antibiotics. 
8.6. Conclusion 
This study is one of the most extensive follow -up studies of the twin issues of antibiotic 
prescribing and pneumococcal antibiotic -resistance in childhood. The size and duration 
of the study created some problems of data completeness but enabled me to conclude 
that, in the Australian community setting: 
use of beta lactam antibiotics increases the likelihood that a child will carry 
penicillin- resistant pneumococcus in the following six months. 
the greater the duration of beta lactam use, the higher the likelihood of carriage of a 
penicillin -resistant pneumococcus in children. 
Also, my comparative analysis of the clinical outcomes of antibiotic use in respiratory 
infections in the general practice setting strongly suggested that the high use of 
antibiotics was not associated with evidence of reduced morbidity, even when severity 
of illness at the time of presentation to the GP was controlled for. This evidence, taken 
in conjunction with the emerging evidence from RCTs, provides added justification for 
greater conservatism in the prescription of antibiotics for these ubiquitous infections. 
148 
References 
1. Bridges -Webb C, Britt H, Miles DA, Neary S, Charles J, Traynor V. Morbidity and 
treatment in General Practice in Australia 1990 -1991. Med J Aust 
1992; 157(supplement):33 -42. 
2. Gwaltney JM. The common cold. Principles and practice of infectious diseases. 3rd 
ed, 1990. 
3. Collignon PJ, Bell -JM. Drug resistant Streptococcus pneumoniae: the beginning of 
the end for many antibiotics? Med JAust 1996;164(2):64 -67. 
4. Turnidge JD, Bell JM, Collignon PJ. Rapidly emerging antimicrobial resistance in 
Streptococcus pneumoniae in Australia. Med JAust 1999;170:152 -155. 
5. Arason VA, Kristinsson KG, Sigurdsson JA, Stefansdottir G, Molstad S, 
Gudmundsson S. Do antimicrobials increase the carriage rate of penicillin 
resistant pneumococci in children? Cross sectional prevalence study. BMJ 
1996;313:387 -91. 
6. Brook I, Gober AE. Prophylaxis of amoxicillin or sulfisoxazole for otitis media: 
Effect on the recovery of penicillin resistant bacteria from children. Clin Infect 
Dis 1996;22:143 -5. 
7. Molstad S, Ekedahl A, Hovelius B, Thimansson H. Antibiotics prescription in 
primary care: a 5 -year follow -up of an educational programme Family Practice 
1994;11:282 -286. 
149 
8. Reichler MR, Allphin AA, Breiman RF, Schreiber JR, Emold JE, McDougal LK, et 
al. The spread of multiply resistant Streptococcus pneumoniae at a day care 
center in Ohio. Jlnfect Dis 1992;166:1346 -53. 
9. Stansfield SK, Shepard DS. Acute Respiratory Infection. In: Jamison D, Mostly W, 
Measham A, Bobbabilla J, editors. Disease control priorities in developing 
countries: Oxford U.Press, 1993:67 -89. 
10. Berman S. Epidemiology of acute respiratory infections in children of developing 
countries. Rev Infect Dis 1991;13:454 -62. 
11. Campbell H. Acute respiratory infection:a global challenge. Archives of Disease in 
Childhood 1995 1995;73:281 -286. 
12. Berman S, McIntosh K. Acute respiratory infections. 1985. 
13. Gadomski AM. Potential interventions for preventing pneumonia among young 
children: lack of effect of antibiotic treatment for upper respiratory infections. 
Paediatr Infect Dis J1993;12:115-20. 
14. Douglas RM, Woodward A, Miles H, Buetow S, Morris D. A prospective study of 
proneness to acute respiratory illness in the first two years of life. Int J 
Epidemiology 1994;23(4):818 -826. 
15. Coriell LL. Clinical syndromes in children caused by respiratory infection. Med Clin 
NAmer 1967;51. 
150 
16. Denny FW, Clyde WA, Jr. Acute lower respiratory tract infections in non - 
hospitalized children. JPediatr 1986;108:635 -646. 
17. Krugman S, Ward R, Katz S. Infectious diseases of children. 6th ed. St. Louis: CV 
Mosby, 1977. 
18. Ruuskanen O, Heikkinen T. Viral- bacterial interaction in acute otitis media. Pediatr 
Infect Dis J 1994;13:1047 -9. 
19. Arola M, Ruuskanen O, Ziegler T, Mertsola J, Nanto- Salonen K, Putto -Laurila A, et 
al. Clinical role of respiratory virus infection in acute otitis media. Pediatrics 
1990;86:848 -855. 
20. Howie V, Ploussard J, Lester RJ. Otitis media: a clinical and bacteriological 
correlation. Pediatrics 1970;45:29 -35. 
21. Wald E, Milmoe G, Bowen A, Ledesma- Medina J, Salamon N, Bluestone C. Acute 
maxillary sinusitis in children. N Engl J Med 1981;304(13):749 -754. 
22. Glezen WP, Denny FW. Epidemiology of acute lower respiratory disease in 
children. N Engl JMed 1973;288(10):498 -505. 
23. Hall C, Powell K, Schnabel K, Gala C, Pincus P. Risk of secondary bacterial 
infection in infants hospitalized with respiratory syncytial viral infection. J 
Pediatr 1988;113:266 -271. 
151 
24. Torzillo P, Dixon J, Manning K, Hutton S, Gratten M, Hueston L, et al. Etiology of 
acute lower respiratory tract infection in Central Australian Aboriginal children. 
Pediatr Infect Dis J1999;18(8):714-21. 
25. Korppi M, Leinonen M, Koskela M, Makela P, Lavniala K. Bacterial coinfection in 
children hospitalized with respiratory syncytial virus infections. Pediatr Infect 
Dis J 1989;8:687 -692. 
26. Monto AS, Ullman BM. Acute respiratory illness in an American community. The 
Tecumseh study. JAMA 1974;227(2):164 -9. 
27. Berman S, Duenas A, Bedoya A, Constain V, Leon S, Borrero I, et al. Acute lower 
respiratory tract illnesses in Cali, Colombia: a two year ambulatory study. 
Pediatrics 1983;71:210 -218. 
28. Wright AL, Taussig LM, Ray CG, Harrison HR, Holberg CJ. The Tucson Children's 
Respiratory Study. II. Lower respiratory tract illness in the first year of life. Am J 
Epidemiol 1989;129(6):l232-46. 
29. Payling- Wright G, Payling- Wright H. Etiological factors in broncho -pneumonia 
amongst infants in London. JHyg (Camb) 1945;44:15 -30. 
30. Gardner G, Frank AL, Taber LH. Effects of social and family factors on viral 
respiratory infection and illness in the first year of life. J Epidemiol Community 
Health 1984;38:42 -48. 
31. Woods H. The influence of external factors on the mortality from pneumonia in 
childhood and later adult life. JHyg (Camb) 1927;26:36 -43. 
152 
32. Monto AS, Ross H. Acute respiratory illness in the community: effect of family 
composition, smoking, and chronic symptoms. Br J Prey Soc Med 
1977;31(2):101 -8. 
33. Strangert K. Respiratory illness in preschool children with different forms of day 
care. Pediatrics 1976;57(No.2):191 -196. 
34. Fleming DW, Cochi SL, Hightower AW, Broome CV. Childhood upper respiratory 
tract infections: to what degree is incidence affected by day -care attendance? 
Pediatrics 1987;79(1):55 -60. 
35. Hurwitz ES, Gunn WJ, Pinsky PF, Schonberger LB. Risk of respiratory illness 
associated with day -care attendance: a nationwide study. Pediatrics 1991;87(No 
1):62 -69. 
36. Soyka LF, Robinson DS, Lachant N, Monaco J. The misuse of antibiotics for 
treatment of upper respiratory tract infections in children. Pediatrics 
1975;55:552 -6. 
37. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office 
based physicians in the United States. JAMA 1995;273:214 -219. 
38. Cunningham DG, Challapalli M, O'Keefe JP, Gardner HG, Puczynski MS. 
Unprescribed use of antibiotics in common childhood infections. J Pediatr 
1983;103(5):747 -749. 
39. Hossain MM, Glass RI, Khan MR. Antibiotic use in a rural community in 
Bangladesh. Int J Epidemiol 1982;11(4):402 -5. 
153 
40. Stein CM, Todd WT, Parirenyatwa D, Chakonda J, Dizwani AG. A survey of 
antibiotic use in Harare primary care clinics. J Antimicrob Chemother 
1984;14(2):149 -56. 
41. Lexomboon U, Duangmani C, Kusalasai V, Sunakom P, Olson LC, Noyes HE. 
Evaluation of orally administered antibiotics for treatment of upper respiratory 
infections in Thai children. JPediatr 1971;78(5):772 -778. 
42. McManus P, Hammond ML, Whicker SD, Primrose JG, Mant A, Fairall SR. 
Antibiotic use in the Australian community, 1990 -1995. Med J Aust 
1997;167:124 -127. 
43. Harvey KJ, Stewart R, Hemming M, Naismith N, Moulds R. Educational antibiotic 
advertising. Med JAust 1986;145:28 -32. 
44. Fox JP, Hall CE, Cooney MK, Luce RE, Kronmal RA. The Seattle virus watch: II. 
Objectives, study population and its observation, data processing and summary 
of illnesses. Am JEpidemiol 1972;96(4):270 -285. 
45. Selwyn BJ. The epidemiology of acute respiratory tract infection in young children: 
comparison of findings from several developing countries. Rev Infect Dis 
1990;12:S870-8. 
46. Stolley PD, Lasagna L. Prescribing patterns of physicians. J Chronic Dis 
1969;22:395. 
47. McGregor A, Dovey S, Tilyard M. Antibiotic use in upper respiratory tract 
infections in New Zealand. Family Practice 1995;12:166 -170. 
154 
48. Arroll B, Kenealy, T. Antibiotics versus placebo for the common cold (Cochrane 
Review). The Cochrane Library. Oxford: Update Software, 1999. 
49. Ackerman BD. Treatment of undifferentiated respiratory infections in infants. Clin 
Pediatr 1968;7:391. 
50. Hardy LM, Traisman HS. Antibiotics and chemotherapeutic agents in the treatment 
of uncomplicated respiratory infection in children: A controlled study. J Pediatr 
1956;48:146. 
51. Townsend EH, Radebaugh JF. Prevention of complications of respiratory illness in 
pediatric practice: A double blind study. NEngl JMed 1962;266:683. 
52. Wald ER. Sinusitis in children. Pediatr Infect Dis J 1988;7:150 -153. 
53. Fan BM, Hendley JO, Kaiser D, Gwaltney J. Two randomized controlled trials of 
virucidal nasal tissues in the prevention of natural upper respiratory infections. 
American Journal of Epidemiology 1988;128(5):1162 -72. 
54. O'Brien KL, Dowell SF, Schwartz B, Marcy SM, Phillips WR, Gerber MA. Acute 
sinusitis -principles of judicious use of antimicrobial agents. Pediatrics 
1998;101:174 -177. 
55. Wald E. Management of sinusitis in infants and children. Pediatr Infect Dis J 
1988;7:449 -452. 
56. Hays G, Mullard J. Can nasal bacterial flora be predicted from clinical findings? 
Pediatrics 1972;49:596 -599. 
155 
57. Wald E, Chiponis D, Ledesma -Medina J. Comparative effectiveness of amoxicillin 
and amoxicillin -clavulanate potassium in acute paranasal sinus infections in 
children: a double -blind, placebo -controlled trial. Pediatrics 1986;77:795 -800. 
58. Williams JJ, Aguilar C, Makela M, Cornell J, Holleman D, Chiquette E, et al. 
Antibiotics for acute maxillary sinusitis. The Cochrane Library 2000(2). 
59. Paradise JL, Rockette HE, Colborn DK, Bernard BS, Smith CG, Kurs -Lasky M, et 
al. Otitis media in 2253 Pittsburgh -area infants: prevalence and risk factors 
during the first two years of life. Pediatrics 1997;99(3):318 -33. 
60. Bluestone CD, Klein JO. Otitis media in infants and children. Philadelphia PA: WB 
Saunders, 1988. 
61. Douglas RG, Jr., Alford BR, Couch RB. Atraumatic nasal biopsy for studies of 
respiratory virus infection in volunteers. Antimicrob Agents Chemother 
1968;8:340 -3. 
62. Froom J, Culpepper L, Grob P, Bartelds A, Bowers P, Bridges -Webb C, et al. 
Diagnosis and antibiotic treatment of acute otitis media: report from 
International Primary Care Network. BMJ 1990;300:582 -6. 
63. Glasziou PP, Hayem M, Del Mar CB. Antibiotics for acute otitis media in children. 
The Cochrane Library 2000(2). 
64. Froom J, Culpepper L, Jacobs M, DeMelker RA, Green LA, van Buchem L, et al. 
Antimicrobials for acute otitis media? A review from the International Primary 
Care Network. BMJ 1997;315:98 -102. 
156 
65. Rosenfeld RM, Vertrees JE, Can J, Cipolle RJ, Uden DL, Giebink GS, et al. 
Clinical efficacy of antimicrobial drugs for acute otitis media: metaanalysis of 
5400 children from thirty three randomized trials. Jpediatr 1994;124:355 -367. 
66. Van Buchem FL, Peeters MF, Van 't Hof MA. Acute otitis media: a new treatment 
strategy. BMJ 1985;290:1033 -37. 
67. Grenier B. Decision -making in otitis media in children, part 1: epidemiologic data 
and defmitions for a reliable cost -effectiveness analysis. Clin Microbial Infect 
1997;3 (Suppl): S62 -8. 
68. Stool SE, Berg AO, Berman S. Otitis media with effusion in young children. 
Clinical practice guideline. Agency for Health Care Policy and Research, 1994. 
69. Williams RL, Chalmers TC, Stange KC, Chalmers FT, Bowlin SJ. Use of antibiotics 
in preventing recurrent acute otitis media and in treating otitis media with 
effusion. A meta -analytic attempt to resolve the brouhaha. JAMA 
1993;270:1344 -1351. 
70. Rosenfeld RM. What to expect from medical treatment of otitis media. Pediatr 
Infect Dis J1995;14:731-738. 
71. Dowell SF, Marcy SM, Phillips WR, Gerber MA, Schwartz B. Otitis media - 
principles of judicious use of antimicrobial agents. Pediatrics 1998;101:165- 
171. 
157 
72. Schwartz B, Marcy SM, Phillips WR, Gerber MA, Dowell SF. Pharyngitis - 
principles of judicious use of antimicrobial agents. Pediatrics 1198;101:171- 
174. 
73. Putto A. Febrile exudative tonsillitis: viral or streptococcal? Pediatrics 1987;80:6- 
12. 
74. Del Mar C, Glasziou PP, Spinks A. Antibiotics for sore throat (Cochrane Review). 
The Cochrane Library 2000(2). 
75. Little P, Williamson I, Warner G, Gould C, Gantley M, Kinmonth AL. Open 
randomized trial of prescribing stratregies in managing sore throat. BMJ 
1997;314:722 -7. 
76. Alpert JJ, Pickering MR, Warren RJ. Failure to isolate streptococci from children 
under the age of 3 years with exudative tonsillitis. Pediatrics 1966;38:663 -666. 
77. Monto A, Cavallaro J. The Tecumseh study of respiratory illness. 11. Patterns of 
occurrence of infection with respiratory pathogens. Am J Epidemtol 
1971;94:280 -289. 
78. Mainous A, Zoorob R, Hueston W. Current management of acute bronchitis in 
ambulatory care: the use of antibiotics and bronchodilators. Arch Fam Med 
1996;5:79 -83. 
79. Vinson DC, Lutz U. The effect of parental expectations on treatment of children 
with a cough: a report from ASPN. JFam Pract 1993;37:23 -27. 
158 
80. DeLozier J, Gagnon R. National Ambulatory Care Survey, 1989. Hyattsville: 
National Centre for Health Statistics, 1989. 
81. Meza R, Bridges -Webb C, Sayer G, Miles D, Traynor V, Neary S. The management 
of acute bronchitis in general practice: results from the Australian morbidity and 
treatment survey, 1990 -1991. Aust Fam Physician 1994;23(8):1550 -1553. 
82. On PH, Scherer K, Macdonald A, Moffatt MEK. Randomized placebo -controlled 
trials of antibiotics for acute bronchitis: a critical review of the literature. J Fam 
Pract 1993;36:507-512. 
83. Fahey T, Stocks N, Thomas T. Quantitative systematic review of randomised 
controlled trials comparing antibiotic with placebo for acute cough in adults. 
BMJ 1996;316:906 -910. 
84. Becker L, Glazier R, McIsaac W, Smucny J. Antibiotics for acute bronchitis 
(Cochrane Review). The Cochrane Library 2000(2). 
85. Gordon M, Lovell S, Dugdale A. The value of antibiotics in minor respiratory illness 
in children. Med JAust 1974;1:304 -306. 
86. Taylor B, Abbott G, Mckerr M, Fergusson D. Amoxycillin and cotrimoxazole in 
presumed viral respiratory infections of childhood: placebo -controlled trial. BMJ 
1977;2:552 -554. 
87. Swartz MN. Use of antimicrobial agents and drug resistance. N Engl J Med 
1997;337:491 -2. 
159 
88. Little PS, Williamson I. Are antibiotics appropriate for sore throats? Cost outweigh 
the benefits. BMJ 1994;309:1010 -1012. 
89. Seppala H, Nissinen A, Jarvinen H, Huovinen S, Henriksson T, Herva E, et al. 
Resistance to erythromycin in group A streptococci. N Engl J Med 
1992;326(5):292-7. 
90. Eliasson I, Holst E, Molstad S, Kamme C. Emergence and persistence of beta - 
lactamase- producing bacteria in the upper respiratory tract in children treated 
with beta -lactam antibiotics. Am J Med 1990;88(5A):51S -55S. 
91. Kunin C. Problems in antibiotic usage. In: Mandel G, Douglas RJ, Bennett J, 
editors. Principles and practice in infectious diseases. 3rd ed. New York: NY: 
Churchill Livingstone Inc, 1990:427 -434. 
92. Levy S. The antibiotic paradox: how miracle drugs are destroying the miracle. New 
York: Plenum Press, 1992. 
93. Datta N, Faiers MC, Reeves DS, Brumfitt W, Orskov F, Orskov I. R Factors in 
Escherichia coli in faeces after oral chemotherapy in general practice. Lancet 
1971;1(7694):312 -5. 
94. Levy SB. Microbial resistance to antibiotics. An evolving and persistent problem. 
Lancet 1982;2(8289):83 -8. 
95. Butler JC, Hofmann J, Cetron MS, Elliot JA, Facklam RR, Breiman RF. The 
continued emergence of drug- resistant Streptococcus pneumoniae in the United 
States: an update from the Centers for Disease Control and Preventions 
Pneumococcal Sentinel Surveillance System. JInfect Dis 1996;174:986 -93. 
160 
96. Hammond ML, Norriss MS. Antibiotic resistance among respiratory pathogens in 
preschool children. Med JAust 1995;163:239 -242. 
97. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug - 
resistant pneumococcal infections in the United States. JAMA 1994;271:1831- 
1835. 
98. Heffernan R, Henning K, Labowitz A, Hjelte A, Layton M. Laboratory survey of 
drug- resistant Streptococcus pneumoniae in New York City, 1993 -1995. 
Emerging Infectious Diseases 1998;4:113 -116. 
99. Istre GR, Tarpay M, Anderson M, Pryor A, Welch D, Group TPS. Invasive disease 
due to Streptococcus pneumoniae in an area with a high rate of relative penicillin 
resistance. J Infect Dis 1987;156(5):732 -735. 
100. Hofmann J, Cetron MS, Farley MM, Baughman WS, Facklam RR, Elliott JA, et al. 
The prevalence of drug- resistant Streptococcus pneumoniae in Atlanta. N Engl J 
Med 1995;333:481 -486. 
101. Haglund LA, Istre GR, Pickett DA, Welch DF, Fine DP, Group TPS. Invasive 
pneumococcal disease in Central Oklahoma: emergence of high -level penicillin 
resistance and multiple antibiotic resistance. Jlnfect Dis 1993;168:1532 -6. 
102. Collignon PJ, Bell J, Hufton IW, Mitchell D. Meningitis caused by a penicillin and 
chloramphenicol resistant Streptococcus pneumoniae. Med JAust 1988;149:497- 
498. 
103. Hansman D, Bullen MM. A resistant pneumococcus. Lancet 1967;2:264 -265. 
161 
104. Klugman KP, Koornhof HJ. Drug resistance patterns and serogroups or serotypes 
of pneumococcal isolates from cerebrospinal fluid or blood, 1979 -1986. Jlnfect 
Dis 1988;158(5):956 -64. 
105. Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 
1990;3:171 -196. 
106. Grimwood K, Collignon PJ, Currie BJ, Ferson MJ, Gilbert GL, Hogg GG, et al. 
Antibiotic management of pneumococcal infections in an era of increased 
resistance. J Paediatr Child Health 1997;33(4):287 -95. 
107. Gray BM, Converse GMd, Dillon HC, Jr. Epidemiologic studies of Streptococcus 
pneumoniae in infants: acquisition, carriage, and infection during the first 24 
months of life. J Infect Dis 1980;142(6):923 -933. 
108. Jacobs MR, Koornhof HJ, Robins -Browne RM, Stevenson CM, Vermaak ZA, 
Freiman I, et al. Emergence of multiply resistant pneumococci. N Engl J Med 
1978;299:735 -740. 
109. Radetsky MS, Istre GR, Johansen TL, Parmelee SW, Lauer BA, Wiesenthal AM, et 
al. Multiply resistant pneumococcus causing meningitis: its epidemiology within 
a day -care centre. Lancet 1981;October 10:771 -773. 
110. Barry B, Gehanno P, Blumen M, Boucot I. Clinical outcome of acute otitis media 
caused by pneumococci with decreased susceptibility to penicillin. Scand J 
Infect Dis 1994;26(4):446 -52. 
162 
111. Gratten M, Naraqi S, Hansman D. High prevalence of penicillin- insensitive 
pneumococci in Port Moresby, Papua New Guinea. Lancet 1980;11:192 -195. 
112. Clavo- Sanchez AJ, Giron -Gonzalez JA, Lopez- Prieto D, Canueto- Quintero J, 
Vergara- Campos A, Marin -Casanova P, et al. Multivariate analysis of risk 
factors for infection due to penicillin- resistant and multidrug- resistant 
Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997;24:1052 -9. 
113. Robins -Browne RM, Kharsany ABM, Koornhof HJ. Antibiotic- resistant 
pneumococci in hospitalized children. JHyg 1984;93:9 -16. 
114. Henderson FW, Gilligan PH, Wait K, Goff DA. Nasopharyngeal carriage of 
antibiotic -resistant pneumococci by children in group day care. J Infect Dis 
1988;157:256 -63. 
115. Klugman KP, Koomhof HJ, Kuhnle V. Clinical and nasopharyngeal isolates of 
unusual multiply resistant pneumococci. Am JDis Child 1986;140(11):1186 -90. 
116. Klugman KP, Koornhof HJ, Wasas A, Storey K, Gilbertson I. Carriage of penicillin 
resistant pneumococci. Arch Dis Child 1986;61(4):377 -81. 
117. Levy SB. The challenge of antibiotic resistance. Scientific American 1998:46 -53. 
118. Cohen D, Creech G, Sayers R. Haemophilus influenzae infections in American 
children living in the U.K. [letter]. Lancet 1982;1(8263):101. 
163 
119. Soares S, Kristinsson KG, Musser JM, Tomasz A. Evidence for the introduction of 
a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to 
Iceland in the late 1980s. J Infect Dis 1993;168(1):158 -63. 
120. Munoz R, Coffey TJ, Daniels M, Dowson CG, Laible G, Casal J, et al. 
Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus 
pneumoniae. J Infect Dis 1991;164:302-6. 
121. McGowen J. Antimicrobial resistance in hospital organisms and its relation to 
antibiotic use. Rev Infect Dis 1983;5:1033 -1048. 
122. Baquero F, Martinez -Beltran J, Loza E. A review of antibiotic resistance patterns 
of Streptococcus pneumoniae in Europe. J Antimicrob Chemother 1991;28, 
Suppl. C:31 -38. 
123. Jackson MA, Shelton S, Nelson JD, McCracken GH, Jr. Relatively penicillin - 
resistant pneumococcal infections in pediatric patients. Pediatr Infect Dis 
1984;3(2):129 -32. 
124. Pallares R, Gudiol F, Linares J, Ariza J, Rufi G, Murgui L, et al. Risk factors and 
response to antibiotic therapy in adults with bacteremic pneumonia caused by 
penicillin- resistant pneumococci. N Engl J Med 1987;317:18 -22. 
125. Amitai Y, Rotenberg M, Wirtschafter D, Haas H, Michel J. Increasing frequency of 
penicillin- resistant pneumococci: epidemiological aspects and case -control 
study. Isr JMed Sci 1985;21(4):340 -5. 
164 
126. Tan TQ, Mason EO, Kaplan SL. Penicillin resistant systematic Pneumococcal 
infections in children: A retrospective case -control study. Pediatrics 
1993;92:761 -767. 
127. Deeks SL, Palacio R, Ruvinsky R, Kertesz DA, Hortal M, Rossi A, et al. Risk 
factors and course of illness among children with invasive penicillin- resistant 
Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group. 
Pediatrics 1999;103(2):409 -13. 
128. Ford KL, Mason EO, Jr., Kaplan SL, Lamberth LB, Tillman J. Factors associated 
with middle ear isolates of Streptococcus pneumoniae resistant to penicillin in a 
children's hospital. JPediatr 1991;119(6) :941 -4. 
129. Melander E, Molstad S, Persson K, Hansson HB, Soderstrom M, Ekdahl K. 
Previous antibiotic consumption and other risk factors for carriage of penicillin - 
resistant Streptococcus pneumoniae in children. Eur J Clin Microbial Infect Dis 
1998;17:834 -838. 
130. Hansman D, Glasgow H, Sturt J, Devitt L, Douglas R. Increased resistance to 
penicillin of pneumococci isolated from man. N Engl J Med 1971;284(4):175 - 
177. 
131. Hansman D, Devitt L, Miles H, Riley I. Pneumococci relatively insensitive to 
penicillin in Australia and New Guinea. Med JAust 1974;2:353 -56. 
132. Naraqi S, Kirkpatrick GP, Kabins S. Relapsing pneumococcal meningitis: Isolation 
of an organism with decreased susceptibility to penicillin G. J Pediatr 
1974;85:671 -673. 
165 
133. Appelbaum PC. World -wide development of antibiotic resistance in pneumococci. 
Eur J Clin Microbiol 1987;6(4):367 -77. 
134. Dixon JMS. Pneumococcus resistant to erythromycin and lincomycin. Lancet 
1967;1 :573. 
135. Kislak JW. Type 6 pneumococcus resistant to erythromycin and lincomycin. N 
Engl JMed 1967;276:852. 
136. Klugman KP, Koornhof HI, Kuhnle V, Miller SD, Ginsburg PJ, Mauff AC. 
Meningitis and pneumonia due to novel multiply resistant pneumococci. BMJ 
1986;292:730. 
137. Howe JG, Wilson TS. Co- trimoxazole- resistant pneumococci. Lancet 
1972;2(7769):184 -5. 
138. Markman M, Mannisi J, Dick JD, Filburn B, Santos GW, Saral R. 
Sulfamethoxazole -trimethoprim- resistant pneumococcal sepsis. JAMA 
1982;248(221:3011-2. 
139. Moore EP, Williams EW. Hospital transmission of multiply antibiotic -resistant 
Streptococcus pneumoniae [letter]. Jlnfect 1988;16(2):199 -200. 
140. Hansman D, Mooris S. Pneumococcal carriage amongst children in Adelaide, 
South Australia. Epidemiol. Infect 1988;101:411 -417. 
141. Evans W, Hansman D. Tetracycline- resistant pneumococcus. Lancet 1963;i:451. 
166 
142. Turner G. Tetracycline -resistant pneumococci in a general hospital. Lancet 
1963;ii:1292 -1295. 
143. Howard AJ, Hince CJ, Williams JD. Antibiotic resistance in Streptococcus 
pneumoniae and Haemophilus influenzae. Report of a study group on bacterial 
resistance. BMJ1978;1(6128):1657 -60. 
144. Cybulska J, Jeljaszewicz J, Lund E, Munksgaard A. Prevalence of types of 
Diplococcus pneumoniae and their susceptibility to 30 antibiotics. 
Chemotherapy 1970;15(5):304 -16. 
145. Garau J, Linares J, Dominguez C. Chloramphenicol -resistant pneumococci [letter]. 
Lancet 1981;2(8238):147 -8. 
146. Meers PD, Matthews RB. Multiply resistant pneumococcus [letter]. Lancet 
1978;2(8082):219. 
147. Levy SB. Confronting multidrug resistance. A role for each of us. JA MA 
1993;269(14):1840 -2. 
148. Phelps CE. Bug/drug resistance. Sometimes less is more. Med Care 
1989;27(2):194 -203. 
149. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of 
antimicrobial resistance. Rev Infect Dis 1987;9(6):1065 -78. 
150. Bradley CP. Uncomfortable prescribing decision: a critical incident study. BMJ 
1992;304:294 -296. 
167 
151. Weiss MC, Fitzpatrick R, Scott DK, Goldcre MJ. Pressures on the general 
practitioner and decisions to prescribe. Family practice 1996;13:432 -438. 
152. Baker R. Development of a questionnaire to assess patient's satisfaction with 
consultations in general practice. Br J Gen Pract 1990;40:487 -490. 
153. Loda FA, Glezen P, Jr WAC. Respiratory disease in group day care. Pediatrics 
1972;49(No.3):428 -437. 
154. Roberts LA. Infection control measures reduce diarrhoeal and acute respiratory 
infections in child care. A randomised controlled trial [PhD]. The Australian 
National University, 1998. 
155. Samet JM, Lambert WE, Skipper BJ, Cushing AH, Hunt WC, Young SA, et al. 
Nitrogen Dioxide and respiratory illnesses in infants. Am Rev Respir Dis 
1993;148:1258 -1265. 
156. Kleinbaum DG. Logistic Regression. 4th ed, 1996. 
157. Young G, Spencer J. General practitioners' views about the need for a stress 
support service. Fam Pract 1996;13(6):517 -21. 
158. Dickinson JA. "The Elsewhere bias ". Med JAust 1996;164(7):438 -40. 
159. ABS. Australian social trends, 1998. 
168 
160. Wilson EJ, Nasrin D, Banwell C, Broom D, Douglas RM. Realities of practice. 
Engaging parents and GPs in developing clinical practice guidelines. Aust Fam 
Physician 2000;29(5):498 -503. 
161. National Committee for Clinical Laboratory Standards. Performance standards for 
antimicrobial susceptibility testing. 5th informational supplement. Document 
M100 -S5. Villanova PN. 1994. 
162. Roberts L, Smith W, Jorm L, Ph DB, Patel M, Douglas RM, et al. Effect óf 
infection control measures on the frequency of upper respiratory infection in 
child care: a randomized, controlled trial. Pediatrics 2000;105(4 Pt 1):738 -42. 
163. Kotch JB, Weigle KA, Weber DJ, Clifford RM, Harms TO, Loda FA, et al. 
Evaluation of an hygienic intervention in child day -care centers. Pediatrics 
1994;94(6 Pt 2):991 -4. 
164. Collet JP, Burtin P, Gillet J, Bossard N, Ducruet T, Durr F. Risk of infectious 
diseases in children attending different types of day -care setting. Epicreche 
Research Group. Respiration 1994;61(Suppl 1):16 -9. 
165. Schwartz B. Preventing the spread of antimicrobial resistance among bacterial 
respiratory pathogens in industrialized countries: the case for judicious 
antimicrobial use. Clin Infect Dis 1999;28:211 -213. 
166. Hennekens CH, Buring JE. Epidemiology in medicine. first ed, 1987. 
167. Graham NMH. The epidemiology of acute respiratory infections in children and 
adults: a global perspective. Epidemiologic reviews 1990;12:149 -178. 
169 
168. Little P, Gould C, Williamson I, Warner G, Gantley M, Kinmonth AL. 
Reattendance and complications in a randomised trial of prescribing strategies 
for sore throat: the medicalising effect of prescribing antibiotics. BMJ 
1997;315:350 -352. 
169. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an 
overview. C1 in Infect Dis 1992;15(1):77-83. 
170 
Appendices 
Appendix 3 (Related to Chapter 3) 173 
Consent form for doctors 174 
Study entry questionnaire for GPs 176 
Information of the study for receptionists 192 
Recruitment sheet for children 194 
Information of the study for parents 195 
Consent form for parents 198 
Study entry questionnaire for parents 199 
Information about respiratory diaries 212 
A sample diary 215 
Guidelines for parents 217 
Principles guiding management of ARI for GPs 218 
Procedure of nasal swab collection 220 
Sample newsletters for parents 222 
Sample newsletters for GPs 227 
Birthday card for children 232 
Appendix 6 (Related to Chapter 6) 233 
6.1: Effect of any beta lactam use during each two monthly period on penicillin 
resistance, adjusting for the cluster effect of a child 234 
6.2: Association of penicillin resistance with 3 groups of beta lactam use: only 
penicllin use, only cephalosporin use and both penicillin and cephalosporin use during 
the 2 months prior to swab collection, adjusting for cluster effect of the children 235 
171 
6.3: Effect of penicillin group use alone during each two monthly period on penicillin 
resistance, adjusting for the cluster effect of repeated positive isolate from a child 236 
6.4: Effect of cephalosporin use alone during each two monthly period on penicillin 
resistance, adjusting for the cluster effect of a child 237 
6.5: Effect of combined penicillin group and cephalosporin use during each 2 monthly 
period on penicillin resistance, adjusting for the cluster effect of repeated 
pneumococcal isolates from the same child 238 
6.6: Penicillin resistance in pneumococci isolated from four groups of children, 
grouped by the duration of beta lactam use during the six months before swab 
collection (n=456 isolates) 239 
6.7: Rate of penicillin resistance among four groupos of isolates, grouped by the 
duration of total penicillin use during the six months before swab collection (n =333 
isolates) 240 
6.8: Effect of total penicillin group use alone during the six months prior to the swab 
collection on penicillin resistance, adjusting for cluster effect of repeated 
pneumococcal isolates from the same child (n =333 pneumococcal isolates) 241 
6.9: Rate of penicillin resistance among four groupes of isolates, grouped by the 
duration of total cephalosporin use during the six months before swab collection 
(n =343 isolates) 242 
Papers (Two published papers from the study) 243 
1. Antibiotic resistance in Streptococcus pneumoniae isolated from children 
2. Realities of practice. Engaging parents and GPs in developing clinical practice 
guidelines 
172 

Consent Form for Doctors Participating in the ARIC Study 
I understand that this is an experimental study designed to test the utility and 
effectiveness of best practice guidelines in the care of childhood respiratory infections. 
I understand that the experiment will involve two groups of general 
practitioners, for whom a random process will determine whether I am assigned to the 
early or late intervention group. 
I understand that this study will involve me in agreeing to the recruitment of 
fifteen of my child patients under two years of age, to participate in the study, and that 
it may require my participation in a series of meetings with the principal investigators 
and colleagues to help in the forming of the guidelines and to monitor the progress of 
the study. 
I understand that the children who will be recruited from my practice will need 
to obtain nasal swabs three times in a year for this study. 
I understand that my time commitment to the study will be renumerated on a 
notional basis. 
I understand that the information collected as part of this study will be 
separated from information which identifies me; that I and my patients will be referred 
to by a code number, and that the code register will be kept separately from the main 
data base. 
The purpose of this study have been explained to me and I support the broad 
objectives which include a better understanding of patient and doctor expectations and 
experiences in the care of childhood respiratory infections; a better understanding of 
174 
resources currently used in the clinical care of these infections; the development of 
best practice guidelines; the utility of these guidelines and the effects of the 
availability of the Cochrane data base of systematic reviews to clinicians. 
I have read the information sheet to be provided to patients, and I am agreeing 
to participate in this study along the lines of the information sheet. 
Signed: 
Witness: 
Date: 
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GP Questionnaire 
Acute Respiratory Infection Study 
GP number: 
There are four parts to this questionnaire: 
Part A general identifying information is asked. This contact information will be 
stored separately to ensure your confidentiality and all information submitted on 
this questionnaire will be stored using a coded number. 
Part B asks some questions about your medical practice and associations. 
Part C asks about your usual clinical practice in treating acute respiratory infections 
(ARI) in young children. 
Part D enquires about your experiences and attitudes of clinical practice guidelines. 
A) General Information 
1. Name. 
2. Practice Address- 
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3. Phone number: 
4. Fax number: 
5. E -mail: 
6. Year of graduation from medical school 
7. Years of practicing as a GP 
8. M O F 
B) Medical Practice and Associations 
1. How many doctors are in your practice? 
solo O 2 -3 GPs O 4 or more GPs 
2. How many hours in the surgery do you work per week? 
please specify 
3. Are you vocationally registered? 
E Yes o No 
4. Are you a member of any of the following medical associations? 
ACT Division of General Practice 
RACGP 
O AMA 
EJ Other (please spec) 
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5. As a member of the above medical associations, how would you describe your 
involvement? 
ACT Division 
RACGP 
AMA 
Other 
Very Somewhat Occasional Member Not 
Active Active Input only Applicable 
E 
o 
6. As a factor in modifying your clinical care of patients, please rank the following in 
order of importance to you. (1 most important, 7 least important) 
Journal articles 
Continuing medical education 
Medical Textbooks 
Pharmaceutical Company Representatives 
Discussions with Colleagues 
Unsatisfactory outcome of previous treatment 
Other, please spec 
7. How many hours per week would you spend reading background material about 
patient care? 
please specify 
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C) Clinical Practice 
(I) Listed below are hypothetical case profiles of children under two years 
of age. Please indicate when you would be likely to prescribe antibiotic? 
Very rarely Rarely Sometimes Usually Often 
1. Two year old boy with history 
of low grade fever and harsh cough 
O O O O O 
for 2 days. On examination, he is 
irritable, with a normal respiratory rate, 
clear lungs. 
2. Persistant cough for 5 days, 
afebrile, history of wheezing 
for the first time, nothing else. On FT 
examination, ronchi are present. 
0 0 0 
3. Cough for one week, thick ( I ( I O O O 
green nasal discharge. Examination 
reveals no abnormal finding. 
4. Very prone to colds and gets 
wheezy. This time watery discharge 
from nose, dry cough, but no fever. n 
Examination reveales no abnormal 
finding. 
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5. In children, how often do you = O O O O 
diagnose Streptococcal tonsillitis 
on the basis of history and clinical 
findings alone? 
6. How often do you start antibiotic= O O O O 
for a child with pharyngitis pending 
results of a throat culture? 
7. A six month old baby with fever, 
cough and pulling at right ear. On 
examination the tympanic membrane 
is congested and retracted, with limited 
mobility. No air /fluid level is visible. 
8. Two year old child is not taking 
food for 2 days due to discomfort 
on swallowing and fever. Examination 
shows congested tonsils and pharynx, 
no pus. 
9. One year old baby developed 
fever three days ago, does not eat 
or play as usual. On examination, 
fast breathing and wheezing present, 
but no chest indrawing. 
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10. Two month old baby is very 
sleepy since yesterday, not able to 
drink. On examination fast breathing 
and chest indrawing with wheezing 
present. 
11. How often do you prescribe O O ( J O O 
antibiotic treatment for a child 
with a nonspecific upper respiratory 
infections (excluding acute otitis 
media, streptococcal pheryngitis, and 
sinusitis)? 
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(II) The following statements are about your experience in treating ARI in 
young children, under two years of age. Please take the time to think about 
the patients that you have seen over the last two weeks and respond to the 
followings. 
<10% 10 -24% 25 -49% 50 -75% 75% 
1. Proportion of cases in which 
you feel parents should have O U O O O 
consulted you earlier. 
2. Proportion of cases in which O I I O O O 
you think parents have consulted 
you earlier than necessary. 
3. Percentage of cases which 
only require symptomatic O O O O O 
treatment. 
4. Percentage of cases in which O 11 O O O 
you prescribed antibiotics. 
5. Percentage of cases admitted O O O O O 
to hospital. 
6. Percentage of cases where O O O O O 
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consultation were unnecessary. 
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(III) Please indicate your opinion whether you agree or disagree or 
not sure about the following statements. 
Strongly Agree Not Disagre Strongly 
agree sure disagree 
1. Parents can distinguish those 
infections that require medical 
attention from those that don't. 
2. Parents want an explanation 
of their child's illness. 
3. You need to explain the difference 
between viral and bacterial respiratory 
infections in terms of signs and 
symptoms and effective treatment. 
O t 1 t 1 t I 
O i 1 O ( 1 
n ( I O O 
O 
4. Parents understand the difference O O O O O 
between viral and bacterial respiratory 
infections. 
5. Parents understand the role of O O O O O 
antibiotics. 
6. Parents expect antibiotics when O O O O O 
they consult a doctor. 
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7. Your prerscribing practices would 
be different if parents did not pressure 
you for antibiotics. 
8. In your practice, you could decrease O O O O O 
the rate of antibiotic prescribing in ARIs 
without compromising patient care. 
9. Parents are satisfied with 
reassurance and advice regarding 
symptomatic treatment for viral 
infections. 
10. Parent's expectations affect 
your management decision. 
11. As a way of providing parental 
satisfaction, you prescribe antibiotics, 
though it is not indicated. 
12. Parents are satisfied with the 
information that they receive regarding O 
their children's illnesses. 
O O O O 
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13. Antibiotic use is a major factor 
contributing to the spread of antibiotic 
resistance 
14. Most parents expect to receive 
an antibiotic prescription for their child 
with a nonspecific URI. 
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(IV). What are the factors other than the physical findings, that 
influence you in antibiotic prescribing? 
Strongly Agree Not Disagree Strongly 
agree sure disagree 
Child's irritability. O O o O O 
Parent's expectation O O O O O 
Previous experience 
with this patient 
( ] O [ ] O 
The question of litigation O 1 1 O O O 
Day care center attendance 
( 1 O [ ] O O 
Both parents work 
I 1 O [] O O 
History of asthma in the family O I I O ( ] O 
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D) Clinical Practice Guidelines 
1. The following statements are about clinical practice guidelines (CPGs). Please 
tick the response that best reflects your view. 
strongly agree not disagree strongly 
agree sure disagree 
a) CGPs are a useful tool 0 0 0 0 
in assisting with patient care. 
b) CPGs guidelines are often 
ambiguous and difficult 0 0 0 0 
to interpret. 
c) CPGs can improve the 0 0 0 0 O 
quality of health care. 
d) CPGs are inflexible and 
do not allow for the 
management of each patient's 
unique condition. 
e) Use of CPGs will increase 
health care cost. 
f) CPGs are produced by 
WO O 
0 0 0 O O 
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organizations that do not 0 0 0 0 0 
understand the needs of the 
local clinician. 
g) CPGs should be produced 0 0 0 0 0 
only for complicated and 
ambiguous clinical conditions. 
h) If CPGs are going to work, 0 0 0 0 0 
general practitioners must be 
involved in their development. 
i) CPGs stifle clinical freedom 0 0 0 
and innovation. 
j) CPGs are a convenient and 0 0 0 0 0 
quick source of infonnation. 
k) CPGs can be used in medical 0 0 0 0 0 
litigation. 
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strongly 
agree 
agree not 
sure 
disagree strongly 
disagree 
1) CPGs are effective in changing 
clinical practice. 
m) CPGs represent the most 
up -to -date and scientifically 
sound evidence on clinical care. 
n) CPGs developed by clinicians 
and speciality groups are more 
medically sound than those 
developed by government 
agencies or health insurers. 
o) There is too widespread a 
development of CPGs. 
p) CPGs are a bureaucratic 
imposition. 
q) CPGs can be used to 
improve doctor -patient 
communication and informed 
decisions. 
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r) CPGs will be used as a 
quality assurance tool 
in medical audits. 
s) Input from consumers should 
be sought when developing 
CPGs. 
3. Have you used clinical guidelines in your practice? 
OYes O No 
4. If yes, what clinical guidelines have you used? 
please specify 
Thank you for your time answering this questionnaire. 
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Recruiting Information 
ARIC study 
To receptionists who prepare case notes for Dr 
Dr. has agreed to participate in a study of general 
practice care of acute respiratory infections in children. As part of the office staff you 
will be an integral part of this study and we would greatly appreciate your help in 
getting this study off the ground. The purpose of this study is to test a new approach 
to the development of clinical guidelines which will involve the GPs, as well as 
parents of young children. The study will take the form of a two year randomised trial 
in which two groups of 30 GPs, randomly assigned, will participate at different times 
in developing new approaches to care. Parents of a group of young children who are 
being looked after by the GPs will maintain diaries of their child's respiratory 
experience, including details of care received from the GP. 
The project is funded by the General Practice Evaluation Program, from the 
Department of Health and Family Services and is being sponsored jointly by the ACT 
Division of General Practice, the ACT Faculty of the RACGP, and the National 
Centre for Epidemiology and Population Health. The Director of the project is 
Professor Bob Douglas who is assisted by two PhD students, Dr Dilruba Nasrin and 
Ms Eileen Wilson and other research assistants. 
We need your help in recruiting patients for this study. Each GP in this study 
is being asked to recruit fifteen of his/her patients under the age of two years. From 
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now until the fifteen patients are recruited (one to two weeks), we are asking you to 
flag the records of any patient under the age of two years who has an appointment 
with Dr. . Could your please flag the potential study patients by attaching the 
following documents to the patient record: 
1. Recruitment Sheet 
2. Parent Information Sheet 
When the child and parent are fmished seeing the doctor, they will return the 
recruitment sheet to you. If the parent has agreed to talk to us about the study, could 
you please fill in the name of the parent and child and their phone number during 
business hours at the bottom of the recruitment sheet. If the doctor has determined 
that the patient is not suitable for the study, please do not fill in any personal details. 
We would appreciate all the recruitment sheets (even those that are not participating in 
the study) to be returned to the study group, every day or two, preferably by Fax or, if 
not available, posted to the following address: 
Fax: 6249 0740 
Dr Dilruba Nasrin/ Ms Eileen Wilson 
NCEPH 
ANU 
Canberra ACT 0200 
Throughout the study, the patients will also be having a total of six nasal 
swabs done. We will be asking for your help in procuring these nasal swabs and will 
be in touch later in the study to go over the necessary procedures. 
If there are any questions about these recruitment procedures, please ring 
Nasrin or Eileen at 6249 3011. 
Thank you for your help and co- operation 
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Recruitment Sheet 
ARIC Study 
Patient's Age (months) Gender ED M 
This patient is NOT a suitable candidate for this study because: 
the patient is not a regular patient of mine 
the patient is unlikely to remain at current residential address for two 
years 
the parent is not willing to participate in this study 
Other (please specify) 
F 
This patient is a suitable canidate for the study. 
El The parent(s) of this child has /have agreed to be contacted by the 
research staff from ANU. 
n I have given the parent the ARIC study information sheet. 
Patient's name 
Parent's name 
Phone number 
Form to be returned by Fax to Eileen Wilson or Dilruba Nasrin at: 6249 0740 
NCEPH, ANU, Canberra ACT 0200 
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A_iJC 
Information on the Study 
of 
Acute Respiratory Infections in Children 
(ARIC) 
What is the purpose of this study? 
This study hopes to tackle a problem that is a common worry for parents and 
doctors alike. How do we best manage cough, colds, ear, chest and sinus infections 
in young children and how do we make sure we are using the available drugs in the 
best possible way? We hope to clarify what patients and their doctors expect and 
experience in the care of young children with these respiratory infections. The study 
will explore new ways of sharing information and knowledge between the doctors, 
scientists and parents or patients. We will also test some new ways for the setting up 
of guidelines for good quality care. The study is a trial which involves fifteen children 
from the practice of each participating doctor. About 60 doctors in Canberra are 
taking part. 
Why do this study? 
These respiratory infections are a very common cause of visits to the doctor. 
They result in the use of very large amounts of antibiotics and other medicines. 
Scientists around the world are concerned by the fact that antibiotics which can 
control these organisms which cause infections are no longer working. The organisms 
are becoming resistant to antibiotics. A great deal of information has become 
available about what might be called `best practice' in the care of these infections. 
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We think it is important that parents of young children are actively involved with 
their doctors in the care of their children with respiratory infections and that this active 
involvement will help to determine and define what happens in the future care of 
children. 
This study is in the form of a controlled trial in which we will collect 
information, not only about what doctors and parents do now in the care of children 
with these infections, but also test the effects of improving the information that is 
given to parents and doctors which helps them to make their decisions about the 
child's care. 
Sixty doctors in Canberra who have recruited a total of 900 children will be 
divided into two equal groups. One group will be involved in this information sharing 
process early on in the study. The other group will be involved a little later. 
What do I have to do? 
We are asking parents of all children in the study to keep a diary of the child's 
medical experiences over a period of two years. To do this we will give you a 
calendar sheet every month which we would like you to record by jotting down on the 
calendar we provide, if your child is feeling well or if he /she is showing any signs of 
illness such as a runny nose or cough. These sheets should be returned every month to 
our researchers and should not take more than a minute or two every day to complete. 
The diary should also be filled in when the child visits your doctor. The treatment that 
your doctor suggests or any home remedies you have given your child should be 
entered onto the diary. After any visits to the doctor we hope you will take some time 
to fill in the supplementary form which asks some questions about your visit with the 
doctor. We also hope that some of the parents will come along to group discussions 
with the researchers where issues, concerns and experiences about their child's care 
can be talked about in an open and frank manner 
We will be comparing the information from the records of the 450 children in 
the early involvement group with the information obtained from the group of 450 
children that is involved a bit later. We want to see if improving the access to 
information makes a difference to the way parents and doctors deal with these 
infections. 
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To monitor the effects of any changes in treatment we will ask that your child 
have a nasal swab three times a year during the two year study. The nasal swab will 
tell us about any changes in the pattern of antibiotic resistance of an organism named 
pneumococcus which is carried in the nose of about 30% of normal healthy children. 
What are the risks and benefits? 
There are no risks involved. Throughout the two years of the study we hope 
that you will continue to receive most of your child's medical care from the same 
doctor so that we can keep track of the effects of your doctor's and child's 
involvement in the study. The relationship you have with your doctor should not 
change in any way. The study will be looking at your views and your doctors about 
the way these infections are treated and prevented. The aim of the study is to improve 
care where parents and doctors agree that improvements are needed. 
Who is running the study? 
The study is being carried out by a partnership between the National Centre for 
Epidemiology and Population Health, the ACT Division of General Practice, and the 
Royal Australian College of General Practitioners Training Program. The chief 
investigator on the study is Professor Bob Douglas, who is Director of the National 
Centre, and who has had a lifetime of research in this area, especially in seeking to 
understand better ways of preventing and treating these common infections in 
children. The project is funded by the National General Practice Evaluation Program. 
The team working on the study is in touch with the latest developments in the 
treatment and prevention of these respiratory infections. 
A research worker will telephone you to discuss further your possible 
involvement in the project, including what you would need to do about keeping the 
diary. 
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Parental Consent Form 
ARIC Study 
I have read the information sheet on this study and understand its contents. I 
understand that participation in the study involves me in maintaining a record of my child's 
medical experiences over the next two years for purposes of research. I will keep a diary on 
my child's illnesses and this will be used to monitor progress in the study. I also understand 
that my child will need to have a nasal swab done six times over the two year study period. I 
understand the information will be stored, using a code number rather than any information 
that enables my child or me to be personally identified on the computer database. 
I agree to my child's participation in the study on the basis of the information 
supplied to me about the studies purposes and activities. 
Signed: 
Witness: 
Date: 
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Parent Questionnaire 
Acute Respiratory Infections in Children 
(ARIC) 
ID number 
This questionnaire will ask questions about the general health of your child 
and more specific questions about the respiratory health of you and your child. We 
will also be asking about environmental factors that may affect the respiratory health 
of your child such as smoking, breastfeeding, childcare and home heating. Finally we 
will be asking questions about specific respiratory illnesses in your child and your 
experiences and expectations in the care and treatment of your child during these 
illnesses. 
General Information 
The following questions ask some general identifying information. This contact information 
will be stored separately to ensure your confidentiality and all information submitted on this 
questionnaire will be stored using a coded number. 
1. Parent's name: 
2. Child's name. 
3. Home address: 
4. Phone number: (H) (W) 
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The following questions asks some general information about yourself, your 
child and other family members. 
5. Date of birth of child: 
6. Sex of child: M 
7. Number of siblings: 
8. Ages of siblings: 
9. Age of mother: 
10. Age of father: 
Q F 
11. Schooling of parents (please circle highest schooling obtained) 
Mother Father 
finished primary school 1 1 
finished high school 2 2 
trades or TAFE training 3 3 
university graduate 4 4 
postgraduate degree 5 5 
12. Approximately what is your family taxable income? 
E 
<$30,000 
E $31,000 - $45,000 
E $46,000 - $60,000 
O >$60,000 
13. In what country were the parents of this child born? 
Mother 
Father 
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The following questions ask about aspects of your child's care and various 
environmental factors in your home. 
14. Was your child breastfed? 
Yes 
15. If yes, for how long? 
O No 
16. Does your child attend day care? 
Yes E No 
17. If yes, what kind of day care does your child attend? 
In the care of another family member 
Private home care 
Family Day Care 
Day Care Centre 
18. How many hours per week does your child attend day care? 
O<20 hours 
0 21 - 40 hours 
>40 hours 
19. Do you, your child's carer or any member of your household smoke? 
Yes O No 
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20. What kind of heating system is in your house? 
Oopen fire 
Owood stove 
Oelectric 
Ogas, unvented 
Ogas, vented 
The following questions ask about the general health history of your child. 
21. Has your child had any major illness? 
OYes O No 
22. If yes, what was the nature of this illness? 
23. Is your child fully immunized for his /her age? 
Yes O No 
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The following questions ask about events concerning the birth of your child. 
24. How many weeks pregnant was the mother when your child was born? 
0 <28 
028 -31 
32 -36 
037 -40 
0 >40 
25. What type of delivery did your child have? 
0 vaginal 
0 caesarean 
0 forceps 
26. Did the mother have any respiratory illness in the year before the birth of 
your child? 
0 Yes 0 No O Don't remember 
27. While the mother was pregnant with your child, did she experience any 
significant sleep difficulties? 
0 Yes 0 No O Don't remember 
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We would like to understand better, how parents deal with a number of common respiratory 
problems in their children under two years of age. The following are a list of symptoms. 
Please think of your children in these situations and tell us whether you would take him/her to 
the doctor always, more than half the time, about half the time, less than half the time or 
never. 
For each symptom, please tick what you would do : 
Always More than About half Less than Never 
half 
a. Harsh cough only 
b. Fever 38° c for 
2 days 
c. Fever, cough, 
Fast breathing 
d. Cough with wheeze 
e. Restlessness only 
f. Runny nose with 
green discharge 
g. Cough with fever 
h. Cough with yellow / 
green sputum 
i. Blueness of lips 
j. Trouble breathing 
k. Sore throat 
1. Not eating normally 
m. Disturbed sleep for 
blocked nose 
n. Ear pain with no 
half 
( J 
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other symptoms 
o. Discharge from ear 
In the following section, some common situations are presented that you may have faced with 
your child. Following the situation are statements about some ways of handling these 
situations. Please think about each statement for a moment and then decide whether you 
strongly agree, agree, disagree or strongly disagree with each statement. 
A. Your child developed a runny nose and mild cough last night and today is off his /her 
food. He /she seems otherwise well, though you think the temperature is slightly raised. 
Strongly Agree Disagree Strongly Not 
agree 
I will just wait and see how the child 
goes throughout the day. 
My child needs to be examined by a 
doctor. 
I will talk to the chemist about what 
kind of treatment to give my child. 
It is very important that my child gets 
antibiotic to help clear the infection. 
disagree sure 
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B. Your child woke with a harsh croupy cough in the middle of the night. His /her voice 
sounded like a seal's bark. Breathing was not rapid. He /she was not distressed. But it worried 
you. 
Strongly Agree Disagree Strongly Not 
agree disagree sure 
I will watch my child throughout the day. ] 
My child needs to be seen by a doctor. u 
Antibiotic will improve my child's 
condition. 
My child needs hospital care, as breathing Li 
difficulties might develop. 
I shall go for some cough medicine. 
7 
C. Your child was restless last night and woke this morning with slight wheezy cough. 
This has never happened to your child before with a cold. What is your idea about this 
situation? 
Slight wheezing is common in 
respiratory infections. 
My child needs to be seen by a doctor. 
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My child should receive antibiotics. 
My child needs to be hospitalised. 
My child may need asthma treatment. 
U U (; 
UL 
U 
D. Your child woke at night crying with what seems to be pain in the ear. He /she was 
irritable, but settled with panadol. Next morning, he /she is still pulling at the ear. There is no 
discharge from the ear but temperature is slightly raised. 
Strongly 
agree 
I'd like to continue panadol for few days. 
My child needs to be examined by a doctor. 
Earache is a natural part of growing up so 
I won't worry about it. 
Ear infections should be treated by 
antibiotic. 
I shall go to the chemist for some ear 
drops. 
Agree Disagree Strongly Not 
U 7 
f 
D 
U 
disagree sure 
.11 L 
U 
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E. Your child is complaining of pain in the throat. He /she is miserable and seems to have 
some enlargement of the glands in the neck. His/ her temperature is raised. 
My child needs to be seen by a doctor. 
I will wait a day or two to see if it 
gets better by itself . 
I will give the child warm, sweet drink 
to sip, such as honey and lemon. 
Strongly Agree Disagree Strongly Not 
agree disagree sure 
U U O U o 
L 
Antibiotic is necessary as soon as 
possible, as complications from sore H o 0 
throat are very common. 
I will go to the chemist for some 
medicine. 
0 
0 0 
0 0 
o 
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F. Please tell me if you agree or disagree with each of the following statements. 
Antibiotic will help to cure a cold 
Treating a cold with antibiotics 
will help to prevent an ear infection. 
Antibiotics should be stopped as soon 
as the child feels better. 
Some germs are becoming harder 
to treat with antibiotics. 
If antibiotics are overused, they will 
not work as well for treating infections. 
If antibiotics are used frequently to a 
child, then the child may be infected 
with bacteria that are hard to treat. 
Agree Disagree Don't know 
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G Think back to your last visit to your GP for your child's illness. Please read 
the following statements and tick the response that best reflects your view. 
I was totally satisfied with my visit 
to the doctor. 
The doctor was very careful to check 
everything when examined my child. 
I wished to spend a little longer with 
the doctor. 
I would have liked the doctor to tell me 
a little more about my child's illness. 
The doctor told me everything about 
the treatment. 
Strongly 
agree 
U 
The doctor gave me very clear advice 
about how to care for my child with this 
illness. 
The doctor was interested in my child 
as a person, and not just his /her illness. 
O 
Agree Disagree Strongly Not 
disagree sure 
n 
o 
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I decided to follow the doctor's advice 
because I thought he /she was right. 
o u 
The time I was allowed to spend with D H U 
the doctor was not long enough to deal 
with everything I wanted. 
Please feel free to make further comments on this topic. 
L 
Thank you for filling out the questionnaire. 
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Diary Information 
Every month you will receive a diary and reply paid envelope in the post. Here is your diary 
for the ARIC study for the next month. We have also included a sample filled -out diary as an 
example. Each diary covers one month. We suggest you to keep the diary on your fridge and 
fill it out each night or a similarly convenient time and place. Some months you will also 
receive a newsletter letting you know the progress of the study. 
If your child is well, all you need to do is tick in the right -lower corner of each box. 
If he/ she has a cold, then you should put an asterisk ( *) in the right -lower corner of the box 
and indicate which symptoms are present, ie. cough, runny nose, blocked nose, fever, wheezy 
breathing, etc. 
If you are giving your child any medication, or go to doctor or hospital or the child has any 
other illness, then you need to turn over the sheet and fill out the detail under the specific 
column like "medication given ", "Doctor or hospital visits" etc. 
Before you send your diary back in the reply paid envelope provided, you should also answer 
the question on the back of the diary about breastfeeding for the month. 
What the sample diary shows is that, Johnny had a cold from the 5th to 12th August started 
with runny nose (R), then a dry cough (D). His parents visited the doctor on 8th (on the back 
of the diary) as he developed wheeze (W) and fever (F). Doctor prescribed panadol, amoxil 
(antibiotic) and ventolin for him He took medication from 8th to 12th. But he visited the 
doctor again on 16 th, as he was pulling the ears since 15th. Doctor examined him and found 
nothing significant. He had a hospital visit on 29th for a cut on the leg and he needed two 
stiches for the cut and was adviced to take panadol for pain. Details of medication, doctor and 
hospital visits are shown on the back of the diary. 
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Below we have given a list of what we mean by the various terms like dry cough, cough with 
phlegm, runny nose, blocked nose, fever, wheezy breathing, pulling at ears, sore throat, hoarse 
voice and discharge from ears. 
A carefully completed diary will give us very important information and will be very valuable 
in our attempt to help GP's and parents to provide better care for children with these acute 
respiratory infections. 
Thank you for helping us in this way. 
Please feel free to ring us for any queries. 
Nasrin or Eileen 
Tel: 6249 3011 
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Symptom definition: 
Dry cough: If the cough is not associated with phlegm. Mark with D if your child coughed 
frequently in the day. 
Cough with phlegm: When the cough sounds loose or your child brings up phlegm with the 
cough. Mark with C if your child has this sort of cough. 
Runny nose: Discharge of clear liquid from the nose. Mark a Ron the days this occurs. 
Green nasal discharge: Discharge of green or yellow liquid from nose. Mark a G if your 
child has this symptom. 
Blocked nose: This refers to your child being unable to breath through the nose and having to 
breathe through the mouth. Mark a B for this symptom. 
Fever: If you feel your baby hot. It is better to measure the temperature under the armpit with 
a thermometer. If it is >37 degrees, it is a fever. Mark a F when this occurs. 
Wheezing: Whistling sound that comes from the chest during breathing. Breathing may be 
difficult in this situation. Mark a W for this symptom. 
Hoarse voice: If the voice is changed and become rough or abnormally deep or harsh. 
Sometimes the voice is so hoarse that it is difficult to talk. Mark a V if your child suffers 
from this. 
Ear pulling / Earache: Sometimes children pull their ear before sleeping. But if your child 
pulls the ear repeatedly other than sleeping, or if you think your child is experiencing pain in 
the ear, please mark a E. 
Discharge from ears: It may be clear or yellow discharge. Mark P when this occurs. 
Sore throat: If you notice or child complains difficulty in swallowing or pain in the throat. 
Mark a T if this occurs to your child. 
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NOVEMBER 
Name ID # 
Sun Mon Tue Wed Thu Fri Sat 
1 2 3 4 5 6 
7 8 9 10 11 12 13 
14 15 16 17 18 9 20 
21 22 23 24 25 26 27 
28 29 30 
Record each symptom your child experiences every day 
Mark each day you think your child has a cold with a star 19 9 7 
C = cough with phlegm T = sore throat/ swallowing difficulty 
P = discharge from ears E-= pulling at ears / earache 
R = runny nose G = green nasal discharge 
B = blocked nose D = dry cough 
F = fever (feels hot) V= hoarse voice 
W = wheezy /noisy breathing 
If any of the following happens to your child 
give more details on the back: 
medication given doctor visit hospital visit 
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Medication Given 
(prescribed or over the counter or home remedy) 
Name Dates given 
start end 
*Doctor (D) or Hospital (H) visits 
Date D/H Study Doctor Reason 
Hospital Stays 
Dates Reason 
Type of Feeding this month (please tick) 
Was the child breast fed at all this month? 
Yes / No 
If yes, 
Whole month- 
To date 
Other Illnesses 
Date Details 
Any Queries about filling in this respiratory diary, please ring Eileen or Nasrin on 6249 3011. 
Comments or Further Information 
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91Rrc STUDY 
Guidelines for Parents 
Children will average about six respiratory infections every year. Children who attend child 
care centres, are not breastfed, have poor nutrition or are exposed to cigarette smoke can expect 
to have more respiratory infections. 
The majority of respiratory infections are caused by viruses and will get better by themselves. 
* Antibiotics have no effect on viruses. 
Green/yellow nasal discharge is a normal part of a cold, usually occurring 2 - 6 days after the 
start of a runny nose and often precedes recovery from colds. 
* Antibiotics are definitely not needed solely for green/yellow nasal discharge. 
Studies have shown that cough medicines, antihistamines, and decongestants do not offer any 
real benefit in the treatment of respiratory infections. 
Paracetamol in the right doses, should be used for symptom relief. Humidification or 
vaporisers, vaporubs, saline nasal drops, vitamin C, honey and lemon drinks, plenty of fluids and 
bed rest all may help in easing the symptoms of respiratory infections. 
* Antibiotics are needed for serious chest infections (rapid breathing or chest indrawing). Most 
middle ear infections and sore throats do not need antibiotics. 
Antibiotics have no effect on the temporary hearing loss seen after ear infections and only a 
moderate benefit on pain. In the majority of ear infections, pain lasts for only one day. This 
pain usually can be treated effectively with proper doses of Paracetamol. 
If you have any concerns about your child's health or any questions about these guidelines, 
please discuss them with your GP. 
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Principles Guiding General Practice Management of 
Respiratory Infections in Children in ARIC Study 
Canberra 1998 
1. The alarming growth in antibiotic resistance by respiratory bacteria means that antibiotics 
must be reserved as far as possible for their life -saving potential and for children at risk of 
serious complications. 
2. The vast majority of respiratory infections in children under 4 years of age are self -limiting. 
Viruses and bacteria are jointly involved in these infections, the most serious and troubling of 
which are otitis media, sore throats, and pneumonia. 
2a. Each of these three can be followed by life -threatening disease or serious 
complications which are avoidable through judicious use of antibiotics. 
3. The tendency to use antibiotics as a general insurance policy whenever middle ear infection 
or streptococcal sore throat infection are suspected is now counterbalanced by the knowledge 
that there are potentially serious consequences from excessive use of these life -saving drugs, 
both to individuals and the community, and that the benefits in the vast majority of cases are 
trivial. 
4. As a group of general practitioners who have carefully explored the evidence together with 
experts who have systematically examined this evidence, we have agreed on a conservative 
course of action with respect to antibiotic prescribing which, nevertheless, recognises that each 
child must be carefully assessed and managed in their own best interest. Parents need 
information of a specific nature about what to do to treat specific symptoms and danger signs to 
alert them to the need for professional assessment. 
We support the use of the ARIC prescription pad and posters and information sheets which 
will improve parental understanding of the issues and reduce unrealistic expectations of the 
benefits of these powerful drugs. 
5. Where pneumonia is suspected (from the presence of a measured respiratory rate in excess 
of 40 respirations per minute, chest indrawing, cyanosis, and/or generally ill appearance) 
antibiotic therapy is certainly desirable. 
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6. Where infection of the middle ear is suspected, antibiotic treatment is by no means 
routinely desirable. Antibiotics do little to shorten the duration of pain and apparently nothing 
to shorten the duration of deafness which accompanies fluid in the middle ear. Careful 
analgesia with Paracetamol at a therapeutic dose will be more effective in reducing symptoms 
than antibiotics and, provided there is no mastoid tenderness and the tympanic membrane is not 
bulging, an expectant approach is justifiable. 
7. Purulent exudate on the tonsils or in the pharyngeal area in children under 4 is very often 
caused by viral infections and not necessarily by group A streptococci. The concern for 
complications of rheumatic fever and glomerulonephritis has dictated a liberal use of antibiotics 
for this condition in the past, but a more conservative approach is now justified. 
8. We believe that sore throats, even in the presence of pus should not be managed with 
antibiotics unless there is laboratory evidence that group A haemolytic streptococci are present 
on the throat swab. That means that in these cases, a throat swab should be collected and the 
result known to be positive before antibiotic therapy is commenced. 
9. Doctors need to evaluate each child with a respiratory illness on its merits and make their 
therapeutic decisions accordingly. However, they also need to instruct parents in the use of 
simple harmless treatments. These include: 
hot lemon and honey drinks; 
steam; 
Paracetamol in appropriate dosage; 
Vitamin C; 
(and gentle chest percussion) for a troublesome productive cough. 
Nasal saline drops may help to clean out a blocked nose and 
warmed olive oil may relieve the discomfort of a painful middle ear. 
Antihistamines and cough suppressants are of little proven usefulness. 
Time spent with parents in helping them to understand the natural course of the illness, which 
afflicts most children about six times a year, is time well spent. 
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Procedure of nasal swab collection 
I employed 2/3 field workers to collect the nasal swabs during each collection. Most of them 
were working as laboratory scientists at the Canberra Hospital. 
Setting: I used two settings for four sets of swab collection. 
The first set of swabs were collected from the children from their GPs' surgeries with the 
anticipation that the parent would feel comfortable to have the procedure done in the GP's 
surgery. I contacted every GP to see if they would agree to allow us to use the surgery for one 
hour in the evening period for swab collection. After deciding a date and time with the GP, I 
sent a letter to each parent informing them the date, time and venue for swabbing. Finally in 
the night before the swab collection, I rang each parent to remind the date. The research 
assistants collected swabs for one hour during the evening at three surgeries for three days in a 
week. During the last week of collection, they collected swabs from the residence of a few 
children who could not attend the swabbing due to inavailability of transport. I also used 
Canberra Hospital Pathology Outpatient for one morning to collect swabs from the children 
who missed their actual date. 
From my experience during first swab collection, it was very difficult to arrange for GPs' 
surgeries for swab collection. Most of the GPs were practising in a group practice where other 
colleagues might not feel comfortable with the procedure during surgery hours. Therefore I 
organised health centres and public Libraries for collecting swabs during second to fourth 
rounds. I made a schedule with all venues with addresses and date and time. About a month 
before collection started, I sent two copies of schedule to every parent, asking them to select 
one specific date and venue and to return me one copy but to keep another copy with them as a 
reminder. I employed a research assistant to help me in reminding parents on the night before 
the date of swab collection. 
Procedure of Swab collection 
The child's name, identification number and specimen site (right or left nostril), date and time 
of collection were recorded on the request form and also on the Stuarts media container and 
agar plate to identify the individual swab. The cotton tip of the swab stick was moistened by 
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inserting into the Stuarts media. The parents were asked to gently held the child's head while 
the swab collector twisted the cotton tip of the swab stick around one nostril. The cotton bud 
was then spread on the surface of the blood agar plate containing 5 .tg/m1 of gentamicin, by 
twisting the swab stick to make a circle of 50 cent size. All the specimens were transported 
immediately to the Canberra Hospital Microbiology Laboratory. The identification number, 
date of birth of the children were immediately entered into the computer system of the 
Pathology Department of the Canberra Hospital. 
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The ARIC Study Newsletter 
National Centre for Epidemiology and Population Health 
in cooperation with Royal Australian College of General Practitioners 
and the ACT Division of General Practice 
MAY 1998 
Dear Parents, 
Thanks for your active and enthusiastic participation in the ARIC study. We have 
completed the first stage of the study, the success of which is due to your help and the help of 
your GPs. Winter is knocking at the door. We hope you are finding the diary- keeping process 
straightforward and interesting. Diaries and the nasal swabs, are very important parts of the 
research. 
Where are are we now? 
Fifty -four Canberra GPs and five hundred and forty children are participating in the study. We 
are in the late stage of development of some new guidelines for respiratory infections in children 
which will be tried out first by 24 GPs and their patients in the "early" group..The "later" group 
will consider use of these guidelines later this year. 
How have we developed the guideline? 
We have involved GPs and some parents in a series of meetings, where they described their 
expectations and experiences. We have used this material as well as evidence from the medical 
literature to develop the trial guidelines. 
What is your involvement? 
Parents have been enormously helpful by keeping the child's health diary,as well as participating 
in group meetings. We would appreciate you keeping up this effort in recording and sending 
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details of health information, including medication and doctor visits, especially during the 
important Winter season. 
What's the nasal swab for? 
We have now collected nasal swab from 80% of children in the study. Special thanks to you all 
for your cooperation. We hope to complete this process in a couple of weeks. In the next 
newsletter we will provide some data from the swabs. We are working with A/Professor 
Collignon at the Canberra Hospital to discover the levels of drug resistance of common nasal 
bacteria. The information is of scientific importance, but the details of sensitivity are not 
pertinent to clinical care of individual children. So we will provide you the overall level of the 
resistance. We appreciate your continuing contribution in the process. 
Winter!!! 
Respiratory infection season is close upon us. We hope you and your children will come through 
this cough and cold season with minimal problems. We hope to send you another newsletter 
towards the end of Winter with some data of our preliminary analysis. We wish you a happy 
Winter. 
Contact: The ARIC team 
Nasrin or Eileen- 62493011 
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The ARIC Study Newsletter 
National Centre for Epidemiology and Population Health 
in cooperation with Royal Australian College of General Practitioners 
and the ACT Division of General Practice July 1998 
Dear Parents, 
This is to let you know that the ARIC Study is progressing magnificently thanks to the 
warm cooperation we have received from parents, doctors and the Canberra Hospital. It is 
also to let you know what we have learnt from the first round of nasal swab tests in the 461 
children who had their noses swabbed. As you know, one of the concerns that prompted 
this research is the growing resistance of common respiratory germs to widely used 
antibiotic drugs. We are trying to find the best way to deal with common respiratory 
infections in childhood without fostering the development of resistant bugs. 
This first round of swabbing was to get a base -line level in Canberra children of a common 
organism known as the pneumococcus which tends to be present in the noses and/or throats 
of all of us from time to time. At any one time up to 30 or 40% of us carry this germ in our 
noses and mostly they do not cause any problem. Indeed in this study, 37% of the swabs 
collected grew a pneumococcus which is almost exactly what we expected. The laboratory 
has carefully tested the level of antibiotic resistance to a number of antibiotics and found, 
also as we might have predicted, that about half of the bugs were partially "resistant" to 
one or more of the antibiotics tested. This also conforms to the trend around the world. 
The important feature of our study is that we will try to monitor, over time, whether levels 
of resistance will change in response to differing prescribing actions by doctors and 
modified treatment actions by parents. That is why your diaries are so important and why 
we need to continue the study over a total period of two years. 
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Why pneumococcus is so 
important? 
We are using this bug as our marker 
because it is an important cause of 
ear infections, sinus infections, 
pneumonia and other complications 
of respiratory infections and because 
a lot has been learnt in recent years 
about the mechanisms of its growing 
resistance to antibiotic drugs. It is 
quite normal for it to be found 
incidentally in normal healthy 
children. Along with other bacteria, 
this bug is becoming increasingly 
resistant to a number of our most 
widely used antibiotics. This is of 
concern worldwide and our finding 
of resistance level is consistant with 
what is happening elsewhere. We 
need to find effective ways to arrest 
the growing resistance trend before it 
does become a serious threat. 
What does "resistance" mean? 
It means that the bug has partially 
adapted to antibiotic drugs so that 
higher and higher doses of antibiotics 
may be needed to prevent its effects 
if it starts to proliferate in the ear, in 
the lung, in the sinuses, or in the 
blood. There is growing realisation 
around the world that all of us have 
become rather excessive in the use of 
these powerful agents and that we 
will need to be more cautious about 
when and where they are used in the 
future. Our study is about exploring 
new ways of handling respiratory 
infections in childhood that could 
minimise unnecessary antibiotic use. 
How bugs become resistant? 
Each time we take antibiotics, sensitive 
bugs are killed, but the resistant bugs are 
not. They grow and multiply. Frequent 
and long -term uses of antibiotics are the 
main causes of development and spread 
of resistance. Resistant bugs can spread 
to others in the community, even if 
people don't take antibiotics. 
Is resistance permanent? 
The evidence suggests that resistant 
strains don't necessarily persist. 
However carriers of resistant bugs 
can be re- infected which makes the 
treatment difficult and expensive. 
The evidence also suggests that we 
could change the worrying trend of 
increasing resistance. In this study, 
we are comparing the level of 
resistance to the types and extent of 
antibiotic prescription to which 
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children in the study have been 
exposed. We believe this project 
will throw very important light on 
the problem that could benefit not 
only your children but children 
throughout Australia and elsewhere. 
Is the finding on my child's swab 
relevant to her clinical care? 
The fmdings on individual children are 
much less important than the fmdings 
across the whole study population. The 
evidence suggests that these bugs transfer 
rapidly around schools and playgroups 
anyway and what is most important is the 
trend across the whole community. That is 
why we hope you will continue to work 
with us on this very important project. We 
will continue to keep you informed on 
progress as we undertake the analysis of 
the diaries which are being kept so well by 
so many Canberra parents. We know that 
carriage in the nose varies in individuals 
from week to week and therefore the 
fording of a resistant bug in an individual 
child may have no relevance to clinical 
care. But the fmdings emphasise the need 
to monitor the children again at the peak of 
winter, when children frequently get 
antibiotics. The schedule for the next 
round is enclosed with the newsletter. We 
will appreciate your help to collect nasal 
swabs in the next round. 
Contact: The ARIC team 
Nasrin or Eileen -6249 3011 
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The ARIC Study Newsletter 
National Centre for Epidemiology and Population Health 
in cooperation with Royal Australian College of General Practitioners and the 
ACT Division of General Practice July 1998 
Dear Colleagues, 
We are now ten months into the two -year ARIC study. Respiratory data from 
your young patients continues to flow in and we are getting some very important results. 
We believe this project is at the cutting edge of evidence -based health care and has the 
potential to make an empowering change in general practice. 
Where are we with the ARIC study? 
The study includes 519 actively involved study children and 53 GPs. Respiratory diaries 
are consistently coming in and giving us a wealth of important information. During 
November through April, 23 GPs in the early group and some of the parents of their 
patients were involved in a series of meetings to develop a set of guidelines for use in 
managing ARI. This process as well received with very positive and encouraging 
feedback from our evaluation questionnaires. 
Guidelines for parents in the early group have been distributed. GPs in the early group 
also have the clinical guidelines they have helped to develop together with other 
supporting materials. We hope these guidelines will prove useful parents and GPs 
through the winter coughs and colds season. 
Early next year the GPs in the later group will be invited to consider the guidelines that 
the early group has developed. We will be monitoring parent management of ARI and 
consequent health outcomes over the two winters. 
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Results of Nasal Swabs 
During April, we have collected nasal swabs from 461 of our study children (88 %). 
Pneumococcus was isolated from 172 samples. This isolation rate of 37.3% is 
comparable to or better than other studies. We tested these isolates for resistant levels to 
seven commonly prescribed antibiotics. Half of the isolates were resistant to one or more 
of the antibiotics. 23.3% of these isolates were resistant to two or more antibiotics. 1.2% 
of the pneumococcus isolates were resistant to all of the antibiotics tested, except 
cefotaxime to which none of the isolates were resistant. 
We will be starting the next round of nasal swabs at the end of August. We plan to do 
this swabbing at community health centres and The Canberra Hospital. We hope this 
change of venue will be more efficient and reduce the burden on individual surgeries. 
If you have any questions about the study, please do not hesitate to ring us at the 
following number. 
Contact: The ARIC team 
Nasrin or Eileen- 62493011 
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The ARIC Study Newsletter 
National Centre for Epidemiology and Population Health 
in cooperation with Royal Australian College of General Practitioners 
and the ACT Division of General Practice September1998 
Dear Colleagues, 
We are now eleven months into the two -year ARIC study. Respiratory data from 
your young patients continues to flow in and we are getting some very important results. 
We believe this project is at the cutting edge of evidence -based health care and has th4e 
potential to make an empowering change in general practice.Where are we at with the 
ARIC Study? 
The study includes 519 
and 53 GPs. Respiratory 
in and giving us a wealth 
During November through 
and some of the parents of 
actively involved study children 
diaries are consistently coming 
of important information. 
April, 23 GPs in the early group 
their patients were involved in a 
series of meetings to develop a set of guidelines for use in managing ARI. This process 
was well received with very positive and encouraging feedback from our evaluation 
questionnaires. 
Guidelines for parents in the early group have been distributed. GPs in the early group 
also have the clinical guidelines they have helped to develop together with other 
supporting materials. We hope these guidelines will prove useful parents and GPs 
through the winter coughs and colds season. 
Early next year the GPs in the later group will be invited to consider the guidelines that 
the early group has developed. We will be monitoring parent management of ARI and 
consequent health outcomes over the two winters. 
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Results of Nasal Swabs 
During April, we have collected nasal swabs from 461 of our study children (88 %). 
Pneumococcus was isolated from 172 samples. This isolation rate of 37.3% is 
comparable to or better than other studies. We tested these isolates for resistant levels to 
seven commonly prescribed antibiotics. Half of the isolates were resistant to one or more 
of the antibiotics. 23.3% of these isolates were resistant to two or more antibiotics. 1.2% 
of the pneumococcus isolates were resistant to all of the antibiotics tested, except 
cefotaxime to which none of the isolates were resistant. 
We will be starting the next round of nasal swabs at the end of August. We plan to do 
this swabbing at community health centres and The Canberra Hospital. We hope this 
change of venue will be more efficient and reduce the burden on individual surgeries. 
ARI Update 
I recently attended the WONCA Conference (World Organization of National Colleges, 
Academies and Academic Associations of General Practitioners/Family Physicians) in 
Dublin, and participated in a number of meetings that were discussing some of the issues 
we have been discussing in this project. Dutch antibiotic prescribing rates for respiratory 
infections ar4e considerably lower than those in Australia. So is their incidence of 
antibiotic resistance. It is conforting to know that every country in the world is facing our 
dilemmas 
In particular, the issue of what to do about possible streptococcal throats is exercising 
GPs everywhere. I am satisfied that the consensus we reached in the discussions I March 
and April is as practical and defensible as any other course of action being proposed 
elsewhere. That is, sore throats, even in the presence of pus, should not be managed with 
antibiotics unless there is laboratory evidence that group A Haemolytic streptococci are 
present on the thraoat swab. That means that in these cases, a throat swab should be 
considered and the results known to be positive before antibiotic therapy is commenced. 
On the issue of otitis media also, there is very variable prescribing around the world. 
Once again, I think our consensus in Canberra is absolutely defensible. That is, careful 
analgesia at a therapeutic dose will be more effective in reducing symptoms than 
antibiotics and, provided there is no mastoid tenderness and the child does not look 
seriously ill, an expectant approach is justifiable and should be discussed with the parent. 
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I look forward to hearing from you on your experience in implementing the guidelines 
later in the year. We have recently sent out a Newsletter to parents of children in the early 
group, reinforcing the messages contained in the guidelines that was distributed to them 
in May. 
It was clear to me at the Dublin meeting that the study w are doing here is at the 
international cutting edge of this work. 
Looking forward to your continuing support. 
RM Douglas 
for the ARIC Team 
If you have any questions about the study, please do not hesitate to ring us at the 
following number. 
Contact: The ARIC team 
Nasrin or Eileen- 62493011 
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Happy Birthday Christian 
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Appendix 6.1 
To see the association between any beta lactam use during different periods before swab 
collection and isolation of penicillin resistant pneumococci after adjusting for repeated 
swabs fromt he same child. 
Table: Effect of any beta lactam use during each two monthly period on penicillin 
resistance, adjusting for the cluster effect of a child 
Time before swab 
collection (months) 
Total 
isolate 
OR P value Lower 
95% CI 
Upper 
95% CI 
0 -2 522 2.03 0.01 1.15 3.56 
3 -4 518 1.27 0.41 0.72 2.22 
5 -6 459 1.25 0.44 0.71 2.19 
7 -8 366 0.87 0.73 0.41 1.88 
9 -10 353 0.66 0.26 0.32 1.36 
11 -12 295 0.75 0.49 0.34 1.67 
13 -14 213 0.71 0.45 0.29 1.74 
15 -16 206 0.76 0.53 0.32 1.80 
17 -18 165 0.36 0.11 0.10 1.28 
19 -20 92 4.00 0.03 1.18 13.56 
21 -22 69 0.31 0.28 0.04 2.65 
23 -24 25 1.56 0.68 0.20 12.33 
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Appendix 6.2 
Table: Association of penicillin resistance with 3 groups of beta lactam use: only 
penicllin use, only cephalosporin use and both penicillin and cephalosporin use 
during the 2 months prior to swab collection, adjusting for cluster effect of the 
children 
Types of beta- lactam use Total 
isolate 
OR P Lower 
95% CI 
Upper 
95% CI 
Only penicillin 461 1.63 0.29 0.66 4.01 
Only cephalosporin 475 1.93 0.08 0.93 3.98 
Both penicillin 
cephalosporin 
and 434 4.67 0.02 1.27 17.09 
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Appendix 6.3 
Table: Effect of penicillin group use alone during each two monthly period on 
penicillin resistance, adjusting for the cluster effect of repeated positive isolate from 
a child 
Time before swab 
collection (months) 
Total 
isolate 
OR P value Lower 
95% CI 
Upper 
95% CI 
0 -2 461 1.63 0.29 0.66 4.01 
3 -4 447 1.63 0.23 0.73 3.67 
5 -6 398 1.53 0.26 0.73 3.23 
7 -8 330 0.67 0.47 0.22 1.99 
9 -10 304 0.58 0.28 0.21 1.57 
11 -12 263 0.87 0.77 0.34 2.22 
13 -14 177 0.46 0.32 0.10 2.12 
15 -16 168 0.45 0.31 0.10 2.07 
17 -18 122 
19 -20 84 2.1 0.40 0.37 11.81 
21 -22 64 0.5 0.54 0.06 4.51 
23 -24 22 1.17 0.91 0.09 15.41 
*None of the isolates that had penicillin use was resistant to penicillin. 
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Appendix 6.4 
Table: Effect of cephalosporin use alone during each two monthly period on 
penicillin resistance, adjusting for the cluster effect of a child 
Time period before swab 
collection (months) 
Total 
isolate 
OR P value Lower 
95% CI 
Upper 
95% CI 
0 -2 475 1.93 0.08 0.93 3.98 
3 -4 465 0.90 0.80 0.39 2.06 
5 -6 402 0.91 0.83 0.39 2.15 
7 -8 322 1.44 0.49 0.52 4.01 
9 -10 289 0.31 0.13 0.07 1.38 
11 -12 241 0.25 0.19 0.03 1.94 
13 -14 180 0.64 0.50 0.18 2.32 
15 -16 172 1.09 0.88 0.38 3.14 
17 -18 141 0.30 0.25 0.04 2.36 
19 -20 82 9.78 0.007 1.86 51.48 
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Appendix 6.5 
Table: Effect of combined penicillin group and cephalosporin use during each 2 
monthly period on penicillin resistance, adjusting for the cluster effect of repeated 
pneumococcal isolates from the same child 
Time period before swab 
collection (months) 
Total 
isolate 
OR P value Lower 
95% CI 
Upper 
95% CI 
0 -2 434 4.67 0.02 1.27 17.09 
3 -4 420 1.96 0.32 0.52 7.41 
5 -6 357 1.99 0.40 0.40 9.98 
7 -8* 255 
9 -10 266 2.37 0.17 0.69 8.14 
11 -12 225 1.93 0.44 0.37 10.16 
13 -14 158 2.23 0.36 0.40 12.29 
15 -16 152 0.65 0.69 0.08 5.49 
17 -18 129 4.43 0.15 0.59 33.36 
19 -20* 67 
21 -22 64 0.5 0.54 0.06 4.51 
23 -24 22 1.17 0.91 0.09 15.41 
*no penicillin resistant isolates in the exposed group 
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Appendix 6.6 
Table: Penicillin resistance in pneumococci isolated from four groups of children, 
grouped by the duration of beta lactam use during the six months before swab 
collection (n =456 isolates) 
Penicillin 
sensitivity 
0 days 1 -7 days 8 -14 days >14 days 
( %) ( %) ( %) ( %) 
Total isolates 257 64 74 61 
Sensitive 225 (88) 57 (89) 61 (82) 45 (74) 
Resistant 32 (12) 7 (11) 13 (18) 16 (26) 
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Appendix 6.7 
Table: Rate of penicillin resistance among four groupos of isolates, grouped by the 
duration of total penicillin use during the six months before swab collection (n =333 
isolates) 
Penicillin 0 days 1 -7 days 8 
sensitivity 
(° /U) ( %) 
-14 days 
( %) 
>14 days 
( %) 
Total isolates 257 32 28 16 
Sensitive 225 (88) 28 (87) 23 (82) 11 (69) 
Resistant 32 (12) 4 (13) 5 (18) 5 (31) 
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Appendix 6.8 
Table: Effect of total penicillin group use alone during the six months prior to the 
swab collection on penicillin resistance, adjusting for cluster effect of repeated 
pneumococcal isolates from the same child (n =333 pneumococcal isolates) 
OR Robust P value Lower CI Upper 
std err CI 
Penicillin use alone in 6 months 1.04 0.02 0.03 1.00 1.09 
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Appendix 6.9 
Table: Rate of penicillin resistance among four groupes of isolates, grouped by the 
duration of total cephalosporin use during the six months before swab collection 
(n =343 isolates) 
Penicillin 
sensitivity 
0 days 1 -7 days 8 -14 days >14 days 
( %) ( %) ( %) ( %) 
Total isolates 257 30 40 16 
Sensitive 225 (88) 27 (90) 33 (83) 13 (81) 
Resistant 32 (12) 3 (10) 7 (17) 3 (19) 
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Antibiotic resistance in Streptococcus pneumoniae 
isolated from children 
D NASRIN; PJ COLLIGNON,2 EJ WILSON,' LS PILOTTO3 and RM DOUGLAS' 
'National Centre for Epidemiology and Population Health, Australian National University Infectious Diseases Unit 
and Microbiology, Canberra Hospital, Canberra, Australian Capital Territory, 'The Queen Elizabeth Hospital, 
Woodville, South Australia, Australia 
Objective: To determine the level of antibiotic resistance in pneumoniae (S. pneumoniae) isolated from nasal swabs of 
healthy children. 
Method: Cross -sectional community survey. 
Setting: Survey was undertaken in general practice settings in Canberra during March and April 1998. 
Subjects: Four hundred and sbdy -one children under 3 years of age enrolled in a general practice trial of clinical practice 
guidelines for antibiotic use. 
Outcome measures: Resistance to penicillin, erythromycin,.co-trimoxazote, tetracycline, chloramphenicol and cefotaxime 
among the isolates of S. pneumoniae. 
Results: A total of 461 nasal swabs were collected and S. pneumoniae was isolated from 171 (37.1 %). Penicillin resistance 
was found in 12.3% of these isolates, with high levet resistance in 0.6 %. Resistance rates were higher for cottimoxazole 
(44.4 %) and erythromycin (18.1 %) than for penicillin- Muttidnlg resistance was found in 19% of these isolates. There was a 
significant association between the attendance at a day care centre and carriage of pneumococcus (53% vs 32 %, odds ratio 
(OR) 2.4, 95% confidence interval (CI)1.5 -3.7. P< 0.001). Children who attended day care centres and had received anti- 
biotics during the 4 months prior to swab collection were three times more likely to carry an antibiotic -resistant isolate than 
children who had neither attended a day care centre nor received antibiotics (68% vs 40 %, OR 3.1, 95% CI 1.2 -8.4, P. 0.02). 
Conclusion: The level of antibiotic resistance in pneummarci from healthy children was of concern. Carriage of pneumo- 
coccus was significantly higher in children who attended a day. care centre Resistance was significantly correlated with anti- 
biotic use in combination with day -care attendance. These findings warrant more judicious use of antibiotics in children. 
Key words: antibiotic; children; pneumococci; resistance. 
Streptococcus pneumoniae (S. pneumoniae) is a leading cause 
of morbidity and mortality worldwide, especially in children.' 
S. pneumoniae is the single most-common cause of otitis media, 
pneumonia, meningitis and bacteraemia in young children.' 
Although a strain of S. pneumoniae resistant to penicillin was 
first reported in 1967 in Australia,' resistant strains have become 
more prevalent since 1987.' Prescription of antibiotics is directly 
related to the rate of development of resistance. and frequent 
Or long -tern use of antibiotics is a significant risk factor for the 
development of resistance.", Young children are more likely to 
be colonized with antibiotic- resistant organisms'," and atten- 
dance at day care centres has been identified as a factor in the 
spread of resistant organisms between children.c,"Wa 
Respiratory infection is the most common diagnosis in 
Australian children," particularly during winter. Antibiotics are 
widely prescribed to treat common respiratory infections, most of 
which are of viral in origin.'' "." As in other developed countries. 
antibiotic use in Australia is high;'s for example, 77% of cases of 
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Accepted for publication 17 May 1999. 
acute otitis media are treated with antibiotics." The incidence o 
acute otitis media is associated with increased nasopharyngea 
colonization of pneumococci and penicillin resistance is signifi 
candy related to an increased incidence of unresolved otitin 
media.' 
While antibiotic resistance has become a major public healtt 
problem, relatively little work has been reported in outpatìen 
settings to ascertain the level of antibiotic resistance to pneumo 
cocci among Australian children." This study was conducted -ir 
general practice settings to determine the rate of pneumococca 
colonization, the pattern of antibiotic resistance in pneumococc 
and the relationship of resistance to antibiotic use in children. 
METHODS 
This study was undertaken in the course of a randomizes 
controlled trial in Canberra. which is investigating the effects o 
clinical practice guidelines on antibiotic prescribing in acutr 
respiratory infections in general practice. The trial commenced it 
September 1997. A total of 54 randomly selected general practi 
boners (GP) from Canberra subsequently recruited 500 childrer 
under 2 years of age from their practices. Informed consent wan 
obtained from the parents during recruitment. At study entry 
parents completed a questionnaire which included general infor 
mation about their children. The respiratory health of the childrer 
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was followed for a period of 2 years using a series of daily 
diaries, which are being maintained and returned by their 
parents every month. Parents recorded various symptoms of 
respiratory infections that their children suffered during the study 
period. They also reported antibiotic use and duration of 
treatment. Before implementing the intervention, nasal swabs 
were collected during March and April 1998; from healthy 
children, to detect the baseline level of resistance in pneumo- 
coccus. These swabs formed the basis for this study. Nasal 
swab collection was approved by the Ethics in Human Expen- 
mentation Committee. 
Nasal swabs were collected by moistening the swab in 
Amies transport media (Interpath Services Pty Ltd, Melbourne, 
Australia) and then placing the swab directly on the blood agar 
plate containing 5 pg/mL of gentamicin. The child's name, age, 
sex, and date of birth were recorded. Specimens were immedi- 
ately inoculated in blood agar plates and incubated for 18 to 
24 h at 35 °C in an atmosphere with added 5% COT. S. pneu- 
moniae was identified by colonial morphology, a- haemolysis on 
blood agar plates, susceptibility to optochin and/or bile solu- 
bility. The predominant colony -type of each isolate was tested 
for susceptibility to penicillin, erythromycin, co- trimoxazole, 
tetracycline, chloramphenicol and cefotaxime. Susceptibility 
testing was performed on Mueller- Hinton Agar with 5 %delibri- 
nated sheep blood (MHASB), according to the National 
Committee for Clinical Laboratory Standards (NCCLS) guide - 
lines.18 Penicillin and erythromycin susceptibility were also 
tested using E -strips for each isolate. The breakpoints tor 
minimal inhibitory concentration (MIC) published by NCCLS 
guidelines were used.. The isolates were defined as sensitive 
to penicillin when MIC was less than or equal to 0.064 mg/L, 
intermediate when MIC was greater than 0.064 mg/L but less 
than or equal to t mg/L, and highly resistant when MIC was 
greater than 1 mg/L. All isolates were tested for cetotaxime 
susceptibility with a 30 pg disc and those that were penicillin 
resistant were also tested with a cetotaxime E- strip. Antibiotic 
resistance was categorized as either intermediate or high level 
resistance. Multidrug resistance was defined as the presence of 
intermediate or high level resistance to two or more antibiotics. 
Parent questionnaires and diary data were analysed over 
4 months between January to April to ascertain antibiotic use 
and attendance at day care for compatison with swab culture 
and sensitivity results. We considered that antibiotic use during 
the preceding 4 months could affect antibiotic resistance, based 
on the fact that the half -life of naso- pharyngeal carriage 
of a pneumococcal strain is 2 -5 months.. Pearson Chi -square 
tests were used to compare percentages between groups. 
Mann -Whitney tests were used to compare the distribution of 
antibiotic use between groups. Odds ratios (OR) were calculated 
to measure the association between various risk factors and 
resistance. All calculations were performed using SPSS 7.5 for 
Windows (SPSS Inc., Chicago, IL, USA). 
RESULTS 
Nasal swabs were collected from 461 children, representing 
of the children participating in the trial. The mean age of 
the children was 11.7 months ranging from 0.5 months to 
F7.4 months. Of the 461 children 43.6% were male. Strepto- 
s pneumoniae was isolated from 171 of the swabs 
404ected (37.1 %). The overall rate of penicillin resistance was 1%, with high level resistance in 0.6% of isolates (Table 1). 
Isolates also showed resistance to antibiotics other than peni- 
cillin. Forty -nine per cent of the isolates were resistant to one or 
more of the antibiotics tested. Among these isolates, 19% were 
multiresistant and 1% of isolates were resistant to all antibiotics 
tested (Table 2). 
Most of the penicillin- resistant isolates (n =21) were also 
resistant to other antibiotics, 91% (19/21) were resistant to co- 
trimoxazole, 67% (14/21) were resistant to erythromycin, 14% 
(3/21) to chloramphenicol, 62% (13121) to tetracycline and 10% 
(2/21) to cefotaxime either alone or in combination. The resis- 
tance patterns are shown in Table 3. 
A total of 38% (57/150) of the penicillin- sensitive isolates were 
resistant to co-trimozazole, 11% (17/150) to erythromycin, 4% 
(6/150) to tetracycline, either alone or in combinaban (Table 3). 
All penicillin sensitive isolates were also sensitive to chloram- 
phenicol. 
There were no significant differences in age, sex or and 
breast -feeding status between children with sensitive and those 
with resistant isolates. We found a significant relationship 
between day care centre attendance and isolation of pneumo- 
coccus. Pneumococcus was isolated from 53% (60 of 113) of 
the children who attended a day care centre, and from 32% 
(103 of 318) of those who did not (OR 2.4, 95% CI 1.5 -3.7; 
P< 0.001). There was no significant difference in pneumo- 
coccal carriage rate between children who attended family day 
care and those who had home care, although the number of 
children who attended family day care was very small (only six 
children). 
Antibiotic resistance was more common in isolates from 
children who attended day care;. 58% (35/60) were resis- 
tant to one or more antibiotics, compared to 44% (45/103) 
of those isolates children were cared for at home. The trend 
was not statistically significant (OR 1.8, CI 0.95 -3.4, P= 0.07). 
Three out of six isolates from children who attended family 
day care were resistant to at least one antibiotic (OR 1.3, 
CI 0.25-6.7, P = 0.8). The level of antibiotic resistance did 
not show a significant relationship with duration of day rare 
attendance. 
Information regarding antibiotic use during the 4 months prior 
to swabbing was available for 157 of 171 children from whom 
S. pneumoniae was isolated. Of these, 78 children carried 
resistant and 79 carried sensitive isolates. Forty -one per cent 
of children with resistant isolates had received at least one 
day of antibiotic treatment compared with 29% of children 
with sensitive isolates (Fig. 1). Nine percent of the children with 
resistant isolates received antibiotics for at least 20 days 
compared to only 3% of the children with sensitive isolates 
(Fig. 1). The children carrying resistant pneumococci tended to 
receive more days of treatment with antibiotics than those with 
sensitive isolates (mean 8.5 days vs 3.8 days, P=0.07). Two 
children had been taking antibiotic prophylaxis (> 90 days) and 
both were in the group that carried resistant isolates. When 
these two children were excluded, children with resistant 
isolates still had more days of antibiotic use than those with 
sensitive isolates (mean 5.6 days vs 3.8 days, P= 0.1) and 57% 
of children who received antibiotics for at least one day carded 
resistant strains compared with 45% of. those who had received 
no antibiotics (P= 0.2). 
Children who attended day care centres and received anti- 
biotics during the 4 -month period were three times more likely to 
carry a resistant isolate than the children who neither attended a 
day care centre nor received antibiotics (68% vs 40 %, 17/25 vs 
25/62, OR 3.1, CI 1.2 -8.4. P= 0.02). 
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Table 1 Sensitivity of pneunococcal isolates to antibiotics in children 
Sensitivity Penicillin Erythromycin Co- trimoxazole Tetracycline 
result ( %) ( %) (x,) (%) - 
Sensitive 150 (87.7) 
Intermediate resistant 20 (11.7) 
Highly resistant 1 (0.6) 
140 (81.9) 
31 (18.1) 
95 (55.6) 
10 (5.8) 
66 (38.6) 
152 (88.9) 
2(12) 
17 (9.9) 
Minimal inhibitory concentration breakpoint 
Penicillin: Sensible o 0.064 mg/L; intermediate a 0.064 -1 mg/L4 highly resistant > 1 mg/L 
Erythromycin: Sensitive z 0.250 "Nil; intermediate u 0.250 -1 mg/L; highly resistant > 1 mg/L 
Cetotaxime: Sensitive c 0.50 r g/L; intem,eáate a 0.50 -1 mgt; highly resistant > 1 mg/L 
Table 2 Pneurrwwcrat isolates resistant to the number of antibiotics 
Number of antibiotics to 
which the isolate showed 
resistance 
Number and percentage 
of resistant isolates (15) 
0 87 (51) 
1 52 (30) 
2 13 (8) 
3 6 (4) 
4 - 11 (6) 
6 2 (1) 
80 
70 
ó 60 
50 
40 
30 
20 
10 á 0 
1 -10 11 -20 >20 
Days of antibiotic use /120 days 
Fig. 1 Percentage distnbution of antibiotic use for children according to 
their resistance status. (o), non -resistant (n _ 79; (e), resistant (n = 78). 
DISCUSSION 
Chloramphenicol 
( %) 
Cefotaxime 
( %) 
168 
3 
(982) 
(1.8) 
169 
1 
1 
(98.8) 
(0.6) 
(0.6) 
The only other Australian study that has looked at pneumococca 
resistance to commonly prescribed antibiotics in children tool- 
place in 1993), The unique feature of the present study is that i 
has also looked at the antibiotic usage of the children before the 
swab tests, which highlights the effect of antibiotic use on anti- 
biotic resistance. 
- 
The rate of antibiotic resistance in S. pneumoniae has beer 
increasing in Australia, although at a slightly slower rate than it 
some areas of the USA.rs The level of penicillin resistance 
in isolates from children in this study was substantially higher 
than the level found in a study of preschool children in Australia 
in 1993, in which 5% of the isolates of S. pneumoniae were 
resistant to penicillin." 
Resistance to erythromycin, co-trimoxazole, tetracycline anc 
choramphenicol has also increased over the last 5 years., 
Pneumococcal resistance to erythromycin, chloramphenicol anc 
tetracycline is chromosomally mediated and can be transferrec 
by conjugal transposition.° "This could explain our finding a 
tetracycline and chloramphenicol resistance in our stud) 
children, although these drugs are not usually prescribed to the 
children in this age group. Moreover, resistance to these druge 
can be due to the selective pressure of the aminopenicillins due 
to sharing of resistance mechanisms for several drugs in the 
some organism s 
We have not tested isolates for susceptibility to first anc 
second generasen cephalosporins, as the results can be extra- 
polated from penicillin resistance We found little cefotaxime 
Table 3 Resistance to other antibiotics among penicillin -sensitive and penicillin- resistant isolates 
Antibiotics other than penicillin 
to which resistant - 
Penicillin -sensible 
isolates ( %) 
Penicillin- resistant 
isolates ( %) 
(h = 21) (n = 150) 
None 58 (87) 9.5 (2) 
Co- trimoxazole 30 (45) 19 (4) 
Erythromycin 3.3 (5) 
Erythromycin co-trimoxazole 4.7(7) 9.5 (2) 
Erythromycin + tetracycline 0.7(1) 
Erythromycin . co- Mmaxazole 27 (4) 47.6 (10) 
+ tetracycline 
ChlO2mphenicol +co- trimoxazole 
tetracycline 
4.8 (1) 
Co-trimOxaaole + tetracycline 0.7 (1) 
Erythromycin . co-trimoxazole 9.5 (2) 
+ tetracycline o chloramphenicol + cefotaxime 
Antibiotic resistance in Streptococcus pneumoniae isolated from children 
resistance in our study (12 %), and this is slightly higher than the 
rate found in a larger study by Collignon during 1994 -95. in 
which 0.7% of pneumococcal isolates were resistant to celo- 
taxime.e In that study there was no high level resistance to 
cefotaxime, whereas one of the two isolates in our study showed 
high level cefotaxime resistance. We tested cefotaxime resin - 
tepee only in isolates that showed either intermediate or high 
level resistance to penicillin, as the mechanism of resistance is 
usually similar for penicillin and third generation cephalosporin, 
that is, changes in penicillin- binding proteins?' 
Our study showed a trend that the children with resistant 
isolates had more days of antibiotic use than the children with 
sensitive isolates. This is not surprising and supported the 
widely held view that consumption of antibiotics is an important 
factor.for development of resistance? Our finding also reinforced 
the evidence that long -term use of antibiotics is a significant risk 
factor for development of resistance.. 
This study showed a trend towards a higher prevalence of 
antibiotic -resistant pneumococci in children attending day care 
centre, which was of borderline significance (P. 0.07). This 
of antibiotic resistance with day care centre attendance 
has been supported in other studies)," A greater proportion of 
children who attended day care centre carried isolates that were 
resistant to one or more antibiotics compared to the children who 
had home care. Though neither antibiotic use nor attendance at 
day care centre independently had a significant relationship to 
resistance, the combination of both factors showed a highly signif- 
icant association with antibiotic resistance This has important 
implications in treating children in countries like Australia, where a 
high proportion of children attend day cam centres. 
Antibiotic use should be judicious. We need to educate both 
patients and GP to reduce unnecessary antibiotic use, before 
antibiotic resistance rises toy even more alarming levels in this 
community. The study of which the present study was a part has 
been designed to explore the impact of clinical practice guide- 
lines on antibiotic -prescribing, which is implemented to one 
group of GP and parents. 
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OBJECTIVE To integrate evidence based medicine with the experience and expectations of consumers and GPs in the 
development of clinical practice guidelines for acute respiratory infections (AEI) in young children. 
METHOD Focus groups and workshops were held with 21 GPs and 27 parents of young children involved in a 2 year 
randomised controlled trial. 
gEStÍL'tS The acceptäbllity of the guideline development process for participants was determined. Barriers were 
identified which would impede clinical change, including: inadequate time; lack of knowledge; fear of patient 
dissatisfaction; and fear of poor health outcome. 
CONÇWS1QN. This. páperdetails a process of guideline development that addresses the realities of general practice in 
Australia and the concerns ófcoñsumers. We identified potential barriers to change and integrated intervention strategies 
with the evidence toprpduce realistic clinical practice guidelines. 
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rrhe development of clinical practice I guidelines (CPGs) has gained 
momentum over the past decade in. 
Australia and other countries but their 
effectiveness for improving clinical prac- 
tice varies considerably.' Although 
Australian GPs generally have a positive 
attitude toward CPGs, they consider their 
impact for changing everyday clinical 
practice as low.' Low levels of compliance 
with CPGs have been attributed to many 
factors. Some clinicians feel guidelines 
diminish clinical autonomy, are irrelevant 
to everyday practice, have been devel- 
oped by experts who do not understand 
the needs of GPs, or could be used 
against them in litigation'' 
CPGs have often been developed with 
little planning for distribution and imple- 
mentation, although in recent years, 
researchers have begun to address these 
shortcomings.' A sense of ownership, sci- 
entific validity, and a multifaceted 
approach to development and implemen- 
tation are now acknowledged as 
important factors if CPGs are to change 
clinical practice" Social, psychological 
and managerial theories have informed 
methods for changing clinical practice.'-' 
A multifaceted approach for the success- 
ful implementation of CPGs requires 
assessment of the barriers to change in 
the target population,' and development 
of appropriate implementation strategies 
that address these barriers to change.1 "" 
This paper reports on a process of 
guideline development and implementa- 
tion using an evidence based method 
that addresses the realities of general 
practice in Australia and the concerns of 
consumers. 
Methods 
The sample 
This research was conducted as part of a 
2 year randomised controlled trial (RCT) 
448 Australian Family Ptysieian VoL 29. No. 5. May 2000 
in Canberra, ACT, investigating the 
development and implementation of 
CPGs and their effect on the care and 
management of acute respiratory infec- 
tions (ARI) in young children. GPs were 
randomly chosen from a database com- 
piled from: 
a membership list from the ACT divi- 
sion of general practice, 
a list of practices from the ACT immu- 
nisation registry, 
and the Yellow Pages listings. 
Each GP then recruited up to 15 of 
their patients under 2 years of age. In 
total-54 GPs and 500 children were 
involved in the RCT. The GPs along 
with their patients were randomly allo- 
cated to the intervention arm of the 
study (the group helping to develop 
clinical practice guidelines) or to a 
control group. The group of GPs and 
parents described here were in the 
intervention arm of the study. 
3 Parent 3 GP\Vorkshops 
Focus Groups Cough &bronchitis 
Experiences and Dtitiwriedia 
expectations URTI& sore throat 
Figure 1. Guideline development process. 
At recruitment, both GPs and parents 
completed -`study entry questionnaires 
which detailed characteristics of the GPs 
and- their -prn ;Rad -sáetadetnographic 
information of the study children and 
their families. 
Study design 
The process of guideline development 
involved a series of focus groups with 
parents,- and workshops with GPs. A 
series of three focus groups for parents 
were held in various locations in 
Canberra. Parents were contacted by 
phone and invited to attend one of 
these. Next, three GP workshops were 
held as lunchtime meetings. A letter and 
follow up phone calls invited all the GPs 
from the intervention group to attend 
one of these workshops. Short sum- 
maries of the evidence for antibiotic 
treatment of ARI, derived where avail- 
¡ able from the Cochrane Library, were 
sent to the GPs before the meetings to 
facilitate discussions. A second set of 
three parent focus groups was held a 
fortnight after the first GP workshops. 
A month later two more GP workshops 
were held as evening sessions. Three 
weeks later the final guideline develop- 
3 Parent 
Focus Groups 
Experiences and 
expectations 
Evidence 
2 GP Workshops 
Draft guidelines 
ment meeting was held for the GPs to 
amend and. the guidelines. Thus 
GPs were invited to attend up to three 
of the --six workshops and parents were 
invited to attend one of the six focus 
groups. 
These meetings built cumulatively on 
one another and explored the experiences 
and expectations of parents and GPs 
when caring for young children with ARI, 
and the evidence about the treatment of 
ARI. Figure 1 illustrates the format of 
these meetings. 
Initial meetings 
The first set of three parent focus groups 
explored parents' experiences in caring 
for their young children with ARI, their 
concerns about the illness, home nursing 
used, and their expectations of care from 
their GP. This information plus evidence 
on the treatment of ARI, derived largely 
from Cochrane Systematic Reviews,"-" 
was used in the first three GP work- 
shops. Each workshop concentrated on a 
different aspect of ARI: 
cough and acute bronchitis 
acute otitis media 
sinusitis 
sore throat. 
Amended 
& endorsed 
The next step 
Final GP Workshop 
Anal guidelines 
and implementation 
Package 
A second set of three parent focus groups 
further explored parents' experiences and 
expectations for ARI and their views on 
the evidence thathrid been discussed at 
the GP workshops. Two more GP work- 
shops followed, where the evidence was 
explored further and draft guidelines 
were developed. At onè of these work- 
shops, a professor of general practice who 
is a Cochrane reviewer presented the evi- 
dence on otitis media and sore throat. 
The final phase 
The workshops and focus groups culmi- 
nated in a final meeting for GPs. In this, 
they 
edited a 'Principles of Practice' docu- 
ment for GPs 
approved guidelines for parents 
approved an implementation package 
containing educational materials, 
posters and clinical consultation aids. 
An infectious diva e specialist and a profes- 
sor of paediatrics attended this final meeting 
to answer questions and facilitate discussion. 
The specific objective Of the GP meetings 
was to develop the guidelines for GPs and 
parents, using evidence of best practice for 
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ARI -and-incorpomëng- eonsumerand GP 
experiences and expectations. The objective 
of the parent focus groups was to under- 
stand parents' concerns for their children 
and their usual management practices when 
their children were ill with an ARL 
All meetings were audio-recorded and 
ßaunuibed. The transcripts were coded 
and grouped to identify themes. Three of 
the authors (ETW, DN, CB) discussed 
and verified the themes and barriers iden- 
tified. 
Evaluating the process 
Evaluation questionnaires on the guide- 
line development process were 
distributed to the GPs attending the final 
meeting. Parents participating in the 
focus groups were also sent an evaluation 
questionnaire 1 month after receiving the 
parent guidelines. Evaluation question- 
naires were based on previously tested 
questionnaires from continuing medical 
education events. Results from these 
evaluations and the parent and GP study 
entry questionnaires were analysed with 
the assistance of SPSS software. 
Results 
The GPs 
Twenty-one of the 24 GPs who had been 
randomly allocated to the intervention 
group participated in developing guide- 
lines. Of the 21. GPs attending any 
meeting, 17 (81%) attended two or three 
of the three guideline development ses- 
sions. Of the 21 GPs, 47.6% were female. 
Over half of the participants worked in 
small group practices (2 -3 GPs) and spent 
an average of 403 hours per week in the 
surgery. All were vocationally registered 
and 95% were members of the ACT divi- 
sion of general practice. 
The GP response to the process was 
extremely favourable. Table I shows the 
results from the evaluation questionnaire 
from 17 of the 18 GPs who attended the 
final guideline meeting. At the end of 
the process, all were concerned about 
antibiotic resistance and 16 felt the 
process was informative, enjoyable, and 
relevant to their practice. Fifteen of the 
respondents said that consumer input 
was important in the development of 
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guidelines and 16 of the respondents said 
they would be changing their practice 
towards a more judicious use of antibi- 
otics for ARI. 
Parents' characteristics and 
response 
Twenty -seven parents participated in 
focus groups from over 150 contacted A 
large percentage of parents were well 
educated (43.4% of mothers and 34.8% 
of fathers had university or postgraduate 
degrees) and earned an above average 
income. The study child was their first 
child for over half the parents attending 
the focus groups. The average age of the 
mothers was 32 years (range 19-39 years). 
Thus the parents who attended the focus 
groups were better adúcáted and in a 
higher socioeconomic group than the 
average Australian. or the average 
Canberran.' 
The parents' response to their involve- 
ment in the guideline development 
process was also favourable. More than 
90% of the respondents felt the process 
was informative, enjoyed interacting with 
other parents, and were concerned about 
antibiotic resistance. Nearly-67% said 
they gained valuable new knowledge on 
ARI and now felt more confident in 
caring for their sick children. Although 
only 30% of the parents felt they could 
communicate better with their GP, 
several of these respondents commented 
that they already had very good commu- 
nication with their doctor. In the 
evaluation questionnaire, some parents 
mentioned that more information at the 
outset would have been useful and felt 
the discussions were one- sided. At the 
parent focus group stage of the process, 
the researchers were careful not to give 
the parents clinical advice. 
Identified barriers 
Through a systematic analysis of the 
transcripts from all the focus groups and 
workshops, we identified several factors 
that could impede the successful 
implementation of evidence based guide- 
lines into clinical practice. Table 2 lists the 
barriers identified, as well as some imple- 
mentation strategies used to address these 
barriers. 
Tri degsiàte time '_- __._.... __........ 
GPs frequently cited time asA reason for 
prescribing antibiotics. Consultations for 
otitis media, for example, were often seen 
as a chance to `catch up' on the backlog of 
patients in the waiting room. The doctor 
could examine the ear and write a pre- 
scription in a short period. The parents 
said they often expected antibiotics for 
this condition and therefore would accept 
a quick cold; iltátï &à Other GPs felt that 
during the winter-months they spent too 
much time explaining repeatedly to each 
patienta iie4 *éiral aetiology and the 
ineffectiveness of antibiotic treatment for 
upperTespitfentions.. 
Lack of knowledge 
With the flood of new information facing 
GPs, it can be.difficult to stay abreast of 
all the latest evidence. The workshops 
provided an opportunity for comprehen- 
sive exploration of the evidence in 
relation to general.practice. 
Lack of knowledge was a big factor in 
parents', perceptions for the need for 
antibiotics' Although most parents seemed 
to understand that antibiotics were not 
effective for viral infections, there was 
some confusion about the aetiology of 
ARIs and signs and symptoms that may or 
may not indicate a bacterial infection. 
Doubt about evidence 
Some of the GPs felt the evidence in the 
literature, based on randomised con- 
trolled trials, presented an artificial 
situation. Others were sceptical about the 
criteria used for case inclusion in studies. 
They felt the conclusions from the 
research trials might not be relevant to 
everyday practice. There was much dis- 
mission about, the validity of the studies, 
their definitions of disease and their 
applicability to everyday general practice: 
What I'm saying is a lot of the studies 
that say this js useless, (antibiotics for 
sore throat) take unrealistic definitions 
and baoc s np rgyable. criteria for diag- 
nosing disease or non -disease. 
Fear of patient: dissatisfaction 
GPs expressed a fear that dissatisfied 
patients might defect to other doctors 
who may prescribe antibiotics more 
freely. GPs were also concerned about 
possible poor health outcomes if their 
approach towards ARI treatment became 
less interventionist 
you'll lose that patient and you'll lose 
that family and you'll lose all their 
friends because it doesn't matter 
whatñèc.yátt:t llf tStiagugsi tr 
made a right decision, if that child ends 
up in hug tail- with- pneumdlOrg..tny .. 
point... you're going to end up with 
angry parantsat your dgnrstep. 
. . 
Fear of litigation 
Anxiety about litigation was an extension 
of the worry about losing patients and 
income and a concern for loss of prestige 
among their colleagues. Many GPs 
expressed the concern atthe possibility of 
court action if they failed to prescribe an 
antibiotic. Other GPs felt specialists, who 
could testify against them in court, did 
not necessarily advocate the same treat- 
ment as was being developed for 
guidelines based on the evidence. 
Reluctance to change 
Underlying the other barriers was a 
general non specific fear of change, of 
practising medicine differently. Some GPs 
saw prescribing antibiotics for ARI as a 
safety net, an assurance they were treating 
a condition rather than being perceived by 
their patients as doing nothing. Others 
saw no need to change as they felt their 
practice was already evidence based 
Parental expectations of antibiotics 
Parents often had definite ideas about 
when antibiotics were needed. In the case 
of a cough illness, most parents used neb- 
ulisers and chest rubs for several days at 
home before going to the doctor. If these 
home treatments did not work or the 
cough was accompanied by mucus then 
parents thought the infection required 
antibiotics: 
I always wait (to go to the doctor) until 
be gets green mucus. 
If it's a phlegm type cough I tend to 
think it's bacterial and doesn't really 
need the aebuliser but may need an 
antibiotic. 
For many parents in the focus groups, 
earaèñë was a mä o ána- repeated 
problem. They wanted a prescription for 
antibititica.- ánd.believ_ed IjtaS_aAtjbiotics 
would clear up the problem quickly. This 
expe atiorcoantibioties -for otitisraedia 
was often governed by the concern for 
serious eomptications from -earache. 
Parents took what they believed to be 
preventive measures for earaches, includ- 
ing: wearing hats in winter; sterilising 
teats and bottles long after the recom- 
mended time; and avoiding getting water 
in their children's ears. In general, with 
the exceptions of otitis media and the 
presence of green " mucús, parents were 
cautious about antibiotic treatment for 
ARI and desired a judicious use of antibi- 
otics for their children. 
Discussion 
Several aspects of this development 
process are unique. Whereas GP focus 
groups or working groups have been used 
in guideline development before,'" to our 
knowledge, consumer input has not been 
incorporated to this extent. 
Questionnaires showed GPs recognised 
the need for consumers to be active partic- 
ipants in the guideline process. Involving 
consumers in the development process 
gave GPs a better understanding of the 
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needs and expectations of their patients. 
Because they were informed by consumer 
expectations, the guidelines could address 
specific parental concerns and answer 
some common misconceptions. 
The cumulative nature of the alternat- 
ing parent and GP meetings allowed for 
reassessment and refinement of the issues 
discussed by the participants and thus 
produced guidelines that were relevant to 
GPs and consumers. 
Another important aspect of this 
development process was inviting several 
experts to attend some of the GP meet- 
ings. These included an infectious disease 
specialist, a paediatrician, and a GP 
reviewer for the Cochrane Collaboration. 
Even though the GPs accepted responsi- 
bility for the guidelines, we feel the 
presence of these experts gave the GPs 
more confidence that leaders in the field 
would support them and the guidelines. 
This approach to guideline develop- 
ment and implementation systematically 
investigated the barriers to change for the 
target group of GPs and consumers. We 
were able to use the identified barriers to 
devise specific implementation strategies 
to address these barriers. For example, we 
approached the problem of inadequate 
time by providing practitioners with 
patient information sheets on otitis media 
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and sore throat and prescription-like pat 
These pads allowed the GP to tick a seri 
of boxes that explained the diagnosis, re 
ommended symptomatic treatment, as 
described warning signs if parents did zst 
see any improvement 
The workshop format for the:develoi 
ment of the guidelines gave the GPs 
sense of ownership of the guidelines. Tb 
workshops discussed the available ev 
dence for the treatment of ARI an 
explored -variations in- practice. GPs wh 
felt their practice was already evidenc 
based or who lacked the knowledge of th 
evidence, could explore those issue 
among their peers in a professionally sup 
portive environment. The presence o 
academic experts in evidence based medi 
cine, general practice, infectious disease 
and paediatrics at some of the workshop: 
helped_expiàin,the.detarla,of publishes 
studies and strengthened the validity of 
the -evidencefor- ihese6Psr= 
- -r= -- - 
Potential patient dissatisfaction war 
reduced-by preparing a constinier version 
of the guidelines and a poster advocating 
judicious use of antibiotics for display in 
the GP's surgery. These helped to 
educate the consumers and inform them 
of any change in their GP's practice. 
We encouraged GPs to use antibiotics 
less often as first line treatment in the 
mild cases by using -a ttép -wise approach 
which would enable GPs to gain confi- 
dence in the new style of practice and 
provide empirical evidence that it did not 
produce poor health outcomes. We were 
also able to reassure the GPs that the 
results of their changed practice would be 
evaluated as part of the randomised con- 
trolled trial and they would be given 
feedback throughout the study. GPs in 
this study indicated that they planned to 
modify their prescribing practices. As the 
trial proceeds, we will be able to ascertain 
whether their actual prescribing practices 
have changed compared to GPs in the 
control arm of the study, who did not 
receive the guidelines or discuss them 
until the intervention group had worked 
with them for a year. 
This study demonstrates a process of 
guideline development that goes beyond 
a statement of best clinical practice. For 
evidence based health care to be imple- 
-- merited- thfough- linieel - -- practice 
guidelines, all the aspects of decision 
making and behaviour chanlie,need to be 
explored and consolidated in a systematic 
way with the clinical evidence. 
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